aspirin has been researched along with Cerebrovascular Disorders in 835 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Cerebrovascular Disorders: A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA." | 9.16 | Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 9.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe." | 9.12 | Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006) |
| "To investigate whether warfarin is more effective and superior to aspirin for the prevention of thromboembolism in nonvalvular atrial fibrillation in Chinese." | 9.12 | [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. ( Hu, DY; Jiang, LQ; Sun, YH; Zhang, HP, 2006) |
| "We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2." | 9.09 | Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999) |
| "In inhibiting platelet function, aspirin seems to reduce the risk of cerebrovascular accidents, death, and acute coronary events in patients with nonrheumatic atrial fibrillation." | 9.09 | Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. ( Barriales, V; Posada, IS, 1999) |
| "In the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK 2) Study, we studied the rate of bleeding events associated with the incidence of thromboembolic events in patients receiving warfarin sodium, 1." | 9.09 | Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1999) |
| "To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction." | 9.09 | Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000) |
| "The Stroke Prevention in Atrial Fibrillation II study compared the efficacy and safety of aspirin and warfarin in patients with atrial fibrillation." | 9.08 | Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. ( Anderson, DC; Feinberg, WM; Hart, RG; Miller, VT; Pearce, LA; Rothrock, JF, 1996) |
| "Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF)." | 9.08 | Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. ( , 1996) |
| "The Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study was a randomized, controlled trial examining the following therapies: warfarin sodium, 1." | 9.08 | Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. ( Andersen, ED; Boysen, G; Godtfredsen, J; Gulløv, AL; Koefoed, BG; Pedersen, TS; Petersen, P, 1998) |
| "The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand." | 9.07 | A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation. ( Chaithiraphan, S; Opartkiattikul, N; Poungvarin, N; Viriyavejakul, A, 1994) |
| "Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation, but the value of this agent relative to aspirin in unclear." | 9.07 | Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. ( , 1994) |
| "The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) demonstrated that low-intensity warfarin anticoagulation can, with safety, sharply reduce the rate of stroke in patients with nonvalvular atrial fibrillation." | 9.07 | Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. ( Barzegar, S; Bauer, KA; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Millenson, MM; Oertel, LB; Sheehan, MA; Singer, DE, 1993) |
| "Although warfarin and perhaps aspirin may be effective in preventing thromboembolism in patients with nonvalvular atrial fibrillation, some patients develop cerebral infarction despite these therapies." | 9.07 | Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. ( Brace, LD; Helgason, CM; Hoff, JA; Kondos, GT, 1993) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 9.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| "Recent randomized trials have consistently demonstrated the marked efficacy of warfarin in reducing the risk of stroke caused by nonrheumatic atrial fibrillation." | 9.07 | The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1992) |
| "This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)." | 9.07 | Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. ( , 1992) |
| "Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring." | 9.06 | The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1990) |
| " Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%." | 8.87 | Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 8.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| " Although aspirin use seemed particularly effective in younger patients and in those with hypertension in the Stroke Prevention in Atrial Fibrillation 1 Study, this was not the case in the other studies." | 8.79 | The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. ( , 1997) |
| "The roles of heparin and warfarin in reducing morbidity and mortality after acute myocardial infarction (AMI) are reviewed." | 8.78 | Heparin and warfarin therapy after acute myocardial infarction. ( Sproat, TT; Yedinak, KC, 1993) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 8.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "56 patients had previously diagnosed atrial fibrillation; 82% were not taking warfarin and 71% of these were not on aspirin either." | 7.70 | Additional risk factors in atrial fibrillation patients not receiving warfarin. ( Caine, S; Keir, S; Mac Mahon, M; Wensley, S, 1999) |
| "To identify the clinical and radiologic features of intracerebral hemorrhage (ICH) in aspirin users." | 7.70 | Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. ( Chan, YL; Kay, R; Lam, WW; Mok, V; Tang, A; Wong, KS; Woo, J, 2000) |
| "To examine the cost-effectiveness of prescribing warfarin sodium in patients who have nonvalvular atrial fibrillation (NVAF) with or without additional stroke risk factors (a prior stroke or transient ischemic attack, diabetes, hypertension, or heart disease)." | 7.69 | Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. ( Albers, GW; Cardinalli, AB; Gage, BF; Owens, DK, 1995) |
| "The ability of platelets to synthesize thromboxane B2 (TxB2) from arachidonic acid (AA) or prostaglandin H2 (PGH2) was studied in 26 control subjects, 40 patients with essential hypertension, 20 patients with cerebrovascular disease (CVD) not taking aspirin and 11 patients with CVD taking aspirin." | 7.66 | Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. ( Imaizumi, M; Kayama, N; Matsumoto, M; Miyamoto, T; Nukada, T; Uyama, O; Yoneda, S, 1980) |
| "Between 1950 and 1975, 473 Rochester patients had the diagnosis of rheumatoid arthritis and received aspirin treatment." | 7.66 | Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. ( Fuster, V; Kurland, LT; Linos, A; O'Fallon, W; Whisnant, JP; Worthington, JW, 1978) |
| "Aspirin was better than placebo, safer than oral anticoagulants, and no different from clopidogrel." | 6.40 | Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? ( Patrono, C, 1998) |
| "Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo." | 6.39 | Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995) |
| "Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated." | 6.38 | Aspirin in the prevention of thrombosis. ( Bell, WR; Lekstrom, JA, 1991) |
| " All patients were randomly assigned to take aspirin 75 mg/day or placebo, and patients in the aspirin group had a 15% lower rate of major cardiovascular events and myocardial infarctions than did patients who received placebo." | 6.19 | Aggressive blood pressure lowering is safe, but benefit is still hard to prove. ( Pohl, MA; Vidt, DG, 1999) |
| "Seven randomized studies during the past 5 years have evaluated or are evaluating the efficacy of warfarin or aspirin or both in decreasing the risk of embolic events in patients with nonrheumatic atrial fibrillation." | 6.16 | How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. ( Cairns, J; Connolly, SJ; Gent, M; Joyner, C; Laupacis, A; Roberts, RS, 1991) |
| " Conditions characterized by a reduction in platelet survival and where dipyridamole has been used include heart valve replacement, arterial grafting, cerebrovascular disorders, and disorders of peripheral circulation." | 6.15 | Dipyridamole: a critical evaluation. ( Alexander, MR; Rivey, MP; Taylor, JW, 1984) |
| "Aspirin, which is an effective anti-platelet agent, given in the low dosage of 60 to 100 mg per day appears to be beneficial for patients with a history of unstable angina, myocardial infarction, transient ischaemic attacks and stroke." | 5.28 | Aspirin and coronary heart disease. Clinical applications. ( Koutts, J, 1990) |
| " We aimed to clarify the efficacy of rabeprazole for preventing peptic ulcer, esophagitis, and gastrointestinal symptoms associated with LDA." | 5.16 | Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. ( Azuma, T; Fujisawa, T; Fujita, T; Hayakumo, T; Inokuchi, H; Kawai, T; Kutsumi, H; Kuwayama, H; Matsubara, Y; Miyaji, H; Murakami, M; Sanuki, T; Terao, S; Yamazaki, Y; Yoshida, S, 2012) |
| "We compared baseline features and the rates of stroke or vascular death and stroke in the territory of the symptomatic artery between patients ON (n=299) versus OFF (n=269) antithrombotics at the time of their qualifying event for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. ( Chimowitz, MI; Cotsonis, G; Levine, SR; Lynn, MJ; Maidan, L; Romano, JG; Turan, TN, 2009) |
| "We evaluated the location, type (lacunar vs nonlacunar), cause, and severity of stroke in patients who had an ischemic stroke endpoint in the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. ( Chimowitz, MI; Famakin, BM; George, MG; Lynn, MJ; Stern, BJ, 2009) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 5.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe." | 5.12 | Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. ( Doi, Y; Fukuyama, T; Hiramori, K; Hori, M; Ishikawa, K; Izumi, T; Kitabatake, A; Maruyama, Y; Matsumoto, M; Mochizuki, S; Ogawa, S; Origasa, H; Sato, H; Takekoshi, N; Uchiyama, S; Yamaguchi, T; Yokota, Y; Yoshida, K, 2006) |
| "To investigate whether warfarin is more effective and superior to aspirin for the prevention of thromboembolism in nonvalvular atrial fibrillation in Chinese." | 5.12 | [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. ( Hu, DY; Jiang, LQ; Sun, YH; Zhang, HP, 2006) |
| "Aspirin is used commonly to prevent ischemic strokes and other vascular events." | 5.11 | Antiplatelet effect of aspirin in patients with cerebrovascular disease. ( Alberts, MJ; Bergman, DL; Jovanovic, BD; Molner, E; Teruya, J; Ushiwata, I, 2004) |
| " Although the dose of aspirin was not randomly assigned, the finding of increased bleeding with doses >162 mg/d is noteworthy." | 5.10 | Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. ( Amarenco, P; Califf, RM; Davis, S; Diener, HC; Easton, D; Ferguson, J; Fitzgerald, D; Graffagnino, C; Granett, J; Harrington, RA; Koudstaal, PJ; Pieper, K; Shuaib, A; Sigmon, K; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F; Willerson, JT, 2003) |
| " the level of blood pressure associated with the lowest incidence of major cardiovascular events such as fatal and non-fatal stroke and myocardial infarction and other cardiovascular mortality); and (2) to assess the effect of a low dose of acetylsalicylic acid (aspirin) compared with placebo on major cardiovascular events." | 5.09 | The Hypertension Optimal Treatment study and the importance of lowering blood pressure. ( Hansson, L, 1999) |
| "We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2." | 5.09 | Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999) |
| "In inhibiting platelet function, aspirin seems to reduce the risk of cerebrovascular accidents, death, and acute coronary events in patients with nonrheumatic atrial fibrillation." | 5.09 | Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. ( Barriales, V; Posada, IS, 1999) |
| "In the Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation (AFASAK 2) Study, we studied the rate of bleeding events associated with the incidence of thromboembolic events in patients receiving warfarin sodium, 1." | 5.09 | Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1999) |
| "A total of 287 patients from the SPAF III aspirin cohort study, in which patients with atrial fibrillation and a relatively low risk of stroke received 325 mg/d of aspirin and were followed up for a mean of 2 years." | 5.09 | A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. ( Biggs, J; Drake, E; Hart, RG; Laupacis, A; Man-Son-Hing, M; O'Connor, AM; Yetisir, E, 1999) |
| "Compared with aspirin, clopidogrel reduced the combined risk of ischaemic stroke, myocardial infarction or vascular death by 8." | 5.09 | Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Boissel, JP; Gent, M; Harker, LA; Pilgrim, AJ, 1999) |
| "To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction." | 5.09 | Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000) |
| "The Stroke Prevention in Atrial Fibrillation II study compared the efficacy and safety of aspirin and warfarin in patients with atrial fibrillation." | 5.08 | Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. ( Anderson, DC; Feinberg, WM; Hart, RG; Miller, VT; Pearce, LA; Rothrock, JF, 1996) |
| "The Stroke Prevention in Atrial Fibrillation II study compared warfarin vs aspirin for stroke prevention in atrial fibrillation." | 5.08 | Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. ( , 1996) |
| "Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF)." | 5.08 | Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. ( , 1996) |
| "The prothrombin time (expressed as the international normalized ratio [INR]) is the standard method of monitoring warfarin therapy in patients with atrial fibrillation." | 5.08 | Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. ( Bovill, EG; Cornell, ES; Feinberg, WM; Hart, RG; Nightingale, SD; Pearce, LA; Tracy, RP, 1997) |
| "The Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study was a randomized, controlled trial examining the following therapies: warfarin sodium, 1." | 5.08 | Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. ( Andersen, ED; Boysen, G; Godtfredsen, J; Gulløv, AL; Koefoed, BG; Pedersen, TS; Petersen, P, 1998) |
| "The comparative study of the efficacy of coumadin and aspirin in primary cardioembolic stroke prevention of chronic rheumatic heart disease (mitral stenosis) with atrial fibrillation was conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand." | 5.07 | A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation. ( Chaithiraphan, S; Opartkiattikul, N; Poungvarin, N; Viriyavejakul, A, 1994) |
| "Warfarin is an established treatment for prevention of ischaemic stroke in patients with atrial fibrillation, but the value of this agent relative to aspirin in unclear." | 5.07 | Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. ( , 1994) |
| "The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) demonstrated that low-intensity warfarin anticoagulation can, with safety, sharply reduce the rate of stroke in patients with nonvalvular atrial fibrillation." | 5.07 | Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators. ( Barzegar, S; Bauer, KA; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Millenson, MM; Oertel, LB; Sheehan, MA; Singer, DE, 1993) |
| "Although warfarin and perhaps aspirin may be effective in preventing thromboembolism in patients with nonvalvular atrial fibrillation, some patients develop cerebral infarction despite these therapies." | 5.07 | Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. ( Brace, LD; Helgason, CM; Hoff, JA; Kondos, GT, 1993) |
| "Mortality rates in this group were not significantly different for patients not taking aspirin as compared with the rates for those taking aspirin, although patients not taking aspirin had a higher incidence of myocardial infarction (27%) as compared with patients taking aspirin (8%), p < 0." | 5.07 | Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. ( Hobson, RW; Krupski, WC; Weiss, DG, 1993) |
| "We undertook a randomized controlled trial designed to compare the effects of carotid endarterectomy with medical treatment using low-dose aspirin in patients with asymptomatic carotid stenosis." | 5.07 | Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group. ( , 1992) |
| "Recent randomized trials have consistently demonstrated the marked efficacy of warfarin in reducing the risk of stroke caused by nonrheumatic atrial fibrillation." | 5.07 | The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1992) |
| "This report presents information on the effects of aspirin on mortality, the occurrence of cardiovascular events, and the incidence of kidney disease in the patients enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)." | 5.07 | Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. ( , 1992) |
| ") for secondary prevention of cerebral ischemia were compared with the effects of low-dosage aspirin (300 mg/die)." | 5.07 | [Clinical efficacy of picotamide]. ( de Falco, FA; Mastroroberto, G; Montariello, A; Visconti, OS, 1991) |
| "The Stroke Prevention in Atrial Fibrillation Study, a multicenter, randomized trial, compared 325 mg/day aspirin (double-blind) or warfarin with placebo for prevention of ischemic stroke and systemic embolism (primary events), and included 1,330 inpatients and outpatients with constant or intermittent atrial fibrillation." | 5.07 | Stroke Prevention in Atrial Fibrillation Study. Final results. ( , 1991) |
| "To evaluate the efficacy of low-dose aspirin in the primary prevention of myocardial infarction among patients with chronic stable angina." | 5.07 | Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. ( Buring, JE; Gaziano, JM; Hennekens, CH; Manson, JE; Ridker, PM, 1991) |
| "We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years." | 5.06 | European Stroke Prevention Study. ESPS Group. ( , 1990) |
| "Long-term low-dose warfarin therapy is highly effective in preventing stroke in patients with non-rheumatic atrial fibrillation, and can be quite safe with careful monitoring." | 5.06 | The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. ( Blewett, DR; Gress, DR; Hughes, RA; Kistler, JP; Maraventano, SW; Oertel, LB; Rosner, B; Sheehan, MA; Singer, DE, 1990) |
| "The Stroke Prevention in Atrial Fibrillation Study recently found and reported (SPAF Investigators, N Engl J Med, 1990;322:863-868) a beneficial effect of both warfarin and aspirin compared with placebo in the primary prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 5.06 | Progress report of the Stroke Prevention in Atrial Fibrillation Study. ( Anderson, DC, 1990) |
| "A six year randomised trial was conducted among 5139 apparently healthy male doctors to see whether 500 mg aspirin daily would reduce the incidence of and mortality from stroke, myocardial infarction, or other vascular conditions." | 5.06 | Randomised trial of prophylactic daily aspirin in British male doctors. ( Collins, R; Gray, R; Hafner, B; Hennekens, C; Jamrozik, K; Norton, S; Peto, R; Thompson, E; Warlow, C; Wheatley, K, 1988) |
| "The efficacy and safety of a combination of Persantine and aspirin, of aspirin alone and of a placebo as a regimen for preventing reinfarction were compared in 2026 patients who had recovered from a documented acute myocardial infarction (MI) that had occurred 8 weeks to 5 years previously." | 5.05 | The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group. ( , 1980) |
| " These trials were prompted by earlier observations that aspirin takers seemed to fare better after acute myocardial infarction and were further stimulated by the recent growth of knowledge about the role of vascular and platelet prostaglandins." | 5.05 | Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials. ( Castaldi, PA, 1981) |
| " centers, 231 male diabetic patients who had either a recent amputation for gangrene (N = 207) or active gangrene (N = 24) were randomly assigned to a group which received aspirin (325 mg t." | 5.05 | V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics. ( Abraira, C; Anderson, JW; Bingham, SF; Colwell, JA; Kwaan, HC, 1985) |
| "In the overall population, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in comparison to aspirin monotherapy reduced the relative risk of total stroke by 20% (risk ratio [RR], 0." | 4.90 | Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. ( Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M, 2014) |
| " Recent randomized controlled trials in patients who are at moderately increased risk of ulcers have shown that the proton pump inhibitor esomeprazole (the S-isomer of racemic omeprazole) reduces the gastroduodenal ulcer incidence by approximately 70-85% and the gastrointestinal bleeding risk by as much as 90%." | 4.87 | Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid. ( Yeomans, ND, 2011) |
| "Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004." | 4.82 | Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. ( Anand, SS; Tran, H, 2004) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 4.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| " The search terms used were dipyridamole, aspirin, acetylsalicylic acid, ischemic stroke, and cerebrovascular disorders." | 4.81 | Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke. ( Redman, AR; Ryan, GJ, 2001) |
| "To review and evaluate the evidence supporting the use of warfarin and/or aspirin for stroke prevention in patients with atrial fibrillation." | 4.80 | Preventing stroke in patients with atrial fibrillation. ( Ezekowitz, MD; Levine, JA, 1999) |
| "A recent analysis of the literature, published in the 19 May issue of the JAMA, once again demonstrates the efficacy of warfarin, and its superiority on aspirin, in preventing stroke in patients with atrial fibrillation, at least in subjects at highest risk." | 4.80 | [Clinical study of the month. Prevention of cerebral vascular accidents in patients with atrial fibrillation]. ( Scheen, AJ, 1999) |
| " The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events." | 4.80 | Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. ( Boysen, G, 1999) |
| "Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin." | 4.80 | Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. ( Benavente, O; Hart, RG; McBride, R; Pearce, LA, 1999) |
| " (1) Proven: one or more TIAs in the past 6 months and carotid stenosis > or = 70% or mild stroke within 6 months and a carotid stenosis > or = 70%; (2) acceptable but not proven: TIAs within the past 6 months and a stenosis 50% to 69%, progressive stroke and a stenosis > or = 70%, mild or moderate stroke in the past 6 months and a stenosis 50% to 69%, or carotid endarterectomy ipsilateral to TIAs and a stenosis > or = 70% combined with required coronary artery bypass grafting; (3) uncertain: TIAs with a stenosis < 50%, mild stroke and stenosis < 50%, TIAs with a stenosis < 70% combined with coronary artery bypass grafting, or symptomatic, acute carotid thrombosis; (4) proven inappropriate: moderate stroke with stenosis < 50%, not on aspirin; single TIA, < 50% stenosis, not on aspirin; high-risk patient with multiple TIAs, not on aspirin, stenosis < 50%; high-risk patient, mild or moderate stroke, stenosis < 50%, not on aspirin; global ischemic symptoms with stenosis < 50%; acute dissection, asymptomatic on heparin." | 4.79 | Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association. ( Barnett, HJ; Beebe, HG; Bernstein, EF; Brener, BJ; Brott, T; Caplan, LR; Day, A; Goldstone, J; Hobson, RW; Moore, WS, 1995) |
| "English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders." | 4.79 | Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994) |
| "In these five randomized trials warfarin consistently decreased the risk of stroke in patients with atrial fibrillation (a 68% reduction in risk) with virtually no increase in the frequency of major bleeding." | 4.79 | Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. ( , 1994) |
| "Antithrombotic prophylaxis with long term warfarin or aspirin reduces thromboembolic risk in atrial fibrillation." | 4.79 | ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. ( Lip, GY; Lowe, GD, 1996) |
| "Warfarin prophylaxis in patients with nonvalvular atrial fibrillation may be one of the most valuable public-health interventions." | 4.79 | Stroke prevention: the emerging strategies. ( Matchar, DB; McCrory, DC, 1996) |
| "A vast consensus exists in defining a narrow range of recommended daily doses of aspirin, ie, 75 to 160 mg, for the prevention of myocardial infarction, stroke, and vascular death in patients with different manifestations of coronary hearth disease." | 4.79 | Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? ( Patrono, C; Roth, GJ, 1996) |
| "Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely." | 4.79 | Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. ( Appleby, P; Baigent, C; Collins, R; Flather, M; Godwin, J; MacMahon, S; Mortensen, S; Peto, R; Remvig, L; Yusuf, S, 1996) |
| " Although aspirin use seemed particularly effective in younger patients and in those with hypertension in the Stroke Prevention in Atrial Fibrillation 1 Study, this was not the case in the other studies." | 4.79 | The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. ( , 1997) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 4.79 | Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997) |
| "The roles of heparin and warfarin in reducing morbidity and mortality after acute myocardial infarction (AMI) are reviewed." | 4.78 | Heparin and warfarin therapy after acute myocardial infarction. ( Sproat, TT; Yedinak, KC, 1993) |
| " Patients with rheumatic heart disease complicated by atrial fibrillation should receive long-term warfarin therapy to reduce the risk of stroke unless an absolute contraindication exists." | 4.78 | Anticoagulant therapy for atrial fibrillation. Recommendations from major studies. ( Kahn, JK, 1992) |
| "A wide array of clinical trials over the past two decades has established that aspirin is indicated to prevent myocardial infarction in patients with clinically evident coronary artery disease, and to prevent stroke in patients with a history of stroke or TIAs." | 4.78 | Prophylactic aspirin and the elderly population. ( Dalen, JE; Goldberg, RJ, 1992) |
| "Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score." | 4.12 | Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. ( Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H, 2022) |
| " We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease." | 4.02 | Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. ( Bálint, A; El Alaoui El Abdallaoui, O; Komócsi, A; Kupó, P; Tornyos, D, 2021) |
| "In the COMPASS trial, combined aspirin and rivaroxaban treatment reduced ischaemic events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD)." | 3.91 | External applicability of the COMPASS trial: the Western Denmark Heart Registry. ( Eikelboom, JW; Kristensen, SD; Maeng, M; Olesen, KKW; Thim, T; Würtz, M, 2019) |
| " Dual antiplatelet therapy or at least aspirin is recommended to be continued considering the relative risk of stent thrombosis especially during the 4 weeks after DES implantation." | 3.85 | Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents. ( Bahk, JH; Jung, DE; Jung, SA; Kim, WH; Park, SK, 2017) |
| "A growing body of evidence indicates that use of low-dose aspirin (LDA) reduces the risk of certain adenocarcinomas." | 3.83 | Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. ( Cancian, M; Cricelli, C; Cricelli, I; Lapi, F; Levi, M; Parretti, D; Simonetti, M; Sobrero, A, 2016) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| " These results indicate that clopidogrel is more effective and safer than aspirin in reducing adverse cardiovascular events in patients with atherosclerosis." | 3.79 | Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. ( Creager, MA, 1998) |
| "Data obtained in this study suggest a suboptimal clopidogrel response in patients with greater body weight and body mass index." | 3.77 | Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. ( Alexander, MJ; Choulakian, A; Drazin, D; Kornbluth, P; Nuño, M, 2011) |
| "Patients who have had a recent transient ischemic attack (TIA) are at high risk for subsequent stroke." | 3.77 | Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly. ( Adams, HP; Gordon, DL, 1991) |
| "Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent." | 3.75 | Sulfinpyrazone: a review of its pharmacological properties and therapeutic use. ( Margulies, EH; Sherry, S; White, AM, 1980) |
| "Data from the Aspirin in Transient Ischemic Attack (AITIA) study, an ongoing study of two platelet antiaggregant drugs, and other published therapeutic trials were reviewed to determine whether the severity of stroke is reduced in patients taking platelet antiaggregants." | 3.75 | Does platelet antiaggregant therapy lessen the severity of stroke? ( Fields, WS; Gary, H; Grotta, JC; Lemak, NA; Vital, D, 1985) |
| "We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI)." | 3.74 | Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. ( Bauer, T; Gitt, A; Gottwik, M; Heer, T; Jünger, C; Koeth, O; Mark, B; Senges, J; Zahn, R; Zeymer, U, 2008) |
| "Our findings do not concur with the hypothesis that aspirin, dipyridamole, or the combination may be especially effective in preventing vascular events in patients with previous cerebral ischemia that was caused by LVD compared with SVD." | 3.73 | Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. ( Algra, A; Ariesen, MJ; Kappelle, LJ, 2006) |
| "Our results conclude that 10% decrease in body mass index (BMI) among overweight patients, smoking cessation, initiation to undertake a preventive treatment with low-dose aspirin, initiation to undertake or intensify blood pressure control, initiation to undertake or intensify lipidic control, and shift to biguanides among overweight patients are factors associated with significant benefits (avoided costs) which compensate for the increase in treatment costs." | 3.73 | [Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. ( Crainich, D; Lebrun, T; Marissal, JP; Sailly, JC, 2005) |
| "The rapid and significant decline of MES in our stroke and TIA patients suggests the possible efficacy of dual antiplatelet therapy with aspirin and clopidogrel in patients with MES and symptomatic large-artery occlusive disease." | 3.73 | Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases. ( Chang, HM; Chen, CL; Esagunde, RU; Gan, HY; Lee, MP; Wong, KS; Wong, MC, 2006) |
| " He received 325 mg of aspirin daily for at least 6 years, suffered an AMI, and was successfully reperfused with alteplase, but after 44 hours developed a large hemorrhagic stroke resulting in paraplegia." | 3.70 | Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. ( Bahr, RD; Dalesandro, MR; Grabletz, LB; Gumbs, CI; Gurbel, PA; Ohman, EM; Serebruany, VL; Shustov, AR; Topol, EJ, 1998) |
| ", age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with beta-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin." | 3.70 | Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival. ( Gibbs, NM; Mahon, BD; Newman, MA; Sheminant, MR; Weightman, WM; Whitford, EG, 1999) |
| "We performed neurologic examinations and reviewed medical records to investigate the effects of a clinical diagnosis of dementia and other potentially relevant factors on treatment with aspirin or warfarin at hospital discharge." | 3.70 | Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. ( Desmond, DW; Mohr, JP; Moroney, JT; Paik, MC; Tseng, CL, 1999) |
| "Several recent randomized clinical trials have demonstrated that warfarin sodium treatment, and to a lesser extent aspirin, reduces risk of stroke and death compared with placebo in persons with atrial fibrillation." | 3.70 | Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. ( Furberg, CD; Lima, JA; Manolio, TA; Newman, AB; Psaty, BM; Smith, NL; White, R, 1999) |
| "56 patients had previously diagnosed atrial fibrillation; 82% were not taking warfarin and 71% of these were not on aspirin either." | 3.70 | Additional risk factors in atrial fibrillation patients not receiving warfarin. ( Caine, S; Keir, S; Mac Mahon, M; Wensley, S, 1999) |
| "These prospective data indicate that women who take 1 to 6 aspirin per week have a reduced risk of large-artery occlusive infarction, but those who use 15 or more aspirin per week have an increased risk of subarachnoid hemorrhage." | 3.70 | Prospective study of aspirin use and risk of stroke in women. ( Colditz, GA; Hennekens, CH; Iso, H; Manson, JE; Rexrode, KM; Speizer, FE; Stampfer, MJ; Willett, WC, 1999) |
| "To identify the clinical and radiologic features of intracerebral hemorrhage (ICH) in aspirin users." | 3.70 | Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. ( Chan, YL; Kay, R; Lam, WW; Mok, V; Tang, A; Wong, KS; Woo, J, 2000) |
| "To examine the cost-effectiveness of prescribing warfarin sodium in patients who have nonvalvular atrial fibrillation (NVAF) with or without additional stroke risk factors (a prior stroke or transient ischemic attack, diabetes, hypertension, or heart disease)." | 3.69 | Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. ( Albers, GW; Cardinalli, AB; Gage, BF; Owens, DK, 1995) |
| "To assess the risk of bleeding complications in patients treated with combination aspirin and heparin for cerebral ischemia." | 3.69 | Safety of combination aspirin and anticoagulation in acute ischemic stroke. ( Fagan, SC; Kertland, HR; Tietjen, GE, 1994) |
| "Elevated levels of plasma fibrinogen are a risk factor for cerebral infarction." | 3.69 | Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin. ( Kashiwaya, M; Takahashi, H; Tohgi, H; Watanabe, K, 1994) |
| "After reviewing these published studies, I think one can conclude that in the patient population with chronic and/or paroxysmal atrial fibrillation, warfarin is beneficial and the benefits outweigh the risks." | 3.68 | Stroke and atrial fibrillation: to anticoagulate or not. ( Conti, CR, 1993) |
| "To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population." | 3.68 | Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. ( Asplund, K; Britton, M; Gustafsson, C; Marké, LA; Norrving, B; Olsson, B, 1992) |
| "During a 1-year period, we prospectively studied the mechanism and severity of stroke in 47 patients sustaining a cerebral infarction while taking aspirin." | 3.68 | Mechanism of stroke in patients taking aspirin. ( Chimowitz, MI; Furlan, AJ; Nayak, S; Sila, CA, 1990) |
| "Anti-platelet therapy (Aspirin 250 mg/every other day approximately 1000 mg/day + Dipyridamole 150 mg/day) was performed on 51 patients with ischemic cerebrovascular disorders (ICVD)." | 3.67 | [Anti-platelet therapy in ischemic cerebrovascular disorder--clinical and hematological study]. ( Aiba, T; Seki, Y; Shiozawa, R; Tsukada, T; Yoshii, K, 1985) |
| "The ability of platelets to synthesize thromboxane B2 (TxB2) from arachidonic acid (AA) or prostaglandin H2 (PGH2) was studied in 26 control subjects, 40 patients with essential hypertension, 20 patients with cerebrovascular disease (CVD) not taking aspirin and 11 patients with CVD taking aspirin." | 3.66 | Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. ( Imaizumi, M; Kayama, N; Matsumoto, M; Miyamoto, T; Nukada, T; Uyama, O; Yoneda, S, 1980) |
| "Between 1950 and 1975, 473 Rochester patients had the diagnosis of rheumatoid arthritis and received aspirin treatment." | 3.66 | Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. ( Fuster, V; Kurland, LT; Linos, A; O'Fallon, W; Whisnant, JP; Worthington, JW, 1978) |
| " Since 1968 the antithrombotic activity of Aspirin has been under study, and Aspirin has proven effective in preventing arterial thrombosis." | 3.65 | [Ovulation inhibitors from a neurological viewpoint]. ( Gschwend, J, 1976) |
| "Aspirin resistance was defined as ARU > 550, whereas clopidogrel resistance was defined as percentage platelet inhibition < 40%." | 2.73 | Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. ( Flaherty, CA; Lee, VH; Lopes, DK; Prabhakaran, S; Wells, KR, 2008) |
| "To investigate the effect of removing phlegm and dispelling stasis method (RPDSM) combined with Western medicine for treatment of cerebrovascular stenosis." | 2.73 | [Removing phlegm and dispelling stasis method combined with Western medicine for treatment of cerebrovascular stenosis]. ( Gao, L; Liu, Q; Wang, PP, 2008) |
| "The MCA stenosis was demonstrated by conventional angiography or by at least two noninvasive examinations." | 2.72 | Aspirin or anticoagulants in stenosis of the middle cerebral artery: A randomized trial. ( Belvís, R; Bravo, Y; Castellanos, M; Cocho, D; Egido, J; Geffner, D; Gich, I; Gil-Núñez, A; Marta, J; Martí-Fàbregas, J; Martí-Vilalta, JL; Millán, M; Navarro, R; Obach, V; Palomeras, E; Rodríguez-Campello, A, 2006) |
| "Study of the tolerance and pharmacodynamic and pharmacokinetic characteristics of ascolong, a new buccal dosage form of aspirin containing a very low dose of acetylsalicylic acid (ASA): 12." | 2.69 | [Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and antiaggregant]. ( Belolipetskaia, VG; Bochkareva, EV; Davydo, AB; Deev, AD; Demina, EG; Gorin, NN; Ionova, VG; Khromov, GL; Kokurina, EV; Kucheriaeva, NG; Metelitsa, VI; Rumiantsev, DO; Suslina, ZA; Tanashian, MM; Zidra, SI, 1998) |
| "Aspirin use at entry was also associated with a 4-fold (95% CI, 1." | 2.69 | Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group. ( Beauchamp, NJ; Hart, RG; Kronmal, RA; Manolio, TA; Newman, A; Talbert, RL, 1998) |
| "We studied 68 patients with 50% to 99% stenosis of one of the following arteries: intracranial vertebral (n = 31), basilar (n = 28), posterior cerebral (PCA) (n = 6), or posterior inferior cerebellar (PICA) (n = 3)." | 2.69 | Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. ( , 1998) |
| "Dipyridamole was associated with a slight increase in headache, which resolved in most patients if therapy was continued." | 2.69 | Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. ( Forbes, CD, 1998) |
| "Nine patients with recent transient ischemic attack or minor stroke of arterial origin were investigated." | 2.69 | Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid. ( Baeumer, M; Blaser, T; Goertler, M; Jost, S; Kross, R; Lutze, G; Wallesch, CW, 1999) |
| " Two patients in the 100 mg/kg group had adverse events that were possibly drug related: one suffered fatal brain and pulmonary edema, the other transient renal and pancreatic insufficiency." | 2.69 | Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. ( Carton, H; Hacke, W; Kaste, M; Koudstaal, PJ; Przybelski, RJ; Saxena, R; Stern, KN; Wijnhoud, AD, 1999) |
| "Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed." | 2.69 | Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. ( Alberts, MJ; Berdan, LG; Califf, RM; Deckers, J; Graffagnino, C; Granger, CB; Harrington, RA; Laskowitz, DT; Lincoff, AM; MacAulay, CM; Mahaffey, KW; Miller, JM; Simoons, ML; Sloan, MA; Topol, EJ, 1999) |
| "Patients with 50 to 99% stenosis of an intracranial artery (carotid; anterior, middle, or posterior cerebral; vertebral; or basilar) were identified by reviewing the results of consecutive angiograms performed at participating centers between 1985 and 1991." | 2.68 | The Warfarin-Aspirin Symptomatic Intracranial Disease Study. ( Brown, MB; Chimowitz, MI; Furlan, AJ; Kokkinos, J; Levine, SR; Pessin, MS; Sila, CA; Silliman, S; Strong, J; Weichel, E, 1995) |
| "Physicians reporting migraine (n = 1479) had significantly increased risks of subsequent total stroke and ischemic stroke compared with those not reporting migraine." | 2.68 | Migraine and subsequent risk of stroke in the Physicians' Health Study. ( Buring, JE; Cook, N; Hebert, P; Hennekens, C; Kittross, A; Manson, J; Peto, R; Romero, J, 1995) |
| " Twenty-six patients were dosed for 2 weeks, 300 mg aspirin once daily and then for 2 weeks, 250 mg ticlopidine twice daily." | 2.68 | Asymptomatic circulating cerebral emboli and cerebral blood flow velocity under aspirin and ticlopidine in patients with cerebrovascular disease. ( Droste, DW; Kaps, M; Siemens, HJ; Sonne, M, 1996) |
| "Patients with prior stroke or transient ischemic attack (TIA) were randomized to treatment with ASA alone (50 mg daily), modified-release dipyridamole alone (400 mg daily), the two agents in a combined formulation, or placebo." | 2.68 | European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. ( Cunha, L; Diener, HC; Forbes, C; Lowenthal, A; Sivenius, J; Smets, P, 1996) |
| "Hypertension is associated with an increased risk of myocardial infarction, and borderline isolated systolic hypertension predicts a possible but more modest increase in risk." | 2.68 | Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. ( Ajani, U; Berger, K; Glynn, RJ; Hennekens, CH; Manson, JE; O'Donnell, CJ; Ridker, PM, 1997) |
| "Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction." | 2.68 | [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996) |
| "Aspirin was associated with a significant excess of 5 (SD 1) transfused or fatal extracranial bleeds per 1000; in the absence of heparin the excess was 2 (SD 1) and was not significant." | 2.68 | The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. ( , 1997) |
| "Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients." | 2.67 | Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. ( , 1993) |
| "Carotid stenosis was confirmed by arteriography, which demonstrated at least 50% stenosis, measured by comparing the least transverse diameter of the stenosis on lateral arteriography." | 2.67 | 4. Current status of operative treatment for asymptomatic carotid stenosis. ( Hobson, RW; Towne, JB, 1994) |
| "Aspirin-treated subjects had a significant decrease in mean hemoglobin levels of 0." | 2.67 | Adverse effects of low-dose aspirin in a healthy elderly population. ( Campion, K; Donnan, GA; McNeil, JJ; Silagy, CA; Tonkin, AM; Worsam, B, 1993) |
| "048), and the frequency of adverse events was not significantly different between the two treatment groups." | 2.67 | The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. ( Weisberg, LA, 1993) |
| "Ticlopidine has not been formally compared with aspirin in patients with a completed stroke." | 2.67 | Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. ( Harbison, JW, 1992) |
| "The CASANOVA study (Carotid Artery Stenosis with Asymptomatic Narrowing: Operation Versus Aspirin) is a multicenter trial in 410 patients with asymptomatic stenosis (50-90%) of the internal carotid artery who were randomized after angiography." | 2.67 | Carotid surgery versus medical therapy in asymptomatic carotid stenosis. The CASANOVA Study Group. ( , 1991) |
| "The aspirin component was terminated earlier than scheduled, and the preliminary findings were published." | 2.66 | Final report on the aspirin component of the ongoing Physicians' Health Study. ( , 1989) |
| "Ticlopidine was more effective than aspirin in both sexes." | 2.66 | A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. ( Adams, HP; Anderson, S; Easton, JD; Hass, WK; Kamm, B; Molony, BA; Pryse-Phillips, W, 1989) |
| "The efficacy of treatment of cerebrovascular disorders is difficult to establish." | 2.66 | [Recovery following CVA: caused by effective therapy or by the natural course of the disease?]. ( Vermeulen, M, 1987) |
| "The aspirin effect was the same across all risk-factor groups." | 2.66 | Controlled trial of aspirin in cerebral ischemia: an addendum. ( Fields, WS; Gary, HE; Lemak, NA, 1986) |
| "Of 303 patients who had carotid transient ischemic attacks (TIAs), 125 were selected for carotid reconstructive surgery and were then randomly assigned treatment with aspirin or placebo." | 2.65 | Controlled trial of aspirin in cerebral ischemia. ( Bigelow, RH; Fields, WS; Frankowski, RF; Hardy, RJ; Lemak, NA, 1980) |
| "Treatment with aspirin alone ranked with high values both for primary and secondary endpoints (surface under the cumulative ranking curve of 70% and 82%, respectively)." | 2.61 | Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis. ( Agostoni, E; Consoli, A; Consoli, D; Grampa, G; Vidale, S, 2019) |
| " Since the optimal dose of ASA for primary and secondary prevention of events in the broad population is uncertain, dosing considerations should include an evaluation of a patient's individual clinical status as well as an overall cardiovascular and cerebrovascular benefit vs." | 2.43 | The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. ( Fisher, M; Knappertz, V, 2006) |
| "Aspirin reduced all-cause mortality by 18%." | 2.41 | Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. ( Graham, DY; Weisman, SM, 2002) |
| "Aspirin treatment appears to be strongly indicated." | 2.41 | Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. ( Bhatt, DL; Kapadia, SR; Topol, EJ; Yadav, JS, 2000) |
| "Aspirin has a modest effect on reducing stroke (about 20% risk reduction)." | 2.40 | Prevention of stroke in patients with nonvalvular atrial fibrillation. ( Cairns, JA; Easton, JD; Hart, RG; Sherman, DG, 1998) |
| "Aspirin was better than placebo, safer than oral anticoagulants, and no different from clopidogrel." | 2.40 | Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? ( Patrono, C, 1998) |
| "Aspirin has remained the pharmacologic foundation of stroke prevention, primarily because of its low cost." | 2.40 | Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease. ( Harbison, JW, 1998) |
| " This review article examines research on both monotherapy and combination antiplatelet therapy for secondary stroke prevention, with an emphasis on lessons learned about dosage schedules, treatment protocols, and side-effect profiles." | 2.40 | Antiplatelet therapy for secondary stroke prevention. ( Forbes, CD, 1999) |
| " To evaluate the dose-response relationship, we conducted a metaregression analysis of study-specific risk ratios by means of weighted linear regression." | 2.40 | A metaregression analysis of the dose-response effect of aspirin on stroke. ( Abebe, BL; Dicker, LW; Johnson, ES; Lanes, SF; Satterfield, MH; Wentworth, CE, 1999) |
| "Aspirin was first discovered to have antiplatelet properties 30 years ago and since then many randomised clinical trials have sought to determine whether it (or other antiplatelet agents) can protect patients from heart attack or stroke." | 2.39 | Aspirin to prevent heart attack or stroke. ( , 1994) |
| "Thirty-six randomized control trials of aspirin compared with another dosage of aspirin or with placebo." | 2.39 | Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. ( Cappelleri, JC; Chalmers, TC; Kupelnick, B; Lau, J, 1995) |
| " Furthermore, in assessing the potential benefits of long-term use of ASA for prophylactic purposes in these patients, one should also evaluate the side-effects and intolerance related to its chronic use, as well as its potential complications especially from a gastrointestinal perspective." | 2.39 | Aspirin in asymptomatic carotid disease. ( Côté, R, 1994) |
| " Acetylsalicylic acid is the first choice medical treatment, but the optimal dosage is still a matter of debate." | 2.39 | [Large trials in the secondary prevention of stroke]. ( Gensini, GF; Inzitari, D; Pantoni, L; Simone, I, 1996) |
| " In cases with severe cardiac disease, however, a high dosage of ASA or anticoagulation therapy may be necessary to prevent further vascular events." | 2.38 | [Low dose acetylsalicylic acid in secondary prevention of stroke]. ( Deecke, L; Zeiler, K, 1993) |
| " Women presenting with unstable angina or myocardial infarction should receive aspirin 325 mg as soon as the diagnosis is confirmed, and this dosage should be continued on a chronic basis." | 2.38 | Aspirin for the prevention of vascular death in women. ( Corn, CR; Hamilton, SF; McAnally, LE, 1992) |
| "Ticlopidine was more effective than aspirin in reducing stroke in both males and females." | 2.38 | Antiplatelet therapy in the prevention of stroke. ( Easton, JD, 1991) |
| "Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated." | 2.38 | Aspirin in the prevention of thrombosis. ( Bell, WR; Lekstrom, JA, 1991) |
| " Clinical information is available in the literature concerning aspirin dosage and stroke prevention following transient ischemic attack (TIA)." | 2.38 | Aspirin and stroke prevention: how much? ( Toffol, GJ, 1990) |
| "Transient ischemic attacks are associated with a 30 to 35 percent risk of stroke within five years of the initial episode." | 2.37 | Carotid surgery in stroke prevention. ( Busuttil, RW; Sheng, FC, 1986) |
| "Aspirin has been shown in clinical trials to be an effective agent in treating transient ischemic attacks and preventing infarction." | 2.36 | Aspirin for prevention of stroke: a review. ( Fields, WS, 1983) |
| "Aspirin was started, and there was no subsequent recurrence." | 1.91 | Progressive arteriopathy with vasospasm in focal cerebral arteriopathy in childhood: a case report. ( Fujii, N; Hasegawa, S; Inoue, H; Ishihara, H; Nishimoto, T; Nomura, S; Oka, F; Yamane, M, 2023) |
| "Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2." | 1.72 | Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022) |
| "To analyze the significance of ezetimibe in combination with low- to moderate-intensity atorvastatin adjuvant aspirin therapy for cerebrovascular disease." | 1.72 | Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease. ( Tang, X; Wang, L, 2022) |
| "No recurrences were registered in the polypill group, compared to 1 recurrence in the conventional treatment group." | 1.56 | Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. ( Alonso-Canovas, A; Chico-García, JL; Cruz-Culebras, A; de Felipe Mimbrera, A; García-Madrona, S; Gómez-López, A; Masjuan, J; Matute-Lozano, C; Natera-Villalba, E; Ros-Castelló, V; Sánchez-Sánchez, A; Vera-Lechuga, R, 2020) |
| "56%) was the most common triple Western medicine therapy, often combined with antibiotics and blood stasis drugs in use." | 1.46 | [Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world]. ( Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y, 2017) |
| "Few large studies have evaluated the adverse events associated with therapeutic colonoscopy for colorectal neoplasia, including bleeding and bowel perforation." | 1.43 | Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan. ( Fushimi, K; Hirata, Y; Koike, K; Matsui, H; Niikura, R; Yamada, A; Yasunaga, H, 2016) |
| "Measuring platelet thrombus formation (PTF) for evaluating antiplatelet effects was assessed." | 1.43 | Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. ( Hosokawa, K; Kawashima, A; Kitagawa, K; Ohnishi, T; Okada, Y; Uchiyama, S; Yamaguchi, K; Yamazaki, M; Yoneyama, T, 2016) |
| "Aspirin is the key treatment in the secondary prevention of atherothrombosis." | 1.42 | Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy. ( Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S, 2015) |
| "Aspirin-sensitivity was indicated by the absence of either of these criteria; aspirinsensitivity was indicated as both criteria being met." | 1.38 | [Prevalence of laboratory aspirin resistance in 431 old patients]. ( Cao, J; Fan, L; Hu, G; Hu, Y; Li, X; Liu, L; Wang, Q; Wang, Y; Wu, R, 2012) |
| "Cilostazol is an antiplatelet drug often used in Asia; however, it is rarely used in the western hemisphere, particularly for stroke patients." | 1.37 | Cilostazol: a drug particularly effective for Asians? ( Kim, JS; Shinohara, Y, 2011) |
| "'Aspirin resistance' is a poorly defined term to describe the inability of aspirin to protect individuals from thrombotic complications and there are conflicting reports on incidence rates and clinical relevance of this phenomenon." | 1.31 | Towards a definition of aspirin resistance: a typological approach. ( Hohlfeld, T; Przytulski, B; Schanz, A; Schrör, K; Weber, AA, 2002) |
| "History of untreated hypertension prior to the initial stroke (RR = 1." | 1.30 | Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study. ( Baranska-Gieruszczak, M; Czlonkowska, A; Hier, DB; Lechowicz, W; Ryglewicz, D, 1997) |
| "Aspirin-treated and non-aspirin-treated patients did not differ in stroke severity." | 1.30 | Does daily aspirin diminish severity of first-ever stroke? ( Bornstein, NM; Hass, Y; Karepov, V; Korczyn, AD, 1997) |
| "Treatment with aspirin was associated with a significant reduction in cardiac and total mortality among non-insulin-dependent diabetic patients with coronary artery disease." | 1.30 | Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. ( Behar, S; Boyko, V; Gottlieb, S; Graff, E; Harpaz, D; Kishon, Y, 1998) |
| "Treatment with aspirin led to a significant decrease in membrane fluidity in both patients and old controls, but had no apparent effect on the platelet membrane fluidity of younger controls." | 1.29 | Aspirin-induced conformational changes in platelet membrane in subjects with stroke. ( Hasan, M; Jackson, SK; Sinclair, AJ, 1995) |
| " Of the 52 with partial inhibition at initial testing, 35 achieved complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or fluctuation of response at the same dosage, but 8 of those 35 (22." | 1.29 | Development of aspirin resistance in persons with previous ischemic stroke. ( Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994) |
| "Ticlopidine hydrochloride is an antiplatelet agent of proven antithrombotic efficacy that in December 1991 became available for general clinical use in the United States." | 1.29 | Ticlopidine hydrochloride use and threatened stroke. ( Hart, RG; Rothrock, JF, 1994) |
| "Aspirin was usually chosen after initial brain ischemia." | 1.29 | Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. ( Furlan, AJ; Hanna, JP; Sila, CA; Stewart, WJ; Sun, JP; Tan, M, 1994) |
| "To determine whether anticoagulation practices have changed when heparin and warfarin are used to treat cerebrovascular disease, and to determine the dosage of aspirin used to treat carotid territory transient ischemic attacks (TIAs)." | 1.29 | A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. ( Alberts, MJ; Dawson, DV; Massey, EW, 1994) |
| "Aspirin was reported to be prescribed routinely by 75% (95/126) of physicians for patients with completed stroke." | 1.29 | Consultant views on the use of aspirin in acute cerebrovascular disease: implications for clinical trials. ( Bamford, J; Kent, J, 1994) |
| "However, their effects on thrombus formation have rarely been evaluated in experimental animals in vivo." | 1.29 | In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. ( Iwamoto, Y; Naritomi, H; Nishimura, H; Sugita, M; Tachibana, H, 1996) |
| "Advanced age, previous stroke or transient ischemic attack (TIA), hypertension and diabetes were all found to be risk factors for stroke in patients with atrial fibrillation." | 1.29 | [Atrial fibrillation and apoplexy--risks and prevention]. ( Gulløv, AL; Koefoed, BG; Petersen, P, 1996) |
| "The efficacy and safety of thrombolysis with different dose regimens of recombinant tissue plasminogen activator (rt-PA) and its combination with aspirin was tested in an embolic stroke model." | 1.28 | Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model. ( Boysen, G; Overgaard, K; Pedersen, H; Sereghy, T, 1992) |
| " Therefore, the authors recommend 50 mg/d as the optimal dosage for low dose aspirin therapy in geriatric patients." | 1.28 | Optimal low dosage of acetylsalicylic acid (ASA) for the prevention and treatment of ischemic cerebrovascular disease in geriatric patients. ( Li, CF; Li, H; Luo, Y; Ma, ZZ; Tang, HC; Yin, ZJ, 1992) |
| "Ticlopidine was more effective in patients without carotid stenosis." | 1.28 | Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup. ( Grotta, JC; Kamm, B; Norris, JW, 1992) |
| "Cerebrovascular insufficiency is an uncommon but serious complication of cervical spinal manipulation, which can lead to posterior circulatory impairment." | 1.28 | Cerebral stroke in a semi-pro football player: a case report. ( Cantu, RC; Weinstein, SM, 1991) |
| " Additional administration of metoclopramide in combination with 100 mg ASA was more effective as compared to a single dosage of 1000 mg ASA." | 1.28 | Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. ( Grotemeyer, KH, 1991) |
| "Aspirin was used by 91 physicians (36." | 1.28 | Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. ( Kutner, M; Nixon, G; Silverstone, F, 1991) |
| "Aspirin has been successfully used in the secondary prophylaxis of myocardial infarction, cerebral vascular events and peripheral arterial disease." | 1.28 | [Aspirin against aging? For whom and how much?]. ( Meier, PJ; Oelz, O, 1990) |
| "Aspirin, which is an effective anti-platelet agent, given in the low dosage of 60 to 100 mg per day appears to be beneficial for patients with a history of unstable angina, myocardial infarction, transient ischaemic attacks and stroke." | 1.28 | Aspirin and coronary heart disease. Clinical applications. ( Koutts, J, 1990) |
| "Aspirin/dipyridamole-treated patients failed to show suppression of platelet activating factor-induced platelet aggregation even though collagen-induced activation was inhibited, suggesting that platelet activating factor acts by cyclooxygenase-independent mechanisms." | 1.28 | Effect of therapy on platelet activating factor-induced aggregation in acute stroke. ( D'Andrea, G; Joseph, R; Welch, KM, 1989) |
| "In conclusion, AVS inhibited thrombus formation in vivo while it was ineffective in vitro platelet alone system, which may result from the actions of this agent on both platelets and vascular endothelium." | 1.27 | Effects of AVS (1,2-bis(nicotinamido)propane) on platelet function and vascular endothelium. ( Hata, S; Koide, T; Matsushita, H; Mizukami, M; Nakano, M; Neichi, T; Noda, Y; Yamazaki, T, 1984) |
| "In patients with transient ischemic attack (TIA), the risk of stroke increases greatly, especially in the months immediately following the initial attack." | 1.27 | Transient ischemic attacks. Strategies for minimizing stroke risk. ( Furlan, AJ, 1984) |
| "This effect was a consequence of the cerebrovascular occlusion due to platelet aggregates induced by arachidonic acid." | 1.27 | Protective effect of triflusal and acetylsalicylic acid against arachidonic acid induced cerebrovascular occlusion in anesthetized rats. ( Forn, J; García Rafanell, J; Gómez, L, 1987) |
| "Recurrent transient ischemic attack or amaurosis fugax occurred more frequently (P less than 0." | 1.27 | Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. ( Eriksson, SE, 1985) |
| "Eight patients with transient ischemic attacks, and three with partial nonprogressive strokes associated with mitral valve prolapse, are reported." | 1.26 | TIA, stroke, and mitral valve prolapse. ( Watson, RT, 1979) |
| "Unilateral cerebrovascular occlusion was produced in heparinized rats within seconds after injection of microgram quantities of sodium arachidonate into the internal carotid artery." | 1.26 | Arachidonate-induced cerebrovascular occlusion in the rat. The role of platelets and aspirin in stroke. ( Bass, NH; Furlow, TW, 1976) |
| "Myocardial infarctions have decreased from 2." | 1.26 | Complications of percutaneous transfemoral coronary arteriography. ( Silverman, JF; Wexler, L, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 234 (28.02) | 18.7374 |
| 1990's | 470 (56.29) | 18.2507 |
| 2000's | 58 (6.95) | 29.6817 |
| 2010's | 60 (7.19) | 24.3611 |
| 2020's | 13 (1.56) | 2.80 |
| Authors | Studies |
|---|---|
| Gassanov, N | 1 |
| Eicke, M | 1 |
| Er, F | 1 |
| Dai, L | 1 |
| Xu, J | 1 |
| Yan, H | 1 |
| Chen, Z | 1 |
| Pan, Y | 1 |
| Meng, X | 2 |
| Li, H | 2 |
| Wang, Y | 5 |
| Venketasubramanian, N | 2 |
| Ates, O | 1 |
| Yilmaz, I | 1 |
| Karaarslan, N | 1 |
| Ersoz, E | 1 |
| Hacioglu Kasim, FB | 1 |
| Dogan, M | 1 |
| Ozbek, H | 1 |
| Wang, L | 1 |
| Tang, X | 1 |
| Nishimoto, T | 1 |
| Oka, F | 1 |
| Fujii, N | 1 |
| Inoue, H | 1 |
| Hasegawa, S | 1 |
| Yamane, M | 1 |
| Nomura, S | 1 |
| Ishihara, H | 1 |
| Qiu, J | 1 |
| Sun, X | 1 |
| Zhang, W | 2 |
| Ke, X | 1 |
| Yang, G | 1 |
| Zhang, L | 1 |
| Brunetti, ND | 1 |
| De Gennaro, L | 1 |
| Di Biase, M | 1 |
| Caldarola, P | 1 |
| Yang, M | 1 |
| Wang, A | 1 |
| Li, J | 1 |
| Zhao, X | 1 |
| Liu, L | 3 |
| Jing, J | 1 |
| Zhang, N | 1 |
| Johnston, SC | 1 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Cao, D | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Godino, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 1 |
| De Caterina, R | 1 |
| Condorelli, G | 1 |
| Ferrante, G | 1 |
| Stefanini, GG | 1 |
| Gresele, P | 1 |
| Paciullo, F | 1 |
| Migliacci, R | 1 |
| Ros-Castelló, V | 1 |
| Natera-Villalba, E | 1 |
| Gómez-López, A | 1 |
| Sánchez-Sánchez, A | 1 |
| Chico-García, JL | 1 |
| García-Madrona, S | 1 |
| Vera-Lechuga, R | 1 |
| Matute-Lozano, C | 1 |
| de Felipe Mimbrera, A | 1 |
| Cruz-Culebras, A | 1 |
| Alonso-Canovas, A | 1 |
| Masjuan, J | 1 |
| Zhou, B | 1 |
| Wang, Q | 3 |
| Zhao, Z | 1 |
| Feng, X | 1 |
| Liu, C | 1 |
| Du, L | 1 |
| Wang, S | 1 |
| Kong, L | 1 |
| Zhang, S | 1 |
| Li, S | 1 |
| Du, G | 1 |
| Bálint, A | 1 |
| Tornyos, D | 1 |
| El Alaoui El Abdallaoui, O | 1 |
| Kupó, P | 1 |
| Komócsi, A | 1 |
| Griauzde, J | 1 |
| Ravindra, VM | 1 |
| Chaudhary, N | 1 |
| Gemmete, JJ | 1 |
| Mazur, MD | 1 |
| Roark, CD | 1 |
| Couldwell, WT | 1 |
| Park, MS | 1 |
| Taussky, P | 1 |
| Pandey, AS | 1 |
| Ardoino, I | 1 |
| Rossio, R | 1 |
| Di Blanca, D | 1 |
| Nobili, A | 1 |
| Pasina, L | 1 |
| Mannucci, PM | 1 |
| Peyvandi, F | 1 |
| Franchi, C | 1 |
| Wang, GQ | 1 |
| Xie, YM | 1 |
| Liu, H | 1 |
| Zhang, Y | 2 |
| Jia, PP | 1 |
| Zhuang, Y | 1 |
| Chigonda, TG | 1 |
| Chatora, GT | 1 |
| Ngwende, GW | 1 |
| Miller, RF | 1 |
| Ferrand, RA | 1 |
| Park, SK | 1 |
| Jung, DE | 1 |
| Jung, SA | 1 |
| Kim, WH | 1 |
| Bahk, JH | 1 |
| Eichenlaub, M | 1 |
| Pfeufer, A | 1 |
| Behrens, L | 1 |
| Klauss, V | 1 |
| Roettinger, M | 1 |
| Brodherr, T | 1 |
| Lewalter, T | 1 |
| Zhang, XL | 1 |
| Fu, HJ | 1 |
| Yang, GR | 1 |
| Wan, G | 1 |
| Li, D | 1 |
| Zhu, LX | 1 |
| Xie, RR | 1 |
| Lv, YJ | 1 |
| Zhang, JD | 1 |
| Li, YL | 1 |
| Dai, QF | 1 |
| Ji, Y | 1 |
| Gao, DY | 1 |
| Cui, XL | 1 |
| Liu, DY | 1 |
| Yuan, SY | 1 |
| Yuan, MX | 1 |
| Fukushi, K | 1 |
| Tominaga, K | 1 |
| Nagashima, K | 1 |
| Kanamori, A | 1 |
| Izawa, N | 1 |
| Kanazawa, M | 1 |
| Sasai, T | 2 |
| Hiraishi, H | 2 |
| Hu, X | 1 |
| Yang, FY | 1 |
| Chen, M | 1 |
| Vidale, S | 1 |
| Agostoni, E | 1 |
| Grampa, G | 1 |
| Consoli, A | 1 |
| Consoli, D | 1 |
| Würtz, M | 1 |
| Olesen, KKW | 1 |
| Thim, T | 1 |
| Kristensen, SD | 1 |
| Eikelboom, JW | 1 |
| Maeng, M | 1 |
| Mijajlovic, MD | 1 |
| Shulga, O | 1 |
| Bloch, S | 1 |
| Covickovic-Sternic, N | 1 |
| Aleksic, V | 1 |
| Bornstein, NM | 3 |
| Steinberg, BA | 1 |
| Kim, S | 1 |
| Piccini, JP | 1 |
| Fonarow, GC | 1 |
| Lopes, RD | 1 |
| Thomas, L | 1 |
| Ezekowitz, MD | 4 |
| Ansell, J | 2 |
| Kowey, P | 2 |
| Singer, DE | 9 |
| Gersh, B | 1 |
| Mahaffey, KW | 2 |
| Hylek, E | 1 |
| Go, AS | 1 |
| Chang, P | 1 |
| Peterson, ED | 1 |
| Gouya, G | 1 |
| Arrich, J | 1 |
| Wolzt, M | 1 |
| Huber, K | 1 |
| Verheugt, FW | 1 |
| Gurbel, PA | 2 |
| Pirker-Kees, A | 1 |
| Siller-Matula, JM | 1 |
| Goltz, L | 1 |
| Bodechtel, U | 1 |
| Siepmann, T | 1 |
| Kanzaki, R | 1 |
| Inoue, M | 1 |
| Minami, M | 1 |
| Shintani, Y | 1 |
| Nakagiri, T | 1 |
| Funaki, S | 1 |
| Sawabata, N | 1 |
| Okumura, M | 1 |
| Pandit, A | 1 |
| Giri, S | 1 |
| Hakim, FA | 1 |
| Fortuin, FD | 1 |
| Patel, PA | 1 |
| Fleisher, LA | 1 |
| Hollander, Z | 1 |
| Dai, DL | 1 |
| Putko, BN | 1 |
| Yogasundaram, H | 1 |
| Wilson-McManus, JE | 1 |
| Thompson, RB | 1 |
| Khan, A | 1 |
| West, ML | 1 |
| McManus, BM | 1 |
| Oudit, GY | 1 |
| Amsallem, M | 1 |
| Manzo-Silberman, S | 1 |
| Dillinger, JG | 1 |
| Sideris, G | 1 |
| Voicu, S | 1 |
| Bal dit Sollier, C | 1 |
| Drouet, L | 1 |
| Henry, P | 1 |
| Kang, DO | 1 |
| Yu, CW | 1 |
| Kim, HD | 1 |
| Cho, JY | 1 |
| Joo, HJ | 1 |
| Choi, RK | 1 |
| Park, JS | 1 |
| Lee, HJ | 1 |
| Kim, JS | 2 |
| Park, JH | 1 |
| Hong, SJ | 1 |
| Lim, DS | 1 |
| Freitas-Silva, M | 1 |
| Gonçalves, L | 1 |
| Medeiros, R | 1 |
| Nunes, JP | 1 |
| Vališ, M | 1 |
| Krajíčková, D | 1 |
| Malý, J | 1 |
| Malý, R | 1 |
| Fátorová, I | 1 |
| Vyšata, O | 1 |
| Herzig, R | 1 |
| Dretzke, J | 1 |
| Riley, RD | 1 |
| Lordkipanidzé, M | 1 |
| Jowett, S | 1 |
| O'Donnell, J | 1 |
| Ensor, J | 1 |
| Moloney, E | 1 |
| Price, M | 1 |
| Raichand, S | 1 |
| Hodgkinson, J | 1 |
| Bayliss, S | 1 |
| Fitzmaurice, D | 1 |
| Moore, D | 1 |
| Lapi, F | 1 |
| Levi, M | 2 |
| Simonetti, M | 1 |
| Cancian, M | 1 |
| Parretti, D | 1 |
| Cricelli, I | 1 |
| Sobrero, A | 1 |
| Cricelli, C | 1 |
| Ueda, H | 1 |
| Kido, A | 1 |
| Matsuhisa, S | 1 |
| Asawa, K | 1 |
| Yoshida, N | 1 |
| Tsujimoto, M | 1 |
| Sasaki, Y | 1 |
| Kuga, Y | 1 |
| Yamasaki, M | 1 |
| Ueda, K | 1 |
| Shinohara, S | 1 |
| Nishida, Y | 1 |
| Niikura, R | 1 |
| Yasunaga, H | 1 |
| Yamada, A | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Hirata, Y | 1 |
| Koike, K | 1 |
| Yamazaki, M | 1 |
| Ohnishi, T | 1 |
| Hosokawa, K | 1 |
| Yamaguchi, K | 1 |
| Yoneyama, T | 1 |
| Kawashima, A | 1 |
| Okada, Y | 2 |
| Kitagawa, K | 1 |
| Uchiyama, S | 2 |
| Jolly, SS | 1 |
| Natarajan, MK | 1 |
| Algra, A | 16 |
| De Schryver, EL | 6 |
| Halkes, PH | 1 |
| Turan, TN | 1 |
| Maidan, L | 1 |
| Cotsonis, G | 1 |
| Lynn, MJ | 2 |
| Romano, JG | 1 |
| Levine, SR | 2 |
| Chimowitz, MI | 4 |
| Famakin, BM | 1 |
| Stern, BJ | 1 |
| George, MG | 1 |
| Nakayama, M | 2 |
| Iwakiri, R | 1 |
| Hara, M | 1 |
| Ootani, H | 1 |
| Shimoda, R | 1 |
| Tsunada, S | 1 |
| Sakata, H | 1 |
| Fujimoto, K | 1 |
| Richard, E | 1 |
| Kuiper, R | 1 |
| Dijkgraaf, MG | 1 |
| Van Gool, WA | 1 |
| Kitazono, T | 1 |
| Iida, M | 1 |
| Barkun, AN | 1 |
| Bardou, M | 1 |
| Sung, JJ | 1 |
| Lau, JY | 1 |
| Ching, JY | 1 |
| Wu, JC | 1 |
| Lee, YT | 1 |
| Chiu, PW | 1 |
| Leung, VK | 1 |
| Wong, VW | 1 |
| Chan, FK | 1 |
| Svensson, J | 4 |
| Samuelsson, K | 2 |
| Gebel, JM | 1 |
| Mourad, JJ | 1 |
| Rhee, SY | 1 |
| Kim, YS | 1 |
| Chon, S | 1 |
| Oh, S | 1 |
| Woo, JT | 1 |
| Kim, SW | 1 |
| Kim, JW | 1 |
| Komarov, AL | 1 |
| Shibata, T | 1 |
| Kamano, T | 1 |
| Hirata, I | 1 |
| García Rodríguez, LA | 2 |
| Cea Soriano, L | 2 |
| Hill, C | 1 |
| Johansson, S | 2 |
| Maeda, M | 1 |
| Kanke, K | 1 |
| Shimada, T | 1 |
| Shinohara, Y | 1 |
| Brockmann, C | 1 |
| Seker, F | 1 |
| Weiss, C | 1 |
| Groden, C | 1 |
| Scharf, J | 1 |
| Yeomans, ND | 1 |
| Albaladejo, P | 1 |
| Marret, E | 1 |
| Samama, CM | 1 |
| Collet, JP | 1 |
| Abhay, K | 1 |
| Loutrel, O | 1 |
| Charbonneau, H | 1 |
| Jaber, S | 1 |
| Thoret, S | 1 |
| Bosson, JL | 1 |
| Piriou, V | 1 |
| Suslina, ZA | 3 |
| Prokhorov, DI | 1 |
| Shilova, AG | 1 |
| Kaplun, AP | 1 |
| Ionova, VG | 2 |
| Seĭfulla, RD | 1 |
| Drazin, D | 1 |
| Choulakian, A | 1 |
| Nuño, M | 1 |
| Kornbluth, P | 1 |
| Alexander, MJ | 1 |
| Taylor, K | 1 |
| Filgate, R | 1 |
| Guo, DY | 1 |
| Macneil, F | 1 |
| Bueno, H | 1 |
| Soejima, H | 1 |
| Ogawa, H | 1 |
| Morimoto, T | 1 |
| Okada, S | 1 |
| Uemura, S | 1 |
| Kanauchi, M | 1 |
| Doi, N | 1 |
| Sakuma, M | 1 |
| Jinnouchi, H | 1 |
| Sugiyama, S | 1 |
| Waki, M | 1 |
| Saito, Y | 1 |
| Sanuki, T | 1 |
| Fujita, T | 1 |
| Kutsumi, H | 1 |
| Hayakumo, T | 1 |
| Yoshida, S | 1 |
| Inokuchi, H | 1 |
| Murakami, M | 1 |
| Matsubara, Y | 1 |
| Kuwayama, H | 1 |
| Kawai, T | 1 |
| Miyaji, H | 1 |
| Fujisawa, T | 1 |
| Terao, S | 1 |
| Yamazaki, Y | 1 |
| Azuma, T | 1 |
| Manzano-Fernández, S | 1 |
| Tello-Montoliu, A | 1 |
| Marín, F | 1 |
| Li, X | 1 |
| Fan, L | 2 |
| Cao, J | 2 |
| Hu, G | 1 |
| Hu, Y | 1 |
| Wu, R | 1 |
| Sakurai, H | 1 |
| Hanyu, H | 1 |
| Sato, T | 1 |
| Kume, K | 1 |
| Hirao, K | 1 |
| Kanetaka, H | 1 |
| Iwamoto, T | 1 |
| Zhang, SJ | 1 |
| Xue, ZY | 1 |
| Li, XL | 1 |
| Ye, L | 1 |
| Cui, CP | 1 |
| Zhou, FC | 1 |
| Wang, X | 1 |
| Lin, WH | 1 |
| Zhao, YD | 1 |
| Chen, XY | 1 |
| Leung, TW | 1 |
| Chen, C | 1 |
| Fu, J | 1 |
| Markus, H | 1 |
| Hao, Q | 1 |
| Wong, KS | 3 |
| Weber, R | 1 |
| Brenck, J | 1 |
| Diener, HC | 7 |
| Rist, PM | 1 |
| Buring, JE | 9 |
| Kase, CS | 2 |
| Kurth, T | 1 |
| Weisman, SM | 2 |
| Graham, DY | 1 |
| Lorenzo Fernández, P | 1 |
| van Gijn, J | 15 |
| Cotter, G | 1 |
| Cannon, CP | 1 |
| McCabe, CH | 1 |
| Michowitz, Y | 1 |
| Kaluski, E | 1 |
| Charlesworth, A | 1 |
| Milo, O | 1 |
| Bentley, J | 1 |
| Blatt, A | 1 |
| Krakover, R | 1 |
| Zimlichman, R | 1 |
| Reisin, L | 1 |
| Marmor, A | 1 |
| Lewis, B | 1 |
| Vered, Z | 1 |
| Caspi, A | 1 |
| Braunwald, E | 1 |
| Topol, EJ | 4 |
| Easton, D | 1 |
| Harrington, RA | 2 |
| Amarenco, P | 1 |
| Califf, RM | 2 |
| Graffagnino, C | 2 |
| Davis, S | 1 |
| Ferguson, J | 1 |
| Fitzgerald, D | 1 |
| Granett, J | 1 |
| Shuaib, A | 1 |
| Koudstaal, PJ | 9 |
| Theroux, P | 1 |
| Van de Werf, F | 2 |
| Sigmon, K | 1 |
| Pieper, K | 1 |
| Vallee, M | 1 |
| Willerson, JT | 1 |
| Alberts, MJ | 3 |
| Bergman, DL | 1 |
| Molner, E | 1 |
| Jovanovic, BD | 1 |
| Ushiwata, I | 1 |
| Teruya, J | 1 |
| McCabe, DJ | 1 |
| Harrison, P | 1 |
| Machin, SJ | 1 |
| Watt, H | 1 |
| Brown, MM | 2 |
| Varanasi, JS | 1 |
| Steinhubl, SR | 1 |
| Tran, H | 1 |
| Anand, SS | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Bernstein, RA | 1 |
| Albers, GW | 7 |
| Di Napoli, M | 1 |
| Schwaninger, M | 1 |
| Cappelli, R | 1 |
| Ceccarelli, E | 1 |
| Di Gianfilippo, G | 1 |
| Donati, C | 1 |
| Emsley, HC | 1 |
| Forconi, S | 1 |
| Hopkins, SJ | 1 |
| Masotti, L | 1 |
| Muir, KW | 1 |
| Paciucci, A | 1 |
| Papa, F | 1 |
| Roncacci, S | 1 |
| Sander, D | 1 |
| Sander, K | 1 |
| Smith, CJ | 1 |
| Stefanini, A | 1 |
| Weber, D | 1 |
| Gorelick, PB | 2 |
| Toyoda, K | 1 |
| Minematsu, K | 1 |
| Kamouchi, M | 1 |
| Fujimoto, S | 1 |
| Ibayashi, S | 1 |
| Inoue, T | 1 |
| Ariesen, MJ | 1 |
| Kappelle, LJ | 4 |
| Bezerra, DC | 1 |
| Bogousslavsky, J | 5 |
| Marissal, JP | 1 |
| Sailly, JC | 1 |
| Crainich, D | 1 |
| Lebrun, T | 1 |
| Sato, H | 1 |
| Ishikawa, K | 1 |
| Kitabatake, A | 1 |
| Ogawa, S | 1 |
| Maruyama, Y | 1 |
| Yokota, Y | 1 |
| Fukuyama, T | 1 |
| Doi, Y | 1 |
| Mochizuki, S | 1 |
| Izumi, T | 1 |
| Takekoshi, N | 1 |
| Yoshida, K | 1 |
| Hiramori, K | 1 |
| Origasa, H | 1 |
| Matsumoto, M | 3 |
| Yamaguchi, T | 2 |
| Hori, M | 1 |
| Esagunde, RU | 1 |
| Lee, MP | 1 |
| Gan, HY | 1 |
| Wong, MC | 1 |
| Chang, HM | 1 |
| Chen, CL | 1 |
| Wang, CB | 1 |
| Hu, DY | 2 |
| Shi, XB | 1 |
| Zhu, ZY | 1 |
| Zhu, JY | 1 |
| Yang, JG | 1 |
| Martí-Fàbregas, J | 1 |
| Cocho, D | 1 |
| Martí-Vilalta, JL | 1 |
| Gich, I | 1 |
| Belvís, R | 1 |
| Bravo, Y | 1 |
| Millán, M | 1 |
| Castellanos, M | 1 |
| Rodríguez-Campello, A | 1 |
| Egido, J | 1 |
| Geffner, D | 1 |
| Gil-Núñez, A | 1 |
| Marta, J | 1 |
| Navarro, R | 1 |
| Obach, V | 1 |
| Palomeras, E | 1 |
| Zhang, HP | 1 |
| Sun, YH | 1 |
| Jiang, LQ | 1 |
| Habib, GB | 1 |
| Kumar, N | 1 |
| Jivan, S | 1 |
| Thomas, P | 1 |
| McLure, H | 1 |
| Fisher, M | 1 |
| Knappertz, V | 1 |
| Serebruany, V | 1 |
| Schwartz, KA | 1 |
| Rash, A | 1 |
| Downes, T | 1 |
| Portner, R | 1 |
| Yeo, WW | 1 |
| Morgan, N | 1 |
| Channer, KS | 1 |
| Morrison, CM | 1 |
| Gainsborough, N | 1 |
| Rajkumar, C | 1 |
| Ducros, A | 1 |
| Krayenbuehl, PA | 1 |
| Wiesli, P | 1 |
| Schmid, M | 1 |
| Schmid, C | 1 |
| Ehses, JA | 1 |
| Hersberger, M | 1 |
| Vetter, W | 1 |
| Schulthess, G | 1 |
| Jackson, AJ | 1 |
| Teenan, RP | 1 |
| Orr, DJ | 1 |
| Prabhakaran, S | 1 |
| Wells, KR | 1 |
| Lee, VH | 1 |
| Flaherty, CA | 1 |
| Lopes, DK | 1 |
| Zeymer, U | 1 |
| Gitt, A | 1 |
| Jünger, C | 1 |
| Bauer, T | 1 |
| Heer, T | 1 |
| Koeth, O | 1 |
| Mark, B | 1 |
| Zahn, R | 1 |
| Senges, J | 1 |
| Gottwik, M | 1 |
| Fares, RR | 1 |
| Lansing, LS | 1 |
| Gallati, CA | 1 |
| Mousa, SA | 1 |
| Feher, G | 1 |
| Koltai, K | 1 |
| Kesmarky, G | 1 |
| Toth, K | 1 |
| Gao, L | 1 |
| Wang, PP | 1 |
| Liu, Q | 1 |
| Lee, DH | 1 |
| Arat, A | 1 |
| Morsi, H | 1 |
| Shaltoni, H | 1 |
| Harris, JR | 1 |
| Mawad, ME | 1 |
| Ritter, JM | 1 |
| Genton, E | 6 |
| Kelton, JG | 1 |
| Agostoni, A | 1 |
| Tullio, D | 1 |
| de Boer, AC | 1 |
| Turpie, AG | 4 |
| Buckler, P | 1 |
| Douglas, AS | 2 |
| Webster, J | 1 |
| Stewart, ME | 1 |
| Douglas, JT | 1 |
| Lowe, GD | 2 |
| Prentice, CR | 1 |
| Forbes, CD | 5 |
| Sherry, S | 2 |
| Mitchell, JR | 2 |
| Bousser, MG | 5 |
| Eschwège, E | 3 |
| Haguenau, M | 3 |
| Lefauconnier, JM | 2 |
| Thibult, N | 1 |
| Touboul, D | 1 |
| Touboul, PJ | 1 |
| Guiraud-Chaumeil, B | 1 |
| Wilkerson, RJ | 1 |
| Liem, PH | 1 |
| Carter, WJ | 1 |
| Mizukami, M | 1 |
| Neichi, T | 1 |
| Yamazaki, T | 1 |
| Koide, T | 1 |
| Noda, Y | 1 |
| Matsushita, H | 1 |
| Hata, S | 1 |
| Nakano, M | 1 |
| Fields, WS | 10 |
| Lechner, H | 2 |
| Ott, E | 2 |
| Bertha, G | 1 |
| Quan, M | 1 |
| Puffer, JC | 1 |
| Johnson, RA | 1 |
| Kistler, JP | 4 |
| Ropper, AH | 1 |
| Heros, RC | 1 |
| Eichner, ER | 1 |
| Barnett, HJ | 12 |
| Hass, WK | 2 |
| Kamm, B | 3 |
| Clagett, GP | 3 |
| Youkey, JR | 1 |
| Brigham, RA | 1 |
| Orecchia, PM | 1 |
| Salander, JM | 1 |
| Collins, GJ | 1 |
| Rich, NM | 1 |
| Rivey, MP | 1 |
| Alexander, MR | 1 |
| Taylor, JW | 1 |
| Dyken, ML | 3 |
| Rushton, FW | 1 |
| Kukora, JS | 1 |
| Britton, M | 3 |
| Melander, A | 1 |
| Wåhlin-Boll, E | 1 |
| Taylor, DW | 3 |
| Gent, M | 8 |
| Sackett, DL | 3 |
| Donaldson, IM | 1 |
| Bouchier-Hayes, D | 1 |
| Pagano, T | 1 |
| Nair, CK | 1 |
| Sketch, MH | 1 |
| Whisnant, JP | 5 |
| Arai, H | 1 |
| Miyakawa, T | 1 |
| Ozaki, K | 1 |
| Sakuragawa, N | 1 |
| Vysotskaia, VG | 1 |
| Furlan, AJ | 4 |
| Elwood, PC | 1 |
| Fukatsu, A | 1 |
| Itoh, E | 1 |
| Polli, EE | 1 |
| Cortellaro, M | 1 |
| Monreal, M | 1 |
| Monasterio, I | 1 |
| Held, K | 1 |
| Yeung Laiwah, AC | 1 |
| Poliwoda, H | 1 |
| Birgens, HS | 1 |
| Hansen, MS | 1 |
| Margulies, EH | 1 |
| White, AM | 1 |
| Passamani, ER | 1 |
| Lemak, NA | 3 |
| Frankowski, RF | 1 |
| Hardy, RJ | 1 |
| Bigelow, RH | 1 |
| Soyka, D | 1 |
| Hirsh, J | 10 |
| Fuster, V | 10 |
| Chesebro, JH | 3 |
| Olsson, JE | 1 |
| Cristol, R | 1 |
| Wessler, S | 1 |
| Warlow, CP | 2 |
| Kent, S | 1 |
| Castaldi, PA | 1 |
| Frishman, WH | 1 |
| Meloche, JP | 1 |
| Boysen, G | 7 |
| Bøttcher, J | 1 |
| Olsen, JS | 1 |
| Byer, JA | 1 |
| Easton, JD | 7 |
| Cauchie, C | 1 |
| Hamberg, M | 1 |
| Blombäck, M | 1 |
| Mettinger, KL | 1 |
| Uyama, O | 2 |
| Fujisawa, A | 1 |
| Kusunoki, M | 1 |
| Yoneda, S | 2 |
| Imaizumi, M | 2 |
| Kimura, K | 1 |
| Abe, H | 1 |
| Yatsu, FM | 2 |
| Levin, SM | 1 |
| Sondheimer, FK | 1 |
| Levin, JM | 1 |
| Nukada, T | 1 |
| Miyamoto, T | 1 |
| Kayama, N | 1 |
| Bronner, LL | 1 |
| Kanter, DS | 1 |
| Manson, JE | 6 |
| Robicsek, F | 1 |
| Gage, BF | 3 |
| Cardinalli, AB | 3 |
| Owens, DK | 3 |
| Theiss, W | 1 |
| Hasan, M | 1 |
| Jackson, SK | 1 |
| Sinclair, AJ | 1 |
| Kuhn, W | 2 |
| Müller, T | 2 |
| Bttner, T | 1 |
| Gerlach, M | 2 |
| Stratton, JR | 1 |
| Brott, T | 2 |
| Toole, JF | 2 |
| Ganiats, T | 1 |
| van Latum, JC | 2 |
| van Swieten, JC | 2 |
| Kokkinos, J | 1 |
| Strong, J | 1 |
| Brown, MB | 1 |
| Silliman, S | 1 |
| Pessin, MS | 2 |
| Weichel, E | 1 |
| Sila, CA | 3 |
| Day, L | 1 |
| Barnfield, M | 1 |
| Goldstein, LB | 2 |
| Bonito, AJ | 2 |
| Matchar, DB | 4 |
| Duncan, PW | 2 |
| DeFriese, GH | 1 |
| Oddone, EZ | 1 |
| Paul, JE | 1 |
| Akin, DR | 1 |
| Samsa, GP | 2 |
| Harper, G | 1 |
| Casto, L | 1 |
| Camerlingo, M | 1 |
| Finazzi, G | 1 |
| Censori, B | 1 |
| Barbui, T | 1 |
| Mamoli, A | 2 |
| Mas, JL | 1 |
| Hennekens, CH | 12 |
| O'Donnell, CJ | 2 |
| Ridker, PM | 5 |
| Marder, VJ | 1 |
| Hart, RG | 17 |
| Rohack, JJ | 1 |
| Solomon, DH | 2 |
| Feinberg, WM | 5 |
| Rothwell, PM | 1 |
| Tozer, R | 1 |
| Hastie, IR | 1 |
| Wilson, DG | 1 |
| Wisheart, JD | 1 |
| Stuart, AG | 1 |
| Lovell, R | 1 |
| Poungvarin, N | 1 |
| Opartkiattikul, N | 1 |
| Chaithiraphan, S | 1 |
| Viriyavejakul, A | 1 |
| Sivenius, J | 11 |
| Riekkinen, PJ | 6 |
| Laakso, M | 9 |
| Landau, WM | 1 |
| Burger, AJ | 1 |
| Jadhav, P | 1 |
| Kamalesh, M | 1 |
| Stubbe, I | 1 |
| Moore, WS | 3 |
| Beebe, HG | 1 |
| Bernstein, EF | 1 |
| Brener, BJ | 1 |
| Caplan, LR | 2 |
| Day, A | 1 |
| Goldstone, J | 3 |
| Hobson, RW | 5 |
| Hebert, P | 1 |
| Romero, J | 1 |
| Kittross, A | 1 |
| Cook, N | 1 |
| Manson, J | 1 |
| Peto, R | 7 |
| Hennekens, C | 2 |
| McCrory, DC | 2 |
| Feussner, JR | 1 |
| Eriksson, SE | 2 |
| Cappelleri, JC | 1 |
| Lau, J | 1 |
| Kupelnick, B | 1 |
| Chalmers, TC | 2 |
| Laupacis, A | 4 |
| Morocutti, C | 1 |
| Coccheri, S | 1 |
| Bussey, HI | 1 |
| White, HD | 1 |
| James, KE | 1 |
| Côté, R | 2 |
| Gans, M | 1 |
| Anderson, D | 1 |
| Menke, J | 1 |
| Bladin, CF | 1 |
| Norris, JW | 3 |
| Helgason, CM | 3 |
| Bolin, KM | 1 |
| Hoff, JA | 2 |
| Winkler, SR | 2 |
| Mangat, A | 1 |
| Tortorice, KL | 2 |
| Brace, LD | 3 |
| Kohriyama, T | 1 |
| Tanaka, E | 1 |
| Katayama, S | 1 |
| Yamamura, Y | 1 |
| Nakamura, S | 1 |
| Pennese, F | 1 |
| Palombo, V | 1 |
| Taormina, F | 1 |
| Fraccalaglio, L | 1 |
| Brillante, C | 1 |
| Abate, G | 1 |
| Halperin, JL | 4 |
| Pearce, LA | 6 |
| Miller, VT | 4 |
| Fagan, SC | 2 |
| Kertland, HR | 1 |
| Tietjen, GE | 1 |
| Shahar, E | 1 |
| McGovern, PG | 1 |
| Sprafka, JM | 1 |
| Nelson, KM | 1 |
| Talbert, RL | 2 |
| Verhoef, P | 1 |
| Malinow, MR | 1 |
| Kok, FJ | 1 |
| Willett, WC | 2 |
| Stampfer, MJ | 4 |
| Tohgi, H | 4 |
| Takahashi, H | 2 |
| Kashiwaya, M | 1 |
| Watanabe, K | 1 |
| Ramsay, LE | 1 |
| Roth, GJ | 2 |
| Calverley, DC | 1 |
| Rothrock, JF | 3 |
| Lowenthal, A | 8 |
| Buyse, M | 1 |
| Cheng, TO | 1 |
| Towne, JB | 2 |
| Hanna, JP | 1 |
| Sun, JP | 1 |
| Stewart, WJ | 1 |
| Tan, M | 1 |
| Golden, WE | 1 |
| Cleves, M | 1 |
| Dawson, DV | 1 |
| Massey, EW | 1 |
| Bath, PM | 2 |
| Prasad, A | 1 |
| MacGregor, GA | 1 |
| Jonas, MA | 1 |
| Kent, J | 1 |
| Bamford, J | 2 |
| Ben-Hur, T | 1 |
| Falk, RH | 1 |
| Oster, G | 1 |
| Huse, DM | 1 |
| Lacey, MJ | 1 |
| Epstein, AM | 1 |
| Chaturvedi, S | 1 |
| Recht, L | 1 |
| Ranke, C | 2 |
| Creutzig, A | 2 |
| Alexander, K | 2 |
| McCann, RL | 1 |
| Macko, R | 1 |
| Deecke, L | 2 |
| Zeiler, K | 2 |
| Couch, JR | 1 |
| Rothlauf, EB | 1 |
| Grotemeyer, KH | 2 |
| Scharafinski, HW | 1 |
| Husstedt, IW | 1 |
| Lagneau, P | 1 |
| Amano, T | 1 |
| O'Connell, JE | 2 |
| Gray, CS | 2 |
| Lancaster, T | 1 |
| Oliveira, AS | 1 |
| Miranda, MP | 1 |
| Duarte, PC | 1 |
| Sarmento, JN | 1 |
| Karepov, VG | 1 |
| Aronovich, BD | 1 |
| Gorbulev, AY | 1 |
| Treves, TA | 1 |
| Korczyn, AD | 2 |
| Robbins, AS | 1 |
| Lee, IM | 2 |
| Satterfield, S | 1 |
| Norrving, B | 2 |
| Unwin, DH | 1 |
| Greenlee, RG | 1 |
| Silagy, CA | 1 |
| McNeil, JJ | 2 |
| Donnan, GA | 4 |
| Tonkin, AM | 1 |
| Worsam, B | 1 |
| Campion, K | 1 |
| Lindblad, B | 1 |
| Persson, NH | 1 |
| Takolander, R | 1 |
| Bergqvist, D | 1 |
| Conti, CR | 1 |
| Sandercock, PA | 2 |
| Millenson, MM | 1 |
| Bauer, KA | 1 |
| Gress, DR | 3 |
| Barzegar, S | 1 |
| Hughes, RA | 4 |
| Sheehan, MA | 3 |
| Maraventano, SW | 3 |
| Oertel, LB | 3 |
| Bellavance, A | 1 |
| Kondos, GT | 1 |
| Harbison, JW | 3 |
| Weiss, DG | 2 |
| Wright, CB | 1 |
| Biller, J | 2 |
| Love, BB | 2 |
| Weisberg, LA | 1 |
| Anderson, DC | 3 |
| Bower, S | 1 |
| Sandercock, P | 10 |
| Kanter, MC | 1 |
| Sherman, DG | 4 |
| Krupski, WC | 1 |
| Smets, P | 6 |
| Penney, DW | 1 |
| Schuler, JJ | 1 |
| McClelland, TJ | 1 |
| Cillessen, JP | 1 |
| Grotta, J | 1 |
| Yedinak, KC | 1 |
| Sproat, TT | 1 |
| Chiba, K | 1 |
| Tamura, K | 3 |
| Franck, G | 1 |
| Wildemann, B | 1 |
| Schülin, C | 1 |
| Storch-Hagenlocher, B | 1 |
| Hacke, W | 3 |
| Dithmar, S | 1 |
| Kirchhof, K | 1 |
| Jansen, O | 1 |
| Breitbart, A | 1 |
| Lip, GY | 5 |
| Hertzer, NR | 2 |
| Ferguson, JJ | 1 |
| Berger, K | 3 |
| Zippel, C | 1 |
| Büttner, T | 1 |
| Dasgupta, R | 1 |
| Chakraborti, A | 1 |
| Bardhan, S | 1 |
| Sen, SK | 1 |
| Blackshear, JL | 1 |
| Kopecky, SL | 1 |
| Litin, SC | 1 |
| Safford, RE | 1 |
| Hammill, SC | 1 |
| Coller, BS | 1 |
| Anderson, K | 1 |
| Weisman, HF | 1 |
| Kan, BD | 1 |
| Katz, DA | 1 |
| Martinez-Riera, A | 1 |
| Santolaria-Fernandez, F | 1 |
| Gonzalez-Reimers, E | 1 |
| Yanagihara, T | 1 |
| Morley, J | 1 |
| Marinchak, R | 1 |
| Rials, SJ | 1 |
| Friedman, HS | 1 |
| Harrison, MJ | 1 |
| Kaste, M | 2 |
| Meldrum, H | 1 |
| Eliasziw, M | 1 |
| Patrono, C | 2 |
| Boon, A | 1 |
| Lodder, J | 1 |
| Cheriex, E | 1 |
| Kessels, F | 1 |
| Nishimura, H | 1 |
| Naritomi, H | 1 |
| Iwamoto, Y | 1 |
| Tachibana, H | 1 |
| Sugita, M | 1 |
| Gold, JA | 1 |
| Codinach Huix, P | 1 |
| Rodgers, A | 1 |
| MacMahon, S | 4 |
| Gamble, G | 1 |
| Slattery, J | 1 |
| Warlow, C | 6 |
| Koefoed, BG | 5 |
| Gulløv, AL | 4 |
| Petersen, P | 6 |
| Ricou, FJ | 1 |
| Arroyo, JF | 1 |
| Oláh, L | 1 |
| Misz, M | 1 |
| Bereczki, D | 1 |
| Fekete, I | 1 |
| Bordánné, JE | 1 |
| Takács, EI | 1 |
| Connolly, SJ | 3 |
| Ammash, N | 1 |
| Warnes, CA | 1 |
| Aronowski, J | 1 |
| Strong, R | 1 |
| Grotta, JC | 3 |
| Diethrich, EB | 1 |
| Ndiaye, M | 1 |
| Reid, DB | 1 |
| Collins, R | 5 |
| Flather, M | 1 |
| Baigent, C | 2 |
| Remvig, L | 1 |
| Mortensen, S | 1 |
| Appleby, P | 1 |
| Godwin, J | 1 |
| Yusuf, S | 1 |
| Dewarrat, A | 1 |
| Martín, R | 1 |
| Bendixen, BH | 2 |
| Adams, HP | 4 |
| Donati, F | 1 |
| Regli, F | 1 |
| Regli, L | 1 |
| Droste, DW | 2 |
| Siemens, HJ | 2 |
| Sonne, M | 2 |
| Kaps, M | 2 |
| Wagner, T | 1 |
| Yim, JM | 1 |
| Belew, KM | 1 |
| Bittar, N | 2 |
| Hattemer, CR | 2 |
| Phillips, BG | 1 |
| Kemp, S | 1 |
| Hall, EA | 2 |
| Morton, DJ | 2 |
| Vlasses, PH | 2 |
| Huggan, PJ | 1 |
| Milne, AA | 1 |
| Bessos, H | 1 |
| Atkinson, A | 1 |
| Murphy, WG | 1 |
| Cimminiello, C | 1 |
| Milani, M | 1 |
| Yudkin, JS | 1 |
| Gidal, BE | 1 |
| Crismon, ML | 1 |
| Wagner, ML | 1 |
| Privitera, MD | 1 |
| Dalmady-Israel, C | 1 |
| Graves, NM | 1 |
| Cunha, L | 2 |
| Forbes, C | 2 |
| Enserink, M | 1 |
| Lipton, SA | 1 |
| Mariani, M | 1 |
| Biadi, O | 1 |
| Gensini, GF | 1 |
| Simone, I | 1 |
| Pantoni, L | 1 |
| Inzitari, D | 2 |
| Barer, D | 2 |
| Schmitz, C | 1 |
| Lindpaintner, K | 2 |
| Elwood, P | 1 |
| Marwick, C | 1 |
| Catella-Lawson, F | 1 |
| FitzGerald, GA | 1 |
| Glynn, RJ | 1 |
| Ajani, U | 1 |
| Sleight, P | 1 |
| Barner, A | 1 |
| De Keyser, J | 2 |
| Herroelen, L | 1 |
| De Klippel, N | 1 |
| Born, GV | 2 |
| Chalon, S | 1 |
| Lechat, P | 1 |
| Rosa, A | 1 |
| Canaple, S | 1 |
| Vane, JR | 1 |
| Meade, TW | 1 |
| Dippel, DW | 2 |
| Nichols, FT | 1 |
| Polasek, J | 1 |
| Ballotta, E | 1 |
| Abbruzzese, E | 1 |
| Thiene, G | 1 |
| Bottio, T | 1 |
| Dagiau, G | 1 |
| Angelini, A | 1 |
| Saladini, M | 1 |
| Cornell, ES | 1 |
| Nightingale, SD | 1 |
| Tracy, RP | 1 |
| Bovill, EG | 1 |
| Feddersen, C | 1 |
| Young, L | 1 |
| Gandhi, AJ | 1 |
| Kemp, SM | 1 |
| Yim, J | 1 |
| Casey, N | 1 |
| Vickerson, F | 1 |
| Israsena, N | 1 |
| Phanthumchinda, K | 1 |
| Sinsawaiwong, S | 1 |
| Lerdlum, S | 1 |
| Bradford, AP | 1 |
| Khan, SA | 1 |
| Lees, KR | 2 |
| McInnes, GT | 1 |
| Semple, PF | 1 |
| Ricci, S | 1 |
| Cantisani, TA | 1 |
| Celani, MG | 1 |
| Righetti, E | 1 |
| Beevers, DG | 1 |
| Tan, LB | 1 |
| Rosendaal, FR | 1 |
| Ryglewicz, D | 1 |
| Baranska-Gieruszczak, M | 1 |
| Czlonkowska, A | 1 |
| Lechowicz, W | 1 |
| Hier, DB | 1 |
| Griesshammer, M | 1 |
| Bangerter, M | 1 |
| van Vliet, HH | 1 |
| Michiels, JJ | 1 |
| Gillum, RF | 1 |
| Hankey, GJ | 1 |
| Bednar, MM | 2 |
| Gross, CE | 2 |
| Howard, DB | 1 |
| Russell, SR | 1 |
| Thomas, GR | 1 |
| Campion-Smith, C | 1 |
| Manning, WJ | 1 |
| Arlien-Søborg, P | 1 |
| Sánchez García, P | 1 |
| Llop, R | 1 |
| Ferrer, A | 1 |
| Agustí, A | 2 |
| Vidal, X | 1 |
| Arnau, JM | 2 |
| Laporte, JR | 2 |
| Karepov, V | 1 |
| Hass, Y | 1 |
| Chesney, CM | 1 |
| Muir, K | 1 |
| Anderson, NE | 2 |
| Bonita, R | 1 |
| Broad, JB | 1 |
| Chamorro, A | 1 |
| Blanc, R | 1 |
| Ascaso, C | 1 |
| Saiz, A | 1 |
| Vila, N | 1 |
| Serebruany, VL | 1 |
| Shustov, AR | 1 |
| Dalesandro, MR | 1 |
| Gumbs, CI | 1 |
| Grabletz, LB | 1 |
| Bahr, RD | 1 |
| Ohman, EM | 1 |
| Killeen, I | 1 |
| Gascón Ramón, G | 1 |
| Bertomeu i Blanch, F | 1 |
| Baño Aracil, M | 1 |
| Madrigal, JA | 1 |
| Weber, AA | 2 |
| Schrör, K | 2 |
| Landmark, K | 1 |
| Valles, J | 1 |
| Santos, MT | 1 |
| Aznar, J | 1 |
| Osa, A | 1 |
| Lago, A | 1 |
| Cosin, J | 1 |
| Sanchez, E | 1 |
| Broekman, MJ | 1 |
| Marcus, AJ | 1 |
| Masuhr, F | 1 |
| Busch, M | 1 |
| Einhäupl, KM | 1 |
| Pathansali, R | 1 |
| Choussat, R | 1 |
| Montalescot, G | 1 |
| Picano, E | 1 |
| Abbracchio, MP | 1 |
| Kokurina, EV | 1 |
| Khromov, GL | 1 |
| Davydo, AB | 1 |
| Metelitsa, VI | 1 |
| Tanashian, MM | 1 |
| Demina, EG | 1 |
| Bochkareva, EV | 1 |
| Belolipetskaia, VG | 1 |
| Deev, AD | 1 |
| Kucheriaeva, NG | 1 |
| Zidra, SI | 1 |
| Gorin, NN | 1 |
| Rumiantsev, DO | 1 |
| Gibbs, CR | 1 |
| Li-Saw-Hee, FL | 2 |
| Singh, J | 1 |
| Hui, F | 1 |
| Lim, MK | 1 |
| Gibaldi, M | 1 |
| Eccles, M | 1 |
| Freemantle, N | 1 |
| Mason, J | 1 |
| Tijssen, JG | 2 |
| Puranen, J | 2 |
| Riekkinen, P | 3 |
| Gorter, JW | 2 |
| Pellegrino, TR | 1 |
| Dyken, M | 1 |
| Kronmal, RA | 1 |
| Manolio, TA | 2 |
| Beauchamp, NJ | 1 |
| Newman, A | 1 |
| Fernández, PL | 1 |
| Godtfredsen, J | 3 |
| Schipper, JP | 1 |
| Sparks, PB | 1 |
| Mond, HG | 1 |
| Kalman, JM | 1 |
| Jayaprakash, S | 1 |
| Lewis, MA | 1 |
| Grigg, LE | 1 |
| Schneider, D | 1 |
| Stiffman, MN | 1 |
| Pedersen, TS | 1 |
| Andersen, ED | 1 |
| Kurz, X | 1 |
| Annemans, L | 1 |
| Dresse, A | 1 |
| Parving, HH | 1 |
| Grau, AJ | 1 |
| Ruf, A | 1 |
| Vogt, A | 1 |
| Lichy, C | 1 |
| Buggle, F | 1 |
| Patscheke, H | 1 |
| Bosch, X | 1 |
| Cheung, R | 1 |
| Cairns, JA | 2 |
| Bentsen, N | 1 |
| Kendall, MJ | 1 |
| Toescu, V | 1 |
| Köhler, U | 1 |
| Carter, K | 1 |
| Miller, KM | 1 |
| Nademanee, K | 1 |
| Kosar, EM | 1 |
| Albers, G | 1 |
| Dalen, J | 1 |
| Dunn, MI | 1 |
| Jacobson, AK | 1 |
| Ibsen, H | 1 |
| Zambrana, JL | 1 |
| Díez, F | 1 |
| Delgado, M | 1 |
| Salas, J | 1 |
| Maldonado, J | 1 |
| Harpaz, D | 1 |
| Gottlieb, S | 1 |
| Graff, E | 1 |
| Boyko, V | 1 |
| Kishon, Y | 1 |
| Behar, S | 1 |
| Goertler, M | 1 |
| Baeumer, M | 1 |
| Kross, R | 1 |
| Blaser, T | 1 |
| Lutze, G | 1 |
| Jost, S | 1 |
| Wallesch, CW | 1 |
| Maria, BL | 1 |
| Neufeld, JA | 1 |
| Rosainz, LC | 1 |
| Drane, WE | 1 |
| Quisling, RG | 1 |
| Ben-David, K | 1 |
| Hamed, LM | 1 |
| Petty, GW | 2 |
| Brown, RD | 1 |
| Sicks, JD | 1 |
| O'Fallon, WM | 1 |
| Wiebers, DO | 1 |
| Riggs, PN | 1 |
| DeWeese, JA | 1 |
| Creager, MA | 1 |
| Zee, RY | 1 |
| Flaker, GC | 1 |
| McGowan, DJ | 1 |
| Boechler, M | 1 |
| Fortune, G | 1 |
| Gage, B | 1 |
| Marcus, RR | 1 |
| Atwood, JE | 2 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Sheminant, MR | 1 |
| Whitford, EG | 1 |
| Mahon, BD | 1 |
| Newman, MA | 1 |
| Vidt, DG | 1 |
| Pohl, MA | 1 |
| Isles, C | 1 |
| Norrie, J | 1 |
| Paterson, J | 1 |
| Ritchie, L | 1 |
| Zielinski, R | 1 |
| French, L | 1 |
| Thrift, AG | 1 |
| Forbes, A | 1 |
| Rosenberg, R | 1 |
| Matanin, D | 1 |
| Rojas-Fernandez, CH | 1 |
| Kephart, GC | 1 |
| Sketris, IS | 1 |
| Kass, K | 1 |
| Charleston, AJ | 1 |
| Barber, PA | 1 |
| Bennett, P | 1 |
| Spriggs, DA | 1 |
| Harris, RG | 1 |
| Catherwood, E | 1 |
| Fitzpatrick, WD | 1 |
| Greenberg, ML | 1 |
| Holzberger, PT | 1 |
| Malenka, DJ | 1 |
| Gerling, BR | 1 |
| Birkmeyer, JD | 1 |
| Saxena, R | 1 |
| Wijnhoud, AD | 1 |
| Carton, H | 1 |
| Przybelski, RJ | 1 |
| Stern, KN | 1 |
| Rodríguez, D | 1 |
| Merz, B | 3 |
| Simoons, ML | 1 |
| Granger, CB | 1 |
| Laskowitz, DT | 1 |
| Miller, JM | 1 |
| Sloan, MA | 1 |
| Berdan, LG | 1 |
| MacAulay, CM | 1 |
| Lincoff, AM | 1 |
| Deckers, J | 1 |
| Benavente, O | 2 |
| Bloom, JM | 1 |
| Mollison, LC | 1 |
| James-Wallace, MJ | 1 |
| Kirke, AB | 1 |
| Stein, GR | 1 |
| Jamrozik, KD | 1 |
| Puri, V | 1 |
| Riggs, G | 1 |
| Koudstaal, A | 1 |
| Levine, JA | 1 |
| Hansson, L | 1 |
| Labovitz, AJ | 1 |
| Fukuuchi, Y | 1 |
| McBride, R | 3 |
| Rothbart, RM | 1 |
| Asinger, RW | 1 |
| Johnson, ES | 1 |
| Lanes, SF | 1 |
| Wentworth, CE | 1 |
| Satterfield, MH | 1 |
| Abebe, BL | 1 |
| Dicker, LW | 1 |
| Chen, F | 1 |
| Posada, IS | 1 |
| Barriales, V | 1 |
| Haynes, RB | 1 |
| Ferguson, GG | 1 |
| Thorpe, KE | 1 |
| Simard, D | 1 |
| Silver, FL | 1 |
| Hachinski, V | 3 |
| Barnes, R | 1 |
| Spence, JD | 1 |
| Moroney, JT | 1 |
| Tseng, CL | 1 |
| Paik, MC | 1 |
| Mohr, JP | 5 |
| Desmond, DW | 1 |
| Smith, NL | 1 |
| Psaty, BM | 1 |
| Furberg, CD | 1 |
| White, R | 1 |
| Lima, JA | 1 |
| Newman, AB | 1 |
| Wellman, M | 1 |
| Martin, AC | 1 |
| Bellelli, G | 1 |
| Barbisoni, P | 1 |
| Gusmeri, A | 1 |
| Sabatini, T | 1 |
| Rozzini, R | 1 |
| Trabucchi, M | 1 |
| Scheen, AJ | 1 |
| Gubitz, GJ | 1 |
| Wensley, S | 1 |
| Keir, S | 1 |
| Caine, S | 1 |
| Mac Mahon, M | 1 |
| Gollub, SB | 1 |
| Man-Son-Hing, M | 1 |
| O'Connor, AM | 1 |
| Biggs, J | 1 |
| Drake, E | 1 |
| Yetisir, E | 1 |
| Iso, H | 1 |
| Rexrode, KM | 1 |
| Colditz, GA | 1 |
| Speizer, FE | 1 |
| Wilterdink, JL | 1 |
| Gupta, I | 1 |
| Bennett, G | 1 |
| Gompertz, P | 1 |
| Almdal, TP | 1 |
| Eldrup, E | 1 |
| Kofoed-Enevoldsen, A | 1 |
| Sulter, G | 1 |
| Harker, LA | 5 |
| Boissel, JP | 1 |
| Pilgrim, AJ | 1 |
| Steiner, M | 1 |
| Cruz-Fernández, JM | 1 |
| López-Bescós, L | 1 |
| García-Dorado, D | 1 |
| López García-Aranda, V | 1 |
| Cabadés, A | 1 |
| Martín-Jadraque, L | 1 |
| Velasco, JA | 1 |
| Castro-Beiras, A | 1 |
| Torres, F | 1 |
| Marfil, F | 1 |
| Navarro, E | 1 |
| Awtry, EH | 1 |
| Loscalzo, J | 1 |
| Mok, V | 1 |
| Lam, WW | 1 |
| Kay, R | 1 |
| Tang, A | 1 |
| Chan, YL | 1 |
| Woo, J | 1 |
| Cohen, SN | 1 |
| Bhatt, DL | 1 |
| Kapadia, SR | 1 |
| Yadav, JS | 1 |
| Heidebrink, JL | 1 |
| Paganini-Hill, A | 1 |
| Perez Barreto, M | 1 |
| Redman, AR | 1 |
| Ryan, GJ | 1 |
| Przytulski, B | 1 |
| Schanz, A | 1 |
| Hohlfeld, T | 1 |
| Soriano, D | 1 |
| Carp, H | 1 |
| Seidman, DS | 1 |
| Schiff, E | 1 |
| Langevitz, P | 1 |
| Mashiach, S | 1 |
| Dulitzky, M | 1 |
| Dougherty, JH | 1 |
| Levy, DE | 1 |
| Weksler, BB | 1 |
| Jobin, F | 1 |
| Spetzler, RF | 1 |
| Myers, MD | 1 |
| Bell, M | 1 |
| Didisheim, P | 4 |
| Weiss, HJ | 1 |
| Machleder, HI | 1 |
| De Mey, C | 1 |
| Wellens, D | 1 |
| Vanhoutte, PM | 1 |
| Dettori, AG | 1 |
| Pini, M | 1 |
| Quintavalla, R | 1 |
| Ostendorf, P | 1 |
| Gantmacher, ML | 1 |
| Bogoiavlenskaia, NM | 1 |
| Field, PL | 1 |
| Mathur, JG | 1 |
| Armitage, P | 1 |
| Watson, RT | 1 |
| Blakely, JA | 1 |
| Ts'ao, CH | 1 |
| Ali, N | 1 |
| Kolb, T | 1 |
| Linos, A | 1 |
| Worthington, JW | 1 |
| O'Fallon, W | 1 |
| Kurland, LT | 1 |
| Duncan, GW | 1 |
| Adams, RD | 1 |
| Aledort, LM | 1 |
| Corn, M | 1 |
| Gotshall, RA | 1 |
| Furlow, TW | 1 |
| Bass, NH | 1 |
| Silverman, JF | 1 |
| Wexler, L | 1 |
| Gschwend, J | 1 |
| Cervantes, FD | 1 |
| Schneiderman, LJ | 1 |
| Browder, A | 1 |
| Browder, J | 1 |
| Kalendovsky, Z | 1 |
| Austin, J | 1 |
| Steele, P | 1 |
| Vaisrub, S | 1 |
| Sawaya, JI | 1 |
| Gossmann, J | 1 |
| Jamieson, C | 1 |
| Smith, SE | 1 |
| Pop, GA | 1 |
| Lee, TK | 3 |
| Ng, SK | 1 |
| Huang, ZS | 3 |
| Chen, YC | 3 |
| Long, K | 1 |
| Long, R | 1 |
| Dalen, JE | 4 |
| Harker, LB | 1 |
| Salzman, EW | 2 |
| Anderson, FA | 1 |
| Levine, MN | 2 |
| Wheeler, HB | 1 |
| Konno, S | 1 |
| Kimura, B | 2 |
| Kawano, K | 1 |
| Overgaard, K | 1 |
| Sereghy, T | 1 |
| Pedersen, H | 1 |
| Ma, ZZ | 1 |
| Luo, Y | 1 |
| Tang, HC | 1 |
| Li, CF | 1 |
| Yin, ZJ | 1 |
| Blewett, DR | 2 |
| Rosner, B | 2 |
| Nolan, J | 1 |
| Bloomfield, P | 1 |
| Baume, P | 1 |
| McAnally, LE | 1 |
| Corn, CR | 1 |
| Hamilton, SF | 1 |
| Cowan, S | 1 |
| Gustafsson, C | 1 |
| Asplund, K | 1 |
| Olsson, B | 1 |
| Marké, LA | 1 |
| Kahn, JK | 1 |
| Goldberg, RJ | 1 |
| Maggioni, AP | 1 |
| Franzosi, MG | 1 |
| Santoro, E | 1 |
| White, H | 1 |
| Tognoni, G | 1 |
| Wilcox, M | 1 |
| Fossum, K | 1 |
| Healy, B | 1 |
| Alter, M | 1 |
| Lai, SM | 1 |
| Friday, GH | 1 |
| Sobel, E | 1 |
| Toedter, LJ | 1 |
| Dunbabin, D | 1 |
| Floeter, MK | 1 |
| Weinstein, SM | 1 |
| Cantu, RC | 1 |
| Kilpeläinen, H | 1 |
| Penttilä, I | 1 |
| Ferlito, S | 1 |
| Stachenko, SJ | 1 |
| Bravo, G | 1 |
| Boucher, J | 1 |
| Battista, RN | 1 |
| Hershey, LA | 1 |
| Roberts, RS | 1 |
| Cairns, J | 1 |
| Joyner, C | 1 |
| de Falco, FA | 1 |
| Montariello, A | 1 |
| Mastroroberto, G | 1 |
| Visconti, OS | 1 |
| Penttilä, IM | 1 |
| Gordon, DL | 1 |
| Han, E | 1 |
| Joseph, R | 3 |
| Grunfeld, S | 1 |
| Welch, KM | 3 |
| Weissmann, G | 1 |
| Sharpe, N | 1 |
| Kappelle, J | 1 |
| van Latum, A | 1 |
| Mayo, NE | 1 |
| Levy, AR | 1 |
| Goldberg, MS | 1 |
| Kutner, M | 1 |
| Nixon, G | 1 |
| Silverstone, F | 1 |
| Fossan, G | 1 |
| Duprez, D | 1 |
| Clement, DL | 1 |
| Besson, G | 1 |
| Gaziano, JM | 1 |
| Lekstrom, JA | 1 |
| Bell, WR | 1 |
| Widder, B | 1 |
| Kleiser, B | 1 |
| Krapf, H | 1 |
| Reuchlin, G | 1 |
| Dürr, A | 1 |
| Pramsohler, B | 1 |
| Lupattelli, G | 1 |
| Scholz, H | 1 |
| Sinzinger, H | 1 |
| Nayak, S | 1 |
| Fratiglioni, L | 1 |
| Baldereschi, M | 1 |
| Candelise, L | 1 |
| Anzalone, N | 1 |
| Bonatti, ML | 1 |
| Prencipe, M | 1 |
| Gandolfo, C | 1 |
| Rasura, M | 1 |
| de Gaetano, G | 1 |
| Thompson, J | 1 |
| McDonald, PJ | 1 |
| Johnson, CD | 1 |
| Toffol, GJ | 1 |
| Oelz, O | 2 |
| Meier, PJ | 1 |
| Nelson, E | 1 |
| Jonas, S | 1 |
| Lima, JM | 1 |
| Thorngren, M | 1 |
| Eckert, B | 1 |
| Vinge, E | 1 |
| Marshall, J | 1 |
| Koutts, J | 1 |
| Landercasper, J | 1 |
| Merz, BJ | 1 |
| Cogbill, TH | 1 |
| Strutt, PJ | 1 |
| Cochrane, RH | 1 |
| Olson, RA | 1 |
| Hutter, RD | 1 |
| Kollegger, H | 1 |
| Oder, W | 1 |
| Carné, X | 1 |
| Gao, BT | 1 |
| Kuo, TL | 1 |
| Lien, IN | 2 |
| Liu, MC | 2 |
| Makuch, R | 1 |
| Johnson, M | 1 |
| Stein, B | 1 |
| Israel, DH | 1 |
| Cohen, M | 1 |
| Badimon, L | 1 |
| Badimon, JJ | 1 |
| Goyan, JE | 1 |
| D'Andrea, G | 2 |
| Bennett, DA | 1 |
| Fox, JH | 1 |
| Pryse-Phillips, W | 1 |
| Molony, BA | 1 |
| Anderson, S | 1 |
| Abildgaard, U | 1 |
| Dahl, T | 1 |
| Sandset, PM | 1 |
| Belcaro, G | 1 |
| Errichi, BM | 1 |
| Laurora, G | 1 |
| Marinucci, R | 1 |
| Cesarone, MR | 1 |
| De Cenzo, A | 1 |
| Starkey, I | 1 |
| Sacco, RL | 1 |
| Hauser, WA | 1 |
| Tatemichi, TK | 1 |
| Oster, SB | 1 |
| Baudoin, C | 1 |
| Wilhelmsen, L | 1 |
| Scheinberg, P | 1 |
| Callow, AD | 1 |
| Correll, JW | 1 |
| Robertson, JT | 1 |
| Patterson, RH | 1 |
| Dobkin, BH | 1 |
| Gómez, L | 1 |
| García Rafanell, J | 1 |
| Forn, J | 1 |
| Orme, M | 1 |
| Gray, R | 1 |
| Wheatley, K | 1 |
| Jamrozik, K | 1 |
| Hafner, B | 1 |
| Thompson, E | 1 |
| Norton, S | 1 |
| Weber, E | 1 |
| Alijotas Reig, J | 1 |
| Dubach, P | 1 |
| Cusimano, MD | 1 |
| Sze, PC | 1 |
| Reitman, D | 1 |
| Pincus, MM | 1 |
| Sacks, HS | 1 |
| Mirsen, TR | 1 |
| Hachinski, VC | 1 |
| Vermeulen, M | 1 |
| Monti, M | 1 |
| Matías-Guiu, J | 1 |
| Dávalos, A | 1 |
| Picó, M | 1 |
| Monasterio, J | 1 |
| Vilaseca, J | 1 |
| Codina, A | 1 |
| Becker, WL | 1 |
| Burde, RM | 1 |
| Young, FE | 1 |
| Nightingale, SL | 1 |
| Temple, RA | 1 |
| Kimura, M | 1 |
| Suzuki, H | 1 |
| Pinna, AD | 1 |
| Argiolu, F | 1 |
| Marongiu, L | 1 |
| Pinna, DC | 1 |
| Brick, JF | 1 |
| Brick, JE | 1 |
| Sheng, FC | 1 |
| Busuttil, RW | 1 |
| Gary, HE | 1 |
| Caneschi, S | 1 |
| Bonaventi, C | 1 |
| Finzi, F | 1 |
| Tito, P | 1 |
| Freeman, JW | 1 |
| Maekawa, T | 1 |
| Tuhrim, S | 1 |
| Reggia, JA | 1 |
| Lecompte, T | 1 |
| Samama, M | 1 |
| Colwell, JA | 2 |
| Bingham, SF | 2 |
| Rosenthal, D | 1 |
| Lamis, PA | 1 |
| Stanton, PE | 1 |
| Clark, MD | 1 |
| Ellison, RG | 1 |
| Perry, MO | 1 |
| David, JL | 1 |
| Kasuya, A | 1 |
| Holm, K | 1 |
| Brandon, RA | 1 |
| Eadie, MJ | 1 |
| Diaz, FG | 1 |
| Ausman, JI | 1 |
| Chapman, CS | 1 |
| Swart, SS | 1 |
| Wood, JK | 1 |
| Aoki, N | 1 |
| Foster, JW | 1 |
| Geeraert, AJ | 1 |
| Al Saigh, AH | 1 |
| Long, JB | 1 |
| Lynch, TG | 1 |
| Karanfilian, RG | 1 |
| Gary, H | 1 |
| Vital, D | 1 |
| Preston, FE | 1 |
| Greaves, M | 1 |
| Findlay, JM | 1 |
| Lougheed, WM | 1 |
| Gentili, F | 1 |
| Walker, PM | 1 |
| Glynn, MF | 1 |
| Houle, S | 1 |
| Abraira, C | 1 |
| Anderson, JW | 1 |
| Kwaan, HC | 1 |
| Boss, AH | 1 |
| Olseen, JS | 1 |
| Bunt, TJ | 1 |
| Haynes, JL | 1 |
| Rubin, JR | 1 |
| Mocchi, N | 1 |
| Sbalzarini, G | 1 |
| Cantaluppi, P | 1 |
| Loeliger, EA | 1 |
| Yoshii, K | 1 |
| Seki, Y | 1 |
| Aiba, T | 1 |
| Tsukada, T | 1 |
| Shiozawa, R | 1 |
| Frisén, L | 1 |
| Kazmier, FJ | 1 |
| Géraud, J | 1 |
| Rascol, A | 1 |
| Bierme, R | 1 |
| Boneu, B | 2 |
| Guiraud, B | 2 |
| Fernet, P | 2 |
| Géraud, G | 1 |
| David, J | 1 |
| Vroom, FQ | 2 |
| Greenhouse, AH | 1 |
| Currier, RD | 1 |
| Haerer, AF | 1 |
| Millikan, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Postoperative Pain Control Between Transarticular VS Periartiucular Multimodal Drug Infiltration in Total Hip Arthroplasty: Double-blinded Randomized Control Trial[NCT05325671] | 120 participants (Anticipated) | Interventional | 2022-04-05 | Not yet recruiting | |||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China[NCT05316311] | 194 participants (Anticipated) | Interventional | 2022-05-24 | Recruiting | |||
| The Predictive Value of Retinal Vascular Signs for Patients With Intracranial Artery Stenosis: A Prospective, Continuity Study, Cross-sectional Study[NCT05270746] | 1,000 participants (Anticipated) | Observational | 2022-02-27 | Not yet recruiting | |||
| [NCT00153725] | 156 participants | Interventional | 2003-02-28 | Completed | |||
| Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention[NCT01888575] | 35,604 participants (Actual) | Observational | 2012-09-30 | Completed | |||
| The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users[NCT01814943] | 39,000 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Multicenter, Prospective Cohort of Patient With Coronary Stents Undergoing Non Cardiac Surgery or Invasive Procedures.[NCT01045850] | 1,312 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414] | 12 participants | Observational | 2000-10-31 | Completed | |||
| Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233] | 400 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073] | Phase 1/Phase 2 | 95 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Atrial Fibrillation Registry at the Emergency Department of the Medical University of Vienna: A Tool for Structured Diagnosis and Treatment[NCT03272620] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2014-10-22 | Recruiting | |||
| Clinical and Laboratory Predictors Associated With Stroke or Systemic Embolism in Atrial Fibrillation Patients Defined as Population With a Low Risk of Stroke Based on a CHA2DS2-VASc Score[NCT03147911] | 1,181 participants (Actual) | Observational | 2017-04-06 | Completed | |||
| [NCT00000517] | Phase 3 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)[NCT02603406] | Phase 2 | 44 participants (Actual) | Interventional | 2016-07-15 | Completed | ||
| National Institute of Health Research (NIHR) Global Health Research Group on Warfarin Anticoagulation in Patients With Cardiovascular Disease in Sub-Saharan Africa[NCT03512080] | 1,500 participants (Anticipated) | Observational | 2018-06-11 | Active, not recruiting | |||
| An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent With Neurotrophic Properties in Major Depression[NCT00026052] | Phase 2 | 31 participants | Interventional | 2001-11-30 | Completed | ||
| Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty[NCT00597974] | 108 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| Phase II Dose-finding Open Study of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Injection Administered Within 3 Hours After Onset of Hyperacute Ischemic Stroke[NCT04676659] | Phase 2 | 240 participants (Actual) | Interventional | 2018-05-12 | Completed | ||
| Thrombolysis Treated by TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Control and Non-inferior Phase Ⅲ Trial, 3T Stroke-Ⅲ[NCT05745259] | Phase 3 | 1,630 participants (Anticipated) | Interventional | 2022-10-26 | Recruiting | ||
| Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Controlled Phase II Trial[NCT05281549] | Phase 2 | 225 participants (Anticipated) | Interventional | 2021-05-02 | Active, not recruiting | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups[NCT01645306] | Phase 2 | 158 participants (Actual) | Interventional | 2013-03-08 | Completed | ||
| First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment[NCT04037397] | Phase 3 | 120 participants (Anticipated) | Interventional | 2019-09-24 | Active, not recruiting | ||
| Vascular Access Options in Coronary Angiogram Procedures: A Patient Decision Aid Randomized Controlled Trial[NCT01032551] | 100 participants (Anticipated) | Interventional | 2010-06-30 | Completed | |||
| Nurses' Health Study (Cardiovascular Component)[NCT00005152] | 121,700 participants (Actual) | Observational | 1980-08-31 | Active, not recruiting | |||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781] | Phase 3 | 476 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| [NCT00000151] | Phase 3 | 0 participants | Interventional | 1979-12-31 | Completed | ||
| Echocardiographic Risk Factors of Stroke in Patients With Atrial[NCT03824509] | 140 participants (Actual) | Observational | 2019-01-01 | Completed | |||
| Stroke Prediction Study Using a Model Based on Internet Search Queries[NCT04755959] | 450 participants (Anticipated) | Observational | 2021-02-28 | Not yet recruiting | |||
| Induction of Mucosal Tolerance to E-Selectin for the Secondary Prevention of Stroke[NCT00012454] | Phase 2 | 60 participants | Interventional | 2001-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
"Anti-drug antibodies were measured at baseline and 3 month after IMP application.~Number of patients with positive anti-drug antibodies compared to baseline are counted." (NCT01645306)
Timeframe: 3 month (+/- 1 month) after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| 40 mg Revacept | 0 |
| 120 mg Revacept | 0 |
patients with any stroke & TIA, myocardial infarction & percutaneous coronary intervention (PCI), death or bleeding within one year (365 days) after IMP application. (NCT01645306)
Timeframe: 365 days after IMP application
| Intervention | Number of Events (Number) |
|---|---|
| Placebo | 19 |
| 40 mg Revacept | 15 |
| 120 mg Revacept | 10 |
patients with major bleedings occuring within 90 days after IMP application (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 5 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline). (NCT01645306)
Timeframe: 1 day post intervention
| Intervention | Number of new lesions (Mean) |
|---|---|
| Placebo | 1.2 |
| 40 mg Revacept | 1.0 |
| 120 mg Revacept | 0.6 |
patients with any stroke or TIA occuring within 90 days after IMP application. (NCT01645306)
Timeframe: 90 days after IMP application
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 6 |
| 40 mg Revacept | 6 |
| 120 mg Revacept | 4 |
All adverse events were assessed during complete study period (~ 1 year after IMP application). (NCT01645306)
Timeframe: ~ 365 days after IMP application (whole study period)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| patients with adverse events | patients with drug related AEs | patients with serious AEs | patients with drug related serious AEs | patients with AE with fatal outcome events | |
| 120 mg Revacept | 32 | 2 | 15 | 0 | 1 |
| 40 mg Revacept | 41 | 10 | 17 | 4 | 0 |
| Placebo | 35 | 4 | 17 | 1 | 0 |
233 reviews available for aspirin and Cerebrovascular Disorders
| Article | Year |
|---|---|
[Aspirin in primary prevention of cardiovascular and cerebrovascular diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders | 2021 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Antithrombotic treatment of asymptomatic carotid atherosclerosis: a medical dilemma.
Topics: Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Cerebrovascular Disorders; Fibrinolytic A | 2020 |
A Systematic Review of the Efficacy and Safety of Aspirin When Delivered at Different Medication Times for the Primary and Secondary Prevention of Cardiovascular and Cerebrovascular Diseases.
Topics: Aspirin; Blood Pressure; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Seconda | 2020 |
Differences in the prevention and control of cardiovascular and cerebrovascular diseases.
Topics: Animals; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; | 2021 |
Single versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Topics: Aortic Valve; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Heart Valv | 2018 |
Medical and endovascular treatments of symptomatic intracranial stenosis. A Bayesian network meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cerebrovascular Disorders; Constriction, Pathologic; Endovas | 2019 |
Clinical consequences of aspirin and clopidogrel resistance: an overview.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-450 CYP | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studie | 2014 |
[Statins and ASS for primary prevention of cardiovascular and cerebrovascular disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Cereb | 2014 |
Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Chi-Square Distribution; Coronary Thrombosis; Drug Administratio | 2015 |
Aspirin, clopidogrel, and the surgeon.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Humans; Platelet Aggregati | 2014 |
The prognostic utility of tests of platelet function for the detection of 'aspirin resistance' in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cost-Benefit Analysis; Drug Resistance; | 2015 |
Yosprala - a combination of aspirin and omeprazole.
Topics: Animals; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Dela | 2017 |
[Low-dose aspirin for management of cerebrovascular diseases].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors | 2009 |
Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trial | 2010 |
[Efficacy and safety of various doses of acetylsalicylic Acid in prevention of complications of atherothrombosis].
Topics: Aspirin; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2010 |
[Low-dose aspirin induced intestinal damage -including the influence of low-dose aspirin to existing lesions-].
Topics: Animals; Aspirin; Capsule Endoscopy; Cerebrovascular Disorders; Cyclooxygenase Inhibitors; Gastroint | 2010 |
[Strategy to manage low dose aspirin-induced gastrointestinal injury].
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Famotid | 2011 |
Reducing the risk of gastroduodenal ulcers with a fixed combination of esomeprazole and low-dose acetyl salicylic acid.
Topics: Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Therapy, Combin | 2011 |
Antiplatelet therapy in cerebrovascular disorders.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Platelet Aggr | 2012 |
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; My | 2002 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2003 |
Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Topics: Administration, Oral; Angina Pectoris; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopido | 2004 |
Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Prote | 2005 |
Risk of hemorrhagic stroke with aspirin use: an update.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain | 2005 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2006 |
Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Pl | 2006 |
The dose of aspirin for the prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; Humans; Meta-Analy | 2006 |
Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Resistance; Humans | 2006 |
[Acute and chronic headaches].
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2006 |
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Ische | 2007 |
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug The | 2008 |
Antiplatelet agents: rationale and results.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Aspirin; Blood Plate | 1983 |
[Role of antiaggregant platelet drugs in thromboembolism].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Aspirin; Cerebrova | 1981 |
Chemistry, measurement, and clinical significance of platelet specific proteins.
Topics: Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Coagulation; Blood Coagulation Factors; Blood P | 1982 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Clinical aspects of the arachidonic acid--thromboxane pathway.
Topics: Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Coagulation; Cerebrovascular Disorders; Epoprost | 1983 |
Current therapy of cerebrovascular disease.
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Ische | 1984 |
Aspirin for prevention of stroke: a review.
Topics: Aspirin; Cell Adhesion; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Platelet Aggr | 1983 |
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib | 1983 |
Therapeutical aspects of cerebrovascular disease.
Topics: Aspirin; Blood Coagulation; Cerebrovascular Disorders; Clofibrate; Dipyridamole; Erythrocyte Aggrega | 1983 |
Transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Cerebral Angiography; Cerebral Revascularization; Ce | 1983 |
Therapy of ischemic cerebral vascular disease due to atherothrombosis. (2).
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Auscultation; Basilar Artery; Blood Platelets; | 1984 |
Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets.
Topics: Angina Pectoris; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Carotid Artery Thrombosi | 1984 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
[Prevention of thrombosis by thrombocyte inhibition. 2. Clinical results].
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofibrate; Dextrans; | 1980 |
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
[Specific measures in drug therapy in stroke. Anticoagulants, inhibitors of thrombocyte aggregation, initial barbiturate therapy].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Barbiturates; Carotid Arteries; Cerebral Infar | 1980 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
Recent advances in the treatment of cerebrovascular diseases.
Topics: Anticoagulants; Aspirin; Carotid Arteries; Cerebral Revascularization; Cerebrovascular Disorders; En | 1980 |
[Platelet antiaggregants and arteriopathies].
Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyr | 1981 |
[Medical or chirurgical treatment in transient cerebral ischemia? (author's transl)].
Topics: Aged; Anticoagulants; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy; Female; | 1981 |
Antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyridamole; Hea | 1981 |
Cerebrovascular disease.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Blood Platelets; Cerebrovascular Disorders; Fibrin | 1981 |
Antiplatelet therapy in coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disor | 1982 |
Primary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Contraceptives, Oral; Diabetes Complications; Diet; Estrogen Rep | 1995 |
Anticoagulants: when and how?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Randomized Controll | 1994 |
Medical compared with surgical treatment of asymptomatic carotid artery stenosis.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Combined Modality Therapy; Endarterectomy, Car | 1995 |
Aspirin to prevent heart attack or stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction | 1994 |
Warfarin or aspirin for non-rheumatic atrial fibrillation?
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Randomized Controlled Trials as Top | 1994 |
Who should be taking daily aspirin?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Randomized Controlled Trials as T | 1995 |
Treatment of stroke in older patients. A state of the art review.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Community Health Services; Deglutitio | 1995 |
Stroke prevention.
Topics: Alcohol Drinking; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1995 |
[Thromboembolic complications in the course of non-valvular atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Tr | 1995 |
Current issues concerning thrombolytic therapy for acute myocardial infarction.
Topics: Anistreplase; Aspirin; Cerebrovascular Disorders; Forecasting; Humans; Myocardial Infarction; Random | 1995 |
What's new in stroke?
Topics: Acute Disease; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrova | 1995 |
Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Combined Modality Th | 1995 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Gastroint | 1995 |
Aspirin in asymptomatic carotid disease.
Topics: Aspirin; Brain Ischemia; Carotid Artery Diseases; Carotid Stenosis; Cerebrovascular Disorders; Human | 1994 |
Prevention of stroke in atrial fibrillation: an update.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Intracra | 1994 |
Atrial fibrillation and stroke. Three new studies, three remaining questions.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; H | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; | 1994 |
Preventing stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male; Randomized Cont | 1994 |
Aspirin, platelets, and thrombosis: theory and practice.
Topics: Animals; Aspirin; Blood Platelets; Cerebrovascular Disorders; Humans; Models, Biological; Myocardial | 1994 |
Secondary prevention of stroke: does dipyridamole add to aspirin?
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Humans; Randomized Cont | 1994 |
Arkansas Foundation for Medical Care report: preventing stroke in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as | 1994 |
Antithrombotic therapies for stroke prevention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Fibrinolyti | 1994 |
[Advances in prophylactic treatment of cerebrovascular diseases].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Endarterectomy, Carotid; Humans | 1994 |
Current management of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Electric C | 1994 |
[Acetylsalicylic acid in arterial circulatory disorders. Which dosage in which indication?].
Topics: Arterial Occlusive Diseases; Aspirin; Blood Circulation; Cerebrovascular Disorders; Coronary Disease | 1994 |
Surgical management of carotid artery atherosclerotic disease.
Topics: Aged; Angiography; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Cause of Death; Cerebrovascul | 1993 |
[Low dose acetylsalicylic acid in secondary prevention of stroke].
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Trans | 1993 |
Antiplatelet therapy in the treatment of cerebrovascular disease.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Male; Midd | 1993 |
Stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Humans; Ran | 1993 |
[Asymptomatic carotid stenoses. Analysis of randomized studies].
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Randomized Co | 1993 |
[The prevention of stroke in atrial fibrillation].
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Pro | 1993 |
Prophylactic drug therapy in cerebrovascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ticlopidine; Warfarin | 1993 |
Diabetes and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Diabetes Complications; Humans; Risk Factors | 1993 |
Antiplatelet and anticoagulant therapy.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; | 1993 |
Strategies for preventing stroke.
Topics: Adult; Aged; Aspirin; Blood Pressure; Cerebrovascular Disorders; Endarterectomy, Carotid; Female; Hu | 1993 |
Heparin and warfarin therapy after acute myocardial infarction.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Injections, Intraven | 1993 |
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fibrinolytic Agents; Humans | 1996 |
[Current status of primary and secondary prevention of cerebral apoplexy].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidi | 1995 |
Management of atrial fibrillation in adults: prevention of thromboembolism and symptomatic treatment.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Aspirin; Atrial Fibri | 1996 |
New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Anticoagulants; Aspirin; | 1995 |
Stroke prevention: the emerging strategies.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Decision Trees; Humans; Isc | 1996 |
Atrial fibrillation, anticoagulation, and stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fe | 1996 |
Aspirin wars: the optimal dose of aspirin prevent stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, | 1996 |
Aspirin dose in stroke prevention: beautiful hypotheses slain by ugly facts.
Topics: Aspirin; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, | 1996 |
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Coronary Circulatio | 1996 |
[Atrial fibrillation due to non-valvular causes: indications for antithrombotic therapy].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as To | 1996 |
[Diagnosis and treatment of cerebrovascular accidents of cardioembolic origin].
Topics: Aged; Anticoagulants; Aortic Diseases; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cardiomyopath | 1996 |
Antithrombotic therapy in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio | 1996 |
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Myoc | 1996 |
[Antithrombotic agents and prevention of cerebrovascular accidents].
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clopidogrel; Echocardiography; Humans; Intr | 1996 |
The role of dipyridamole in stroke prevention.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Humans; | 1996 |
Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Humans; Platelet Aggregation Inhibi | 1996 |
[Antiplatelet drugs as a preventive measure of stroke--treatment strategies by subtypes of ischemic stroke].
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Male; Middle Age | 1996 |
Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
Current developments in neurology, Part II: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke.
Topics: Alzheimer Disease; Anticoagulants; Apomorphine; Aspirin; Cerebrovascular Disorders; Cholinergic Agen | 1996 |
[Clinical studies of the effectiveness of aspirin in the prevention of major cardio-cerebrovascular occurrences].
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Myocardial I | 1995 |
[Large trials in the secondary prevention of stroke].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Cost-Benefit Analysis; | 1996 |
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fi | 1997 |
Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Hepa | 1997 |
[Antithrombotic therapy of atrial fibrillation].
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascular Diso | 1996 |
Recent advances in stroke management.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Female; Fibrinolytic Agents; Humans; In | 1997 |
The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators.
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; Fem | 1997 |
Aspirin in essential thrombocythemia: status quo and quo vadis.
Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome | 1997 |
Role of transesophageal echocardiography in the management of thromboembolic stroke.
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Aspirin; Cerebrovascular Disorde | 1997 |
Low- versus high-dose aspirin in prevention of ischemic stroke.
Topics: Animals; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Human | 1993 |
[Intervention in risk factors and protection of target organs].
Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Est | 1997 |
[Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Thrombosis; Death, Sudden, Cardiac; Humans | 1997 |
[Acetylsalicylic acid in the treatment of cardiovascular and cerebrovascular diseases].
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors | 1997 |
Atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Electrocardiography; Humans | 1998 |
Prevention and treatment of stroke: where do we stand?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Risk Factors; Warfarin | 1997 |
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.
Topics: Angina Pectoris; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Consumer Product Safet | 1998 |
[Consensus antithrombotic prophylaxis of vascular incidents in patients with manifest atherosclerotic vascular diseases. Central Guidance Organization for Peer Review].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Coronary | 1998 |
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel | 1998 |
Anticoagulants and antiplatelet agents in acute ischemic stroke.
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials a | 1998 |
Antiplatelet drugs in secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Huma | 1998 |
Choice of antithrombotic therapy for stroke prevention in atrial fibrillation: warfarin, aspirin, or both?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; D | 1998 |
Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results.
Topics: Aspirin; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 1998 |
What have we learned from recent antiplatelet trials?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Randomized Controlled T | 1998 |
Prevention of stroke in patients with nonvalvular atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?
Topics: Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial I | 1998 |
Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibito | 1998 |
Long-term antithrombotic treatment for atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Europe; Fibrinolytic Agents; Humans; | 1998 |
Antithrombotic therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascular Disorders; Electric Countershock; | 1998 |
Carotid endarterectomy.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Pressure; Car | 1998 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Aspirin and its friends: an old standby with new prospects.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Colo | 1999 |
Atrial fibrillation and anticoagulation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chemoprevention; Drug Combi | 1999 |
Antiplatelet agents and stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Dipy | 1998 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agen | 1999 |
Antiplatelet therapy in acute cerebral ischemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhi | 1999 |
Stroke: part I. A clinical update on prevention.
Topics: Aspirin; Atrial Fibrillation; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; | 1999 |
Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascul | 1999 |
Very low-intensity antithrombotic therapy in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Fibrinolytic Agen | 1999 |
Preventing stroke in patients with atrial fibrillation.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Echocardiograp | 1999 |
Atrial fibrillation, thromboembolism and antithrombotic therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hu | 1999 |
[Recent advances in pathophysiology and treatment of acute ischemic stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Cerebrovascular Disorders; Humans; Hyperthermia, Induced; Pl | 1998 |
Antiplatelet therapy for secondary stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therap | 1999 |
A metaregression analysis of the dose-response effect of aspirin on stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Female; Fibrinolytic Age | 1999 |
[Clinical study of the month. Prevention of cerebral vascular accidents in patients with atrial fibrillation].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Evidence-Based Medicine; Hu | 1999 |
Aspirin and heparin in acute ischaemic stroke in older patients.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular D | 1999 |
Aspirin in the prevention of strokes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topi | 1999 |
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 1999 |
Dipyridamole plus aspirin in cerebrovascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combinatio | 1999 |
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hemorrhage; Humans; Placebo | 1999 |
Aspirin.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Digestive System; Humans; Myocardial Infarctio | 2000 |
Update on clinical trials of antiplatelet therapy for cerebrovascular diseases.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Humans; Pla | 2000 |
Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; Humans; I | 2001 |
Acetylsalicylic acid, hemostasis and human thromboembolism.
Topics: Adenosine Monophosphate; Aspirin; Blood Coagulation Tests; Blood Platelets; Cardiac Catheterization; | 1978 |
Actions and clinical status of platelet-suppressive agents.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Heart Valve Dis | 1978 |
Platelet function inhibitors: their clinical use.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease | 1978 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coro | 1978 |
Strokes, transient ischemic attacks and asymptomatic bruits.
Topics: Aged; Anticoagulants; Aspirin; Auscultation; Blood Platelets; Blood Pressure; Carotid Arteries; Cere | 1979 |
Physiopathology and pharmacotherapy of occlusive arterial disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Platelets; Blood Viscosity; Cerebrovas | 1979 |
The pathophysiology of transient cerebral ischemic attacks.
Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Cholesterol; Embolism; Endoc | 1979 |
[Treatment with antiplatelet drugs. Current status of knowledge].
Topics: Aspirin; Blood Platelet Disorders; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dextrans | 1979 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Transient cerebral ischemic attacks.
Topics: Anticoagulants; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blindn | 1976 |
Platelets and thromboembolism.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Dext | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts).
Topics: Animals; Antidepressive Agents, Tricyclic; Aspirin; Blindness; Blood Platelets; Cerebrovascular Diso | 1975 |
Antithrombotic therapy. Introduction.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis; Warfarin | 1992 |
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Dose-Response Relationship, Drug; | 1992 |
Prevention of venous thromboembolism.
Topics: Anticoagulants; Aspirin; Bandages; Cerebrovascular Disorders; Gravity Suits; Humans; Myocardial Infa | 1992 |
Controversies in the management of cerebrovascular disease in older patients.
Topics: Adult; Aged; Angiography; Aspirin; Cerebrovascular Disorders; Endarterectomy; Evaluation Studies as | 1992 |
Non-rheumatic atrial fibrillation: warfarin or aspirin for all?
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Hemorrhage; Humans; Randomized Controlled T | 1992 |
Aspirin is good for you.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Musculoskeletal Disease | 1992 |
Aspirin for the prevention of vascular death in women.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Risk | 1992 |
Anticoagulant therapy for atrial fibrillation. Recommendations from major studies.
Topics: Acute Disease; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chronic Disease; Electric Co | 1992 |
Aspirin: dose and indications in modern stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Trans | 1992 |
Prophylactic aspirin and the elderly population.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Male; Middle Aged; Myoca | 1992 |
Blood pressure reduction and the prevention of stroke.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Blood Pressure; Cerebrovascular Disor | 1991 |
Antiplatelet therapy in the prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomize | 1991 |
[Platelet antiaggregants in the treatment of arterial thrombosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Coronary Artery | 1991 |
Aspirin in transient ischemic attacks and minor stroke: a meta-analysis.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 1991 |
Stroke prevention in women: role of aspirin versus ticlopidine.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Meta-Analysis as Topic; Recurrence; Sex Factors; | 1991 |
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Com | 1991 |
Stroke prevention in nonvalvular atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Meta-Analysis as Topic; Platelet Ag | 1991 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
Long-term antiplatelet therapy for the prevention of vascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Evaluation Studies as Topic; Humans; Long-Term Care; Myocardial | 1991 |
Therapy in cerebrovascular disease: current status and future directions.
Topics: Age Factors; Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Forecasting; H | 1991 |
Carotid artery disease: when and how to treat?
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Hum | 1991 |
Aspirin in the prevention of thrombosis.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Thrombosis | 1991 |
[Study Group: "Evaluation of the efficacy of therapeutic treatments in cerebrovascular diseases"].
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Female; | 1990 |
Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Meta-Analysis as Topic; Myocardial Infarction; Platelet | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Surgery offers no more than medical treatment in the management of transient ischaemic attack.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Risk Factors | 1990 |
Aspirin and stroke prevention: how much?
Topics: Aspirin; Cerebrovascular Disorders; Humans | 1990 |
Current use of antiplatelet drugs in stroke syndromes in the USA.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidi | 1990 |
Aspirin and platelets in relation to cerebrovascular disease.
Topics: Animals; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Thrombosis; Cerebrovascular Diso | 1990 |
Aspirin in stroke prevention. An overview.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Female; Humans; Male | 1990 |
Current management of amaurosis fugax. The Amaurosis Fugax Study Group.
Topics: Aspirin; Blindness; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; Constricti | 1990 |
[Clinical aspects of treatment and preventive treatment with thrombocyte aggregation inhibitors in cerebrovascular diseases].
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hum | 1989 |
Issues in planning and interpreting active control equivalence studies.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Random Allocation; Rese | 1989 |
Platelet inhibitor agents in cardiovascular disease: an update.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Graf | 1989 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
Controversies in the management of cerebral vascular disease.
Topics: Aspirin; Atrial Fibrillation; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; | 1988 |
Diagnosis and initial management of stroke.
Topics: Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Endarterectomy; Humans; Risk Factors | 1988 |
Stroke. An overview.
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectom | 1988 |
Medical prevention of ischemic stroke.
Topics: Adult; Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Foll | 1985 |
Transient ischemic attacks and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Risk Factors; Ticlopidine | 1988 |
[Acetylsalicylic acid therapy in vascular diseases].
Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary | 1988 |
[Primary prevention of intermittent claudication and frequently associated arteriopathies].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Coronary Disease; Diet; Humans; Hypercholesterolemia; Hyp | 1987 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Carotid surgery in stroke prevention.
Topics: Aged; Arteriosclerosis; Aspirin; Blindness; Carotid Arteries; Carotid Artery Diseases; Cerebrovascul | 1986 |
The management of TIAs in 1986.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyridamo | 1986 |
[Antiplatelet therapy of thrombosis].
Topics: Animals; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Postoperative Complications; | 1986 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
Does platelet antiaggregant therapy lessen the severity of stroke?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Humans; Ischemic | 1985 |
[Controversy on platelet-inhibiting drugs].
Topics: Angina, Unstable; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Cor | 1985 |
Platelet suppressive therapy in clinical medicine.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Female; Heart Valve Prosthesi | 1985 |
Management of thrombotic diseases.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cerebrovascular Disorders; Coronary Dis | 1971 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
218 trials available for aspirin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Effect of topical tranexamic acid in total hip arthroplasty patients who receive continuous aspirin for prevention of cardiovascular or cerebrovascular events: A prospective randomized study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement | 2019 |
Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy | 2016 |
Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Constriction, Pathologic; Double-Blind Met | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Aspirin; Cerebrovascular Disorders; Cost-Benefi | 2009 |
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
Topics: Aged; Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Chi-Square Distribu | 2012 |
Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; | 2012 |
Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspirin; Cerebrovascular Circulati | 2013 |
Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia.
Topics: Aged; Aspirin; Blood Flow Velocity; Cardiovascular Agents; Cerebrovascular Disorders; Cognition Diso | 2012 |
The effectiveness of dual antiplatelet treatment in acute ischemic stroke patients with intracranial arterial stenosis: a subgroup analysis of CLAIR study.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combination | 2013 |
Effect of low-dose aspirin on functional outcome from cerebral vascular events in women.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Ischemic Attack, Transi | 2013 |
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysi
Topics: Aged; Alanine; Aspirin; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Drug Thera | 2003 |
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Benzodiazepines; Cerebrovascular Diso | 2003 |
Antiplatelet effect of aspirin in patients with cerebrovascular disease.
Topics: Age Factors; Aspirin; Blood Platelets; Cerebrovascular Disorders; Cohort Studies; Dose-Response Rela | 2004 |
Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives.
Topics: Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Therapy, Combination; Femal | 2005 |
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Japan | 2006 |
Aspirin or anticoagulants in stenosis of the middle cerebral artery: A randomized trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Arterial Diseases; Cerebrovascular Disorders; Constriction, | 2006 |
[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord | 2006 |
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO).
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; | 2007 |
Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis; Cerebrovascular Disorders; Clopidogrel; C | 2008 |
[Removing phlegm and dispelling stasis method combined with Western medicine for treatment of cerebrovascular stenosis].
Topics: Adult; Aged; Aspirin; C-Reactive Protein; Carotid Stenosis; Cerebrovascular Disorders; Clopidogrel; | 2008 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
[Controlled cooperative trial of secondary prevention of cerebral ischemic accidents caused by atherosclerosis, using aspirin and dipyridamole].
Topics: Aged; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; | 1983 |
[Critical approach to a therapeutic trial in secondary prevention of cerebral ischemic accidents by antiaggregants].
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dihydroergotoxine; Dipyri | 1983 |
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib | 1983 |
Prevention of stroke.
Topics: Aged; Aspirin; Canada; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Female; He | 1984 |
The North American ticlopidine aspirin stroke study: structure, stratification variables, and patient characteristics.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Fem | 1984 |
Asymptomatic cervical bruit and abnormal ocular pneumoplethysmography: a prospective study comparing two approaches to management.
Topics: Aged; Angiography; Arterial Occlusive Diseases; Aspirin; Auscultation; Carotid Arteries; Carotid Art | 1984 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
Anticoagulant and platelet-antiaggregating therapy in stroke and threatened stroke.
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1983 |
Variation in the use of angiography and carotid endarterectomy by neurologists in the UK-TIA aspirin trial.
Topics: Aged; Angiography; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Clinical Trials as Topic; E | 1983 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
The Canadian trial of aspirin and sulfinpyrazone in threatened stroke.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Canada; Cerebrovascular Disorders; Clinical Trials a | 1980 |
Randomized trial of therapy with platelet antiaggregants for threatened stroke.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 1980 |
Aspirin for transient ischemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Trans | 1980 |
Sulfinpyrazone: a review of its pharmacological properties and therapeutic use.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseas | 1980 |
Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials a | 1980 |
The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group.
Topics: Aspirin; Blood Pressure; Blood Urea Nitrogen; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1980 |
Controlled trial of aspirin in cerebral ischemia.
Topics: Actuarial Analysis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Is | 1980 |
A randomized trial of aspirin and sulfinpyrazone in patients with threatened stroke. Results and methodologic issues.
Topics: Actuarial Analysis; Aspirin; Canada; Cerebrovascular Disorders; Clinical Trials as Topic; Death, Sud | 1980 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
Series on pharmacology in practice. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease (third of three parts).
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1981 |
Drug prophylaxis for arterial thromboembolism--1981.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coumarins; Decision M | 1981 |
Can aspirin prevent recurrence of heart attacks and strokes?
Topics: Adult; Aged; Antithrombins; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Hu | 1982 |
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo | 1981 |
Antiplatelet therapy and cerebrovascular diseases.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Double- | 1982 |
[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders | 1995 |
Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebral Arteries; Cerebrovascular Disorders; Double-Blind Method; Female; | 1995 |
The Warfarin-Aspirin Symptomatic Intracranial Disease Study.
Topics: Animals; Aspirin; Cerebral Angiography; Cerebral Hemorrhage; Cerebrovascular Disorders; Cohort Studi | 1995 |
[Thromboembolic complications in the course of non-valvular atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Tr | 1995 |
A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation.
Topics: Adolescent; Adult; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distribution; | 1994 |
Antiplatelet treatment in elderly people with transient ischaemic attacks or ischaemic strokes.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind | 1995 |
Migraine and subsequent risk of stroke in the Physicians' Health Study.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Cerebrovascular Disorders | 1995 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Aspirin and prevention of stroke.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Isoindoles; Phenylbutyrates; Platel | 1994 |
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Follow-Up Studies; | 1994 |
[Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters].
Topics: Aged; Aspirin; Blood Coagulation; Cerebrovascular Disorders; Chronic Disease; Fibrinolysis; Humans; | 1994 |
[Comparative study of ASA and heparan sulfate in the secondary prevention of cerebrovascular disorders].
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Female; Fibrinolytic Agents; Follow-Up | 1993 |
A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Brain Ischemi | 1994 |
Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Confidence Intervals; Drug Hypersensiti | 1993 |
4. Current status of operative treatment for asymptomatic carotid stenosis.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Combined Modality Therapy; Endarterectomy, Car | 1994 |
Failure of aspirin treatment after stroke.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Female; | 1994 |
Cigarette smoking and stroke in a cohort of U.S. male physicians.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Double-Blind M | 1994 |
Adverse effects of low-dose aspirin in a healthy elderly population.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind M | 1993 |
Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug | 1993 |
Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemostasis | 1993 |
Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Fol | 1993 |
Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Co | 1993 |
Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group.
Topics: Adult; Aspirin; Blindness; Carotid Arteries; Carotid Stenosis; Cerebrovascular Disorders; Endarterec | 1993 |
The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Stu | 1993 |
Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis.
Topics: Aspirin; Carotid Artery, External; Carotid Stenosis; Cerebrovascular Disorders; Chi-Square Distribut | 1993 |
European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly.
Topics: Actuarial Analysis; Aged; Aspirin; Cause of Death; Cerebral Infarction; Cerebrovascular Disorders; D | 1993 |
Aspirin response and failure in cerebral infarction.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Drug Evaluation; Female; | 1993 |
Does cerebral infarction after a previous warning occur in the same vascular territory?
Topics: Aspirin; Atenolol; Basilar Artery; Carotid Arteries; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
[2nd European study on secondary prevention of stroke (ESPS 2). Respective roles of acetylsalicylic acid, dipyridamole and their combination].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Humans; Platelet Aggreg | 1995 |
Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin | 1996 |
Second European Stroke Prevention Study.
Topics: Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Humans | 1996 |
Interobserver agreement in the classification of stroke in the physicians' health study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Carotenoids; Cerebral Hemorrhage; Cerebral I | 1996 |
Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular | 1996 |
Aspirin wars: the optimal dose of aspirin prevent stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, | 1996 |
Warfarin encouraged for stroke prevention in atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male; | 1996 |
Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group.
Topics: Aspirin; Cerebrovascular Disorders; Diastole; Female; Humans; Hypertension; Male; Middle Aged; Recur | 1996 |
[Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke].
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Brain Ischemia; Cerebrovascular Disorders | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy, Combina | 1996 |
The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Female; Health Status; Humans; Male; Plate | 1996 |
Hemostaseologic and hematologic parameters with aspirin and ticlopidine treatment in patients with cerebrovascular disease: a cross-over study.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cerebrovascular Disorders; Collagen; Cross-Over Studies; Epine | 1996 |
Asymptomatic circulating cerebral emboli and cerebral blood flow velocity under aspirin and ticlopidine in patients with cerebrovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Flow Velocity; Carotid Stenosis; Cell Survival; Cereb | 1996 |
European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Demography; Dipyridamole; Double-Blind Method; Fema | 1996 |
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Aspirin; beta Carotene; Cardiovascular Diseases; Cereb | 1997 |
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re | 1996 |
We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; | 1997 |
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical | 1997 |
The elongation of the internal carotid artery: early and long-term results of patients having surgery compared with unoperated controls.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebrov | 1997 |
Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Cerebrovascular Disorders; Dr | 1997 |
Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Do | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
European Stroke Prevention Study 2. Efficacy and safety data.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Data Interpretation, Statistical; Delayed-Action Preparati | 1997 |
European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Disease-Free Survival; Double-Blind Method; | 1997 |
[Antithrombotic treatment of acute ischemic apoplexy].
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Plat | 1997 |
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Double-Blind Method; | 1998 |
European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation?
Topics: Adenosine; Aspirin; Blood-Brain Barrier; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Comb | 1998 |
[Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and antiaggregant].
Topics: Administration, Buccal; Aspirin; Cerebrovascular Disorders; Chromatography, High Pressure Liquid; Co | 1998 |
Up to date review of the secondary preventive measures for recurrent ischaemic stroke and transient ischaemic episodes.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Hu | 1998 |
Risk factors and antiplatelet therapy in TIA and stroke patients.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Eu | 1998 |
[Prevention of vascular complications following cerebral ischemia of arterial origin; the ESPRIT trial: mild anticoagulant therapy, combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone?].
Topics: Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aspirin; Brain Ischemia; Cerebrovascular Disor | 1998 |
Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.
Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorde | 1998 |
Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Basilar Artery; Brain Ischemia; Cerebellum; Cerebral Arteries; Cerebr | 1998 |
Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord | 1998 |
Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke.
Topics: Aspirin; Blood Pressure; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therapy, | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Disease-Free Su | 1998 |
The HOT Study. Hypertension Optimal Therapy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular | 1998 |
[Recommended article of the month: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial].
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cerebrovascular Disorders; Female; Humans; Hypertensi | 1998 |
Exercise and risk of stroke in male physicians.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; Cerebral Hemorrhage; Cerebro | 1999 |
Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid.
Topics: Adult; Aged; Aspirin; Carotid Stenosis; Cerebral Arteries; Cerebrovascular Disorders; Female; Fibrin | 1999 |
Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Follow-Up Studies; Humans; Myocar | 1998 |
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke.
Topics: Adult; Aged; Alleles; Antioxidants; Aspirin; beta Carotene; Case-Control Studies; Cerebrovascular Di | 1999 |
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; | 1999 |
Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Risk of major gastrointestinal bleeding with aspirin.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Delayed-Action Pr | 1999 |
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agen | 1999 |
Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Blood Pressure; Blood Substitutes; Brain Ischemia; | 1999 |
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Topics: Acute Disease; Age Factors; Aged; Angina, Unstable; Aspirin; Brain Damage, Chronic; Cerebral Hemorrh | 1999 |
The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti | 1999 |
Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study. The STEPS Investigators. Significance of Transesophageal Echocardiography in the Prevention of Recurrent Stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Echocardiography | 1999 |
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.
Topics: Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascula | 1999 |
[Prevention of vascular complications after cerebral ischemia of arterial origin. European Stroke and Australian Stroke Prevention in Reversible Ischemia Trial (ESPRIT): moderated coagulation, aspirin-dipyridamole combination or aspirin alone?].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Humans; | 1999 |
Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Administratio | 1999 |
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord | 1999 |
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators.
Topics: Aged; Aspirin; Blood Pressure; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Double-B | 1999 |
A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Decision Making; Deci | 1999 |
Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Gastrointest | 1999 |
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H | 1999 |
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; My | 2000 |
Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events.
Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Cerebrovascular Disorders; Cohort Studies; Female; Fib | 2002 |
Stroke therapy: status of anti-platelet aggregation drugs.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Evaluation; Humans; Ischemic Atta | 1977 |
Drug therapy: antiplatelet therapy (second of two parts).
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical T | 1978 |
A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; | 1978 |
Preventing stroke.
Topics: Aspirin; Canada; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Female; H | 1978 |
The Canadian trial of aspirin and sulfinpyrazone in threatened stroke.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Male; Research Design; | 1978 |
Aspirin to prevent a stroke?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Trans | 1978 |
Does aspirin prevent stroke?
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyr | 1979 |
The role of platelets in transient ischemic attacks and cerebral vascular accidents.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; Mal | 1978 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Anticoagulants in cerebrovascular disease. A critical review of studies.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coumarins; Evaluation | 1975 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (first of three parts).
Topics: Animals; Antidepressive Agents, Tricyclic; Aspirin; Blindness; Blood Platelets; Cerebrovascular Diso | 1975 |
SALT trial.
Topics: Aspirin; Cerebrovascular Disorders; Ethics, Medical; Humans | 1992 |
SALT trial.
Topics: Aspirin; Cerebrovascular Disorders; Gout; Humans; Male; Middle Aged | 1992 |
Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebrovascular Disorders; Death, Sudden, Cardiac; Diagnosis, Differential; | 1992 |
Aspirin in ischemic heart disease.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Myocardial Ischemia | 1992 |
Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Asymptomatic Carotid Endarterectomy Study Group.
Topics: Aged; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Female; Follow- | 1992 |
Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Diarrhea; Double-Blind Method; Female; Humans; Male; Midd | 1992 |
The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Ma | 1992 |
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.
Topics: Adolescent; Adult; Aged; Aspirin; Cerebrovascular Disorders; Diabetes Mellitus; Diabetic Retinopathy | 1992 |
European stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Diabetes Complications; Diabetes Mellitus; Dipyridamole; D | 1992 |
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therapy, Combina | 1992 |
Asymptomatic carotid atherosclerosis study: role of the clinical coordinator.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Combined Modali | 1992 |
Aspirin to prevent stroke in nonrheumatic atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans | 1992 |
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group.
Topics: Aspirin; Cerebrovascular Disorders; Chi-Square Distribution; Female; Follow-Up Studies; Humans; Isch | 1991 |
Carotid endarterectomy.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans | 1992 |
Antiplatelet therapy is effective in the prevention of stroke or death in women: subgroup analysis of the European Stroke Prevention Study (ESPS).
Topics: Aspirin; Cause of Death; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; | 1991 |
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Com | 1991 |
[Clinical efficacy of picotamide].
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Tr | 1991 |
Natural history and effectiveness of aspirin in asymptomatic patient with cervical bruits. The Asymptomatic Cervical Bruit Study Group.
Topics: Aspirin; Auscultation; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Humans | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
Stroke Prevention in Atrial Fibrillation Study. Final results.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Female; Follow-Up Studies; | 1991 |
The European Stroke Prevention Study: results according to sex.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male; | 1991 |
Epidemiology of and stroke-preventive strategies for atherothromboembolic brain infarction in the elderly.
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Fem | 1991 |
The European Stroke Prevention Study (ESPS): results by arterial distribution.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Drug Therap | 1991 |
A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Studies; Humans; Is | 1991 |
Carotid surgery versus medical therapy in asymptomatic carotid stenosis. The CASANOVA Study Group.
Topics: Aged; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiography; Cerebrovascular Dis | 1991 |
[European atrial fibrillation trial (EAFT). Secondary prevention with anticoagulants and aspirin in patients with non-valvular atrial fibrillation having suffered a transient ischemic attack or a regressive vascular accident].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Tr | 1991 |
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; beta Carotene; Cardiovascular Diseases; Ca | 1991 |
Secondary prevention of myocardial infarction in the first European Stroke Prevention Study.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Europe; Humans; Myocard | 1990 |
[Study Group: "Evaluation of the efficacy of therapeutic treatments in cerebrovascular diseases"].
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Double-Blind Method; Female; | 1990 |
Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use?
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocardial Infarction; Rando | 1990 |
Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Multicenter Studies as Topic; Rando | 1990 |
European Stroke Prevention Study. ESPS Group.
Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Hemorrhage | 1990 |
Progress report of the Stroke Prevention in Atrial Fibrillation Study.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Meth | 1990 |
Aspirin in stroke prevention. An overview.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Female; Humans; Male | 1990 |
Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders | 1990 |
Final report on the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disor | 1989 |
Aspirin for prevention of myocardial infarction and stroke.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Att | 1989 |
Effectiveness of carotid endarterectomy for asymptomatic carotid stenosis: design of a clinical trial. Mayo Asymptomatic Carotid Endarterectomy Study Group.
Topics: Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; Constriction, Patholo | 1989 |
The "trials" of a long-term clinical trial: the Ticlopidine Aspirin Stroke Study and the Canadian-American Ticlopidine Study.
Topics: Aspirin; Canada; Cerebrovascular Disorders; Humans; Legislation, Drug; Multicenter Studies as Topic; | 1989 |
A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.
Topics: Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; M | 1989 |
The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group.
Topics: Actuarial Analysis; Aspirin; Capsules; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyrida | 1987 |
United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Dose-Re | 1988 |
The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group.
Topics: Aspirin; Atenolol; Cerebrovascular Disorders; Disability Evaluation; Follow-Up Studies; Humans; Isch | 1988 |
Secondary prevention of strokes: role of platelet antiaggregant drugs in diabetic and non-diabetic patients.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Diabetic Angiopathies; Dipyridamole; D | 1985 |
[ISIS-2--a study of patients with myocardial infarction. A combination of streptokinase and acetylsalicylic acid diminishes mortality risk, reinfarction and stroke].
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myo | 1988 |
Carotid endarterectomy: what is its current status?
Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; Cli | 1988 |
Stroke. An overview.
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectom | 1988 |
Randomised trial of prophylactic daily aspirin in British male doctors.
Topics: Aspirin; Cerebrovascular Disorders; Drug Evaluation; Humans; Male; Myocardial Infarction; Random All | 1988 |
Randomised trial of prophylactic daily aspirin in British male doctors.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Male; Random Allocation | 1988 |
Medical prevention of ischemic stroke.
Topics: Adult; Age Factors; Aged; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Foll | 1985 |
Preliminary report: Findings from the aspirin component of the ongoing Physicians' Health Study.
Topics: Adult; Aged; Aspirin; beta Carotene; Cardiovascular Diseases; Carotenoids; Cerebrovascular Disorders | 1988 |
The carotid endarterectomy study.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectomy; Foll | 1988 |
Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Human | 1988 |
Carotid endarterectomy--a crisis in confidence.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectomy; Huma | 1988 |
[Acetylsalicylic acid therapy in vascular diseases].
Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary | 1988 |
[Recovery following CVA: caused by effective therapy or by the natural course of the disease?].
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Hemodynamics; Humans; Intracranial Emb | 1987 |
Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks.
Topics: Adult; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; D | 1987 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Hemorrhagic complications of anticoagulant therapy.
Topics: Administration, Oral; Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorde | 1986 |
Controlled trial of aspirin in cerebral ischemia: an addendum.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Di | 1986 |
[Acetylsalicylic acid in the treatment of ischemic cerebrovascular disorders].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Follow-Up Studies; Huma | 1986 |
Aspirin and the prevention of stroke after transient ischaemic attack.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind | 1986 |
A critical appraisal of the clinical efficiency of anti-platelet drugs.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1986 |
VA cooperative study on antiplatelet agents in diabetic patients after amputation for gangrene. IV. Issues in design, interpretation, and analysis.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1986 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
Does platelet antiaggregant therapy lessen the severity of stroke?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Humans; Ischemic | 1985 |
[Controversy on platelet-inhibiting drugs].
Topics: Angina, Unstable; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Cor | 1985 |
Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation. Results of a prospective randomized controlled trial using aspirin and dipyridamole in humans.
Topics: Aged; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders | 1985 |
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics.
Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; | 1985 |
411 other studies available for aspirin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-45 | 2022 |
Antiplatelets and Anticoagulants in Ischemic Stroke,Transient Ischaemic Attack: A Practice Survey Among Singapore Neurologists.
Topics: Adult; Anticoagulants; Aspirin; Cerebrovascular Disorders; Female; Heparin; Humans; Ischemic Attack, | 2022 |
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni | 2022 |
Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease.
Topics: Activities of Daily Living; Anticholesteremic Agents; Aspirin; Atorvastatin; C-Reactive Protein; Car | 2022 |
Progressive arteriopathy with vasospasm in focal cerebral arteriopathy in childhood: a case report.
Topics: Aspirin; Cerebrovascular Disorders; Child; Constriction, Pathologic; Female; Humans; Middle Cerebral | 2023 |
[PEGASUS or COMPASS? A guide for a wise clinical choice.]
Topics: Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Clinical Protocols; Drug Administratio | 2019 |
Lp-PLA
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Aspirin; Cerebrovascular Disorders; Clopidogre | 2020 |
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; At | 2020 |
Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
Topics: Acute Coronary Syndrome; Aspirin; Cerebrovascular Disorders; Coronary Artery Disease; Humans; Intrac | 2021 |
Use of the Pipeline embolization device in the treatment of iatrogenic intracranial vascular injuries: a bi-institutional experience.
Topics: Adolescent; Adult; Angiography, Digital Subtraction; Aspirin; Cerebral Angiography; Cerebrovascular | 2017 |
Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cardiology; Cardiovascular Diseases; Cerebrovascular | 2017 |
[Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world].
Topics: Aspirin; Atorvastatin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Dru | 2017 |
Extensive cerebrovascular disease and stroke with prolonged prodromal symptoms as first presentation of perinatally-acquired human immunodeficiency virus infection in a young adult.
Topics: Adult; Aspirin; Basilar Artery; Cerebrovascular Disorders; Computed Tomography Angiography; Delayed | 2018 |
Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug-Eluting Stents; Female; Humans; In | 2017 |
REduction of THRomboembolic EVents during Ablation using the laserballoon: The RETHREVA registry.
Topics: Administration, Intravenous; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Dis | 2018 |
The effects of cardiovascular risk factor combined anti-platelet therapy and the risk of cerebrovascular events in patients with T2DM in an urban community over 96-months follow-up: The Beijing communities diabetes study 19.
Topics: Aged; Aspirin; Beijing; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Mellitus, Type | 2018 |
Gastroduodenal ulcer bleeding in elderly patients on low dose aspirin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascu | 2018 |
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Coronary Angiography; Coronary A | 2019 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
Feasibility of aspirin continuation during the perioperative period for pulmonary resection in lung cancer patients: a retrospective study at a single institute in Japan.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Feasibility St | 2014 |
Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease.
Topics: Adolescent; Adult; Aged; alpha-Galactosidase; Aspirin; Biomarkers; Blood Proteins; Cerebrovascular D | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Ther | 2015 |
Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chi-Square Distributi | 2015 |
Can the previous therapeutic control of the main risk factors of cerebrovascular disease influence the acetylsalicylic Acid-nonresponsive status in acute ischemic stroke patients? Results from a portuguese prospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; | 2015 |
ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Drug Resistance; Female; Humans; Male; Platelet Aggregatio | 2014 |
Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebr | 2016 |
Factors predicting adverse events associated with therapeutic colonoscopy for colorectal neoplasia: a retrospective nationwide study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ce | 2016 |
Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy.
Topics: Adult; Aged; Arteries; Aspirin; Blood Coagulation Tests; Blood Platelets; Carotid Arteries; Cell Adh | 2016 |
Atrial Fibrillation and PCI - Do We Still Need Aspirin?
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio | 2016 |
[Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Hu | 2008 |
Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Dis | 2009 |
Aspirin withdrawal in acute peptic ulcer bleeding: are we harming patients?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; Pe | 2010 |
Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Bleeding Time; Cerebrovascular Disorders; Dose-Response Relationsh | 1983 |
Withdrawal of clopidogrel in active gastric bleeding.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Gastrointestinal Hemorrhag | 2010 |
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cohort Studies | 2011 |
Cilostazol: a drug particularly effective for Asians?
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders | 2011 |
Acetylsalicylic acid does not prevent digital subtraction angiography-related high signal intensity lesions in diffusion-weighted imaging in cerebrovascular patients. A retrospective analysis.
Topics: Angiography, Digital Subtraction; Aspirin; Cerebrovascular Disorders; Diffusion Magnetic Resonance I | 2012 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
Non-cardiac surgery in patients with coronary stents: the RECO study.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Cerebr | 2011 |
[Effect of acetylsalicylic acid in complex with lipid nanostructures of various compositions on human platelet aggregation].
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Brain Chemistry; Cerebrovascular Disorders | 2011 |
Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting.
Topics: Aspirin; Body Mass Index; Body Weight; Carotid Stenosis; Cerebrovascular Disorders; Clopidogrel; Fem | 2011 |
A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs.
Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Cardiovascular Diseases; Case-Control Studies; | 2011 |
Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; D | 2012 |
Primary prevention with aspirin in type 2 diabetic patients. Searching for the right spot.
Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Diabetes Mellitus, Type 2 | 2012 |
[Prevalence of laboratory aspirin resistance in 431 old patients].
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Drug Resistance; Female; Humans; Male; P | 2012 |
[Correlation analysis of aspirin resistance and cycloxygenase-1 haplotype in old Chinese patients with cardio-cerebrovascular diseases].
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cereb | 2012 |
[Neuroprotection by aspirin in cerebrovascular pathology].
Topics: Adenosine Triphosphate; Algorithms; Amino Acid Transport System X-AG; Animals; Aspirin; Brain Ischem | 2002 |
Measurement of the antiplatelet effects of aspirin in cerebrovascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Drug Resistance; Flow Cytometry; Humans; Platelet Aggregation In | 2004 |
Antiplatelet effect of aspirin in patients with cerebrovascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Drug Resistance; Humans; Plate | 2004 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
Oral antiplatelet therapy.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; | 2005 |
Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage.
Topics: Administration, Oral; Aged; Aspirin; Brain Ischemia; Causality; Cerebral Arteries; Cerebral Hemorrha | 2005 |
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Male; Middle | 2006 |
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France].
Topics: Adolescent; Adult; Aged; Aspirin; Biguanides; Cerebrovascular Disorders; Coronary Disease; Cost-Bene | 2005 |
Efficacy of dual antiplatelet therapy in cerebrovascular disease as demonstrated by a decline in microembolic signals. A report of eight cases.
Topics: Aged; Aspirin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Embolism; F | 2006 |
[Aspirin resistance in patients taking small dose of aspirin].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Re | 2006 |
Sub-Tenon's anesthesia with aspirin, warfarin, and clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Local; Anticoagulants; Aspirin; Cardiovascular Diseases; | 2006 |
Comment and reply on: the dose of aspirin for the prevention of cardiovascular and cerebrovascular events.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Human | 2006 |
Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fi | 2007 |
TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Cytokines; Diabetes Mellitus, Type 2; Di | 2007 |
The use of clopidogrel in carotid endarterectomy: an audit of current practice.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Endarterectomy, Carotid; Hemorrhage; Humans; Medica | 2007 |
Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Clopido | 2008 |
Hemorheological background of acetylsalicylic acid resistance.
Topics: Aged; Anticoagulants; Aspirin; Blood Viscosity; Cerebrovascular Disorders; Erythrocyte Aggregation; | 2008 |
[Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].
Topics: Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Re | 2008 |
Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience.
Topics: Adult; Aged; Angioplasty, Balloon; Aspirin; Cerebrovascular Disorders; Clopidogrel; Drug Administrat | 2008 |
Placebo-controlled, double-blind clinical trials can impede medical progress.
Topics: Adrenergic beta-Antagonists; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Bl | 1980 |
[Current status of medical treatment].
Topics: Aminophylline; Animals; Anticoagulants; Aspirin; Barbiturates; Brain Ischemia; Cerebrovascular Disor | 1980 |
Antithrombotic treatment.
Topics: Ancrod; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Drug Administration Schedule; He | 1983 |
Antiplatelet drugs.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dextrans; Dipyridamole; Epopr | 1983 |
Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia.
Topics: Adult; Age Factors; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Cerebrovas | 1983 |
Effects of AVS (1,2-bis(nicotinamido)propane) on platelet function and vascular endothelium.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Blood Vessels; Cerebrovascul | 1984 |
Surgical management of the occluded carotid artery.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1984 |
Platelet aggregation and plasma levels of acetylsalicylic acid in stroke patients on long-term treatment with an enteric-coated aspirin formulation.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Humans; Platelet Aggregation; Tablets, Enteric-Coated | 1984 |
The relationship between basic biomedical research and the design and analysis of clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Kinetics; Research Design; Sul | 1983 |
The lame brain at the crossroads: which therapeutic road?
Topics: Aged; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; Dipyridamole | 1984 |
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovasc | 1983 |
Use of common antiplatelet drugs for vascular diseases.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Artery Bypass; Coronary Disease; Couma | 1983 |
The role of the neurologist in the decline of stroke.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; En | 1983 |
Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
Topics: Adult; Aged; Antithrombin III; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorde | 1983 |
[Anti-aggregating action and clinical effect of small doses of aspirin in the treatment of patients with arterial hypertension and cerebrovascular disorders].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Middle Aged; Platelet | 1983 |
Transient ischemic attacks. Strategies for minimizing stroke risk.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Ischemic Attack, Transient; Middle A | 1984 |
Aspirin in the prevention of myocardial infarction. Current status.
Topics: Angina Pectoris; Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarct | 1984 |
[Fibrinolytic agents, anticoagulants and anti-platelet agents in the management of ischemic cerebrovascular disorders].
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Endopeptidases; Humans; Ischemic Attack, Transie | 1982 |
[Treatment of transient cerebrovascular accidents].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Endarterectomy; Fibrinolytic Agents; Humans; Isc | 1983 |
[Conservative therapy of stroke from an internist's viewpoint].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Digitalis Glycosides; Dipyridamole; Diuretics; H | 1983 |
Management of transient cerebral ischaemic attacks by hospital doctors in Scotland.
Topics: Anticoagulants; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Dipyridamole; Female; Humans; | 1983 |
[Present situation of therapy with platelet aggregation inhibitors].
Topics: Adult; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Middle Aged; | 1982 |
[Inhibition of thrombocyte aggregation with small doses of acetylsalicylic acid].
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Platelet Aggrega | 1982 |
Special therapeutical aspects of cerebrovascular disease.
Topics: Aspirin; Cerebrovascular Disorders; Drug Combinations; Female; Humans; Male; Pentoxifylline; Platele | 1981 |
Therapy of ischemic cerebrovascular disease.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy | 1980 |
[Ischemic cerebro-vascular accidents: usefulness of anticoagulant and antiaggregating agents (author's transl)].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Plat | 1981 |
Shortened megakaryocyte-platelet regeneration time in patients with ischemic cerebrovascular disease.
Topics: Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Humans; Megakaryocytes; | 1981 |
Plasma concentrations of thromboxane B2 in patients with hypertension or cerebrovascular disease.
Topics: Adolescent; Adult; Aged; Arteries; Aspirin; Cerebrovascular Disorders; Female; Humans; Hypertension; | 1981 |
For your stroke-prone patients: a guide to drug treatment.
Topics: Aged; Antihypertensive Agents; Aspirin; Brain Diseases; Cerebral Angiography; Cerebrovascular Disord | 1980 |
The contralateral diseased but asymptomatic carotid artery: to operate or not? An update.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Endarterec | 1980 |
Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin.
Topics: Adolescent; Adult; Aged; Arachidonic Acids; Aspirin; Blood Platelets; Cerebrovascular Disorders; Dos | 1980 |
Management of venous thromboembolism.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Fibrinolytic Agents; Heparin; Humans; Isometric | 1980 |
Prevention of stroke.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Revascularization; Cerebrovascular Disorders; Endarterectomy | 1980 |
Operative indication in asymptomatic carotid arterial disease.
Topics: Arteriosclerosis; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Gui | 1995 |
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; California; Cerebrovascular Disorders; Cost-Bene | 1995 |
Aspirin-induced conformational changes in platelet membrane in subjects with stroke.
Topics: Adult; Aged; Aged, 80 and over; Aging; Aspirin; Blood Platelets; Case-Control Studies; Cell Membrane | 1995 |
Aspirin as a free radical scavenger: consequences for therapy of cerebrovascular ischemia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Aspirin; Cerebrovascular Disorders; Cy | 1995 |
Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio | 1995 |
ACP guideline on drug therapy for stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Practice Guidelines as Topic; Randomized Controlled Tria | 1995 |
US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices.
Topics: Aspirin; Attitude of Health Personnel; Brain Ischemia; Carotid Arteries; Cerebral Angiography; Cereb | 1995 |
Essential thrombocytemia and ischemic stroke: report of six cases.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Magnetic Resonance Imaging | 1994 |
Can overall results of clinical trials be applied to all patients?
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Endarterectomy, Caro | 1995 |
Stroke prevention.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dementia, Vascular; Humans; Hypertens | 1995 |
Systemic thromboembolism leading to myocardial infarction and stroke after fenestrated total cavopulmonary connection.
Topics: Aspirin; Cerebrovascular Disorders; Child, Preschool; Drug Administration Schedule; Female; Fontan P | 1995 |
Lord Moran's prescriptions for Churchill.
Topics: Amphetamines; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Famous Persons; History, 20th Ce | 1995 |
Stroking the stroke prevention numbers.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Risk; Ticlopidine | 1995 |
Absence of cerebrovascular events in a prospective study of coronary artery bypass patients with atrial septal aneurysms taking aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Cohort Studies; Coronary Artery Bypass; | 1995 |
Anticoagulant treatment or antiplatelet therapy after a single carotid TIA?
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Heparin; Humans; Isc | 1995 |
Anticoagulants for atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged; | 1993 |
Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation.
Topics: Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Catheter Ablation; Cerebrovascular Disorders; | 1993 |
Aspirin and prevention of stroke.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Recurrence | 1994 |
Aspirin and prevention of stroke.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Monitoring; Humans; Pr | 1994 |
Aspirin or warfarin for non-rheumatic atrial fibrillation?
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Warfarin | 1994 |
Science unblinded.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans | 1994 |
Stroke Prevention in Atrial Fibrillation II Study.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascular Disorders; Humans; Warfarin | 1994 |
Amaurosis fugax: prognosis and the role of acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Blindness; Brain Ischemia; Cerebrovascular Disorders; Female; Foll | 1994 |
Anticoagulation update.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; H | 1994 |
Relative benefits of ticlopidine and aspirin.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Randomized Controlled Trials as Topic; Ticlopidine | 1994 |
Development of aspirin resistance in persons with previous ischemic stroke.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular D | 1994 |
Atrial fibrillation and stroke. Revisiting the dilemmas.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as To | 1994 |
Aspirin in elderly atrial fibrillation patients.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male | 1994 |
Safety of combination aspirin and anticoagulation in acute ischemic stroke.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Stud | 1994 |
Factors associated with failure of aspirin treatment.
Topics: Aspirin; Case-Control Studies; Cerebrovascular Disorders; Humans; Recurrence; Risk Factors | 1994 |
Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin.
Topics: Adenosine Diphosphate; Aged; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Collagen; Fema | 1994 |
Warfarin in chronic atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Chronic Disease; Humans; Thromboembolism; W | 1993 |
Ticlopidine hydrochloride use and threatened stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ticlopidine | 1994 |
Atrial fibrillation, stroke, and antithrombotic treatment.
Topics: Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; M | 1994 |
Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Echocardiography, Transesophag | 1994 |
A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Data Collection; Follow | 1994 |
Survey of use of anticoagulation in patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord | 1993 |
Antiplatelet therapy and risk of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1993 |
Primary and secondary prevention of stroke in patients with nonrheumatic atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Intracranial | 1994 |
Consultant views on the use of aspirin in acute cerebrovascular disease: implications for clinical trials.
Topics: Acute Disease; Aged; Aspirin; Attitude of Health Personnel; Cerebrovascular Disorders; Clinical Tria | 1994 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Ticlopidine, trials, and torture.
Topics: Arterial Occlusive Diseases; Aspirin; Cause of Death; Cerebrovascular Disorders; Clinical Trials as | 1994 |
Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Cohort Studies; Cost-Benefit Analysis; Decision Support Te | 1994 |
Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Disorders; Brain Ischemia; Cerebral Infar | 1994 |
Ticlopidine hydrochloride and prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Ischemic Attack, Trans | 1993 |
Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Carotid Artery, Internal; Cerebrovascular Disorders; | 1993 |
Anticoagulation in patients with atrial fibrillation. Use of warfarin dependent on local services.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Family Practice; Health Promotion; Hu | 1993 |
Anticoagulation in patients with atrial fibrillation. Atrial fibrillation associated with aging.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin | 1993 |
[Essential thrombocythemia. Apropos a case of cerebrovascular stroke].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; | 1993 |
Anticoagulation for atrial fibrillation and stroke prevention.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Denmark; | 1993 |
Low-dose aspirin and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans | 1993 |
Aspirin: optimal dose in stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans | 1993 |
Stroke and atrial fibrillation: to anticoagulate or not.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Humans; Male; Randomized Cont | 1993 |
Recent developments in secondary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Hypercholesterolemia; Myocardia | 1993 |
[Prevention of stroke. Blood pressure lowering changes in life style and diet are highly effective].
Topics: Anticoagulants; Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Carotid; Feedi | 1993 |
Ticlopidine and stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Ticlopi | 1993 |
Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Male; | 1993 |
Is aspirin effective in preventing strokes in diabetic patients?
Topics: Aspirin; Cerebrovascular Disorders; Diabetes Complications; Humans; Ticlopidine | 1993 |
Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication.
Topics: Aged; alpha-2-Antiplasmin; Antifibrinolytic Agents; Antithrombin III; Aspirin; Blood Coagulation; Ce | 1993 |
How should clinicians choose treatment for preventing stroke when therapeutic trials are not available to guide the situation?
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Combined Modality Ther | 1995 |
Susac's syndrome: improvement with combined antiplatelet and calcium antagonist therapy.
Topics: Adult; Aspirin; Calcium Channel Blockers; Cerebrovascular Disorders; Drug Combinations; Female; Hear | 1996 |
A personal view: the Asymptomatic Carotid Atherosclerosis Study results--read the label carefully.
Topics: Arteriosclerosis; Aspirin; Canada; Carotid Stenosis; Cerebrovascular Disorders; Endarterectomy, Caro | 1996 |
[Acetylsalicylic acid as free radical scavenger. An argument for increased dosages in acute and preventive therapy of vascular diseases].
Topics: Adult; Aspirin; Biotransformation; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response | 1995 |
Stroke in a young patient with mitral valve prolapse.
Topics: Adolescent; Age Factors; Aspirin; Cerebrovascular Disorders; Echocardiography; Humans; Male; Mitral | 1995 |
Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cost-Benefit Analysis; Huma | 1996 |
Primary prevention of stroke.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio | 1996 |
Prevention of cardioembolic stroke with anticoagulant therapy.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemorrhage; Cerebrovascula | 1996 |
Tissue plasminogen activator for acute ischemic stroke.
Topics: Acute Disease; Aspirin; Cerebrovascular Disorders; Clinical Protocols; Humans; Platelet Aggregation | 1996 |
Risk of stroke in a cohort of 815 patients with calcification of the aortic valve with or without stenosis.
Topics: Age Factors; Aged; Anticoagulants; Aortic Valve; Aortic Valve Stenosis; Aspirin; Calcinosis; Cause o | 1996 |
In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery Injuries; Carotid Artery, Common; Cerebrov | 1996 |
[Atrial fibrillation and apoplexy--risks and prevention].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Controlled Clinical T | 1996 |
Cerebrovascular events in adult patients with cyanotic congenital heart disease.
Topics: Adult; Aged; Anemia, Iron-Deficiency; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular | 1996 |
US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Medical therapy in patients with carotid artery stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebrovascular Disorders; Data Collectio | 1996 |
Combined neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia.
Topics: Animals; Aspirin; Cardiovascular Agents; Cerebral Infarction; Cerebrovascular Disorders; Drug Therap | 1996 |
Stenting in the carotid artery: initial experience in 110 patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery | 1996 |
Atrial fibrillation and stroke prevention in the community.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Contraindications; Cr | 1996 |
[Atrial fibrillation, carotid stenosis and stroke].
Topics: Aspirin; Atrial Fibrillation; Brain; Carotid Stenosis; Cerebrovascular Disorders; Cyclooxygenase Inh | 1996 |
Considerations in the prophylactic treatment of transient ischemic attack or ischemic stroke in the carotid artery territory.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Stenosis; Cerebrovascular Disorders | 1995 |
Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.
Topics: Academic Medical Centers; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disord | 1996 |
Plasma glycocalicin levels are not elevated in patients with a history of transient ischaemic event and are normal in aspirinated normal volunteers.
Topics: Aspirin; Case-Control Studies; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; P | 1996 |
Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop | 1996 |
Fraud and ethics charges hit stroke drug trial.
Topics: Aspirin; Brain Diseases; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dipyridamol | 1996 |
Janus faces of NF-kappa B: neurodestruction versus neuroprotection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Apoptosis; Aspirin; Cell Death; Cerebrovascul | 1997 |
CAPRIE trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Humans; Platel | 1997 |
Foundation project promotes stroke prevention.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Female; Foundations; Humans; Male; Mi | 1997 |
PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Body Mass Index; Cerebrovascular Disorders; Cohort | 1997 |
Gastric safety and enteric-coated aspirin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infa | 1997 |
Aspirin's role in prevention now official.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Peripheral Vascular Diseases; Pla | 1997 |
Aspirin and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 1997 |
Early outcome in acute ischemic stroke is not influenced by the prophylactic use of low-dose aspirin.
Topics: Aged; Aspirin; Brain Ischemia; Cause of Death; Cerebral Hemorrhage; Cerebrovascular Disorders; Femal | 1997 |
Aspirin versus clopidogrel: the wrong question?
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet A | 1997 |
Second European Stroke Prevention Study (ESPS 2): clinical and pharmacological implications.
Topics: Aspirin; Cerebrovascular Disorders; Cyclooxygenase Inhibitors; Europe; Humans; Platelet Aggregation | 1997 |
Aspirin or heparin immediately after a stroke?
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; | 1997 |
Acetylsalicylic acid and vitamin E in prevention of arterial thrombosis.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Drug Interactions; Humans; Myocardial Infarcti | 1997 |
Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia | 1997 |
The wonder drug.
Topics: Acute Disease; Aspirin; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Time Fac | 1997 |
Inappropriate practices in prescribing: who decides and how.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Prescriptions; Drug Therapy, Combinatio | 1997 |
Spontaneous carotid dissection.
Topics: Adult; Aortic Dissection; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebrovascula | 1997 |
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Prognosis; Severity of | 1997 |
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Diagnosis, Differential; Humans; Male; Middle Aged; Platelet Agg | 1997 |
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Anticoagulants; Aspirin; Bias; Cerebrovascular Disorders; Heparin; Humans; Platelet Aggregation Inhi | 1997 |
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Platelet | 1997 |
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Attitude to Health; Cause of Death; Cerebrovascula | 1997 |
Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation Inhib | 1997 |
Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study.
Topics: Aged; Angina Pectoris; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; F | 1997 |
Secular trends in stroke mortality in African Americans: the role of urbanization, diabetes and obesity.
Topics: Adult; Aged; Aspirin; Black People; Cerebrovascular Disorders; Diabetes Mellitus; Female; Fibrinolyt | 1997 |
Clopidogrel: a new safe and effective antiplatelet agent. But unanswered questions remain.
Topics: Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Pl | 1997 |
Nitric oxide reverses aspirin antagonism of t-PA thrombolysis in a rabbit model of thromboembolic stroke.
Topics: Animals; Antifibrinolytic Agents; Aspirin; Cerebrovascular Disorders; Female; Male; Nitric Oxide; Ra | 1997 |
Evidence-based general practice.
Topics: Aspirin; Cerebrovascular Disorders; Evidence-Based Medicine; Family Practice; Humans; Platelet Aggre | 1997 |
[A 100 years of aspirin: a drug with a future?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cerebrovascular Di | 1997 |
From clinical trials to clinical practice: oral anticoagulation among patients with non-rheumatic, atrial fibrillation.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial | 1997 |
Does daily aspirin diminish severity of first-ever stroke?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Case-Cont | 1997 |
The role of antiplatelet therapy in stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Attack, Transient; Pl | 1997 |
Thrombolytic therapy for acute ischaemic stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Plasminogen Activators; Streptokinase; Thrombolytic Ther | 1997 |
Early management and outcome of acute stroke in Auckland.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Fema | 1997 |
[Myocardial infarct, stroke and vascular events reduced by a third].
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular | 1997 |
[Factors associated to aspirin failure for secondary stroke prevention].
Topics: Aged; Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Multivariate Analysis; | 1997 |
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Antigens, CD; Aspirin; Blood Platelets; Cerebral Hem | 1998 |
Thrombolytic therapy as early management of ischemic stroke.
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Fibrinolytic | 1998 |
[Stroke. Earliest possible acute intervention and promising successful secondary prevention. "Newest trends in epidemiology, pathogenesis and therapy of stroke". Symposium in Dresden, 4 October 1997].
Topics: Aspirin; Cerebrovascular Disorders; Emergencies; Humans; Platelet Aggregation Inhibitors; Secondary | 1997 |
Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocyt
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; | 1998 |
Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Endar | 1998 |
ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillation. American Society of Health-System Pharmacists.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; C | 1998 |
IST and CAST: some answers but more questions.
Topics: Acute Disease; Aspirin; Cerebrovascular Disorders; Humans; Randomized Controlled Trials as Topic | 1998 |
Blocking platelets more: are we skating on thin ice?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Immunogl | 1998 |
Not enough people taking aspirin for heart benefits.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Humans; Male; Myocardial Infarction; Platelet Aggregation | 1998 |
Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care.
Topics: Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cost-Benefit Analysi | 1998 |
Secondary prevention of stroke--new trials.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Delayed-Action Preparations; Dipyridamole; Dr | 1998 |
Aspirin treatment.
Topics: Alcohol Drinking; Aspirin; Cerebrovascular Disorders; Humans; Hypertension; Patient Education as Top | 1998 |
Carotid artery dissection presenting as a painless Horner's syndrome in a pilot: fit to fly?
Topics: Aerospace Medicine; Aortic Dissection; Aspirin; Carotid Artery, Internal; Cerebrovascular Disorders; | 1998 |
Aspirin and stroke.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clinical Trials as Topic; Cyclooxygen | 1998 |
[Neuroprotective action of aspirin].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Ischemia; Cerebrovascular Di | 1997 |
[Atrial fibrillation and anticoagulant therapy].
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged; | 1998 |
[Consensus on antithrombotic prophylaxis of vascular events in patients with manifested atherosclerotic vascular disease].
Topics: Aged; Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cou | 1998 |
Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cohort Studies; Cost- | 1998 |
Atrial fibrillation and anticoagulation in patients with permanent pacemakers: implications for stroke prevention.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Electrocardiography; | 1998 |
[Thrombosis prophylaxis after stroke].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Heparin; Humans; Middle Aged; Plate | 1998 |
Risk of stroke in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Cohort Studies; Dose- | 1998 |
[An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Belgium; Cerebrovascular Disorders; Cost-Benefit An | 1998 |
Transient ischaemic attacks: new treatments, new questions.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Hemorrhage; | 1998 |
Warfarin, aspirin, and atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio | 1998 |
Hypertension Optimal Treatment (HOT) trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium | 1998 |
Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia.
Topics: Aged; Anticoagulants; Aspirin; Case-Control Studies; Cerebrovascular Disorders; Female; Humans; Isch | 1998 |
[Hyperkinetic movements in ischemic ictus].
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Female; Humans; Hyperki | 1998 |
Patients with atrial fibrillation at low risk of stroke.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Ri | 1998 |
Patients with atrial fibrillation at low risk of stroke.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Ri | 1998 |
[Thrombosis prophylaxis after cerebrovascular attack].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Intracranial Embolism and Thrombosis; Plat | 1998 |
[Idiopathic atrial flutter].
Topics: Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Atrial Flutter; Cerebrovascular Disorders; Hum | 1998 |
Phacoemulsification and lens implantation in patients treated with aspirin or warfarin.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Conjunctival Diseases; | 1998 |
Intensive blood pressure lowering warranted. Results of the HOT study: an epitaph for the J-curve concept in hypertension.
Topics: Aspirin; Blood Pressure; Cerebrovascular Disorders; Humans; Hypertension; Myocardial Infarction; Pla | 1998 |
[Secondary prevention of ischemic stroke: aspirin or ticlopidine].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 1998 |
Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Confounding Factors, Epidemiologic; Coronary Disease; Diab | 1998 |
Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression.
Topics: Adolescent; Adult; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Cerebrovas | 1998 |
[Prevention in the 21st century. Athero-thrombosis and ischemic events].
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Female; Forecasting; Human | 1998 |
Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Hemorrhage; Cerebro | 1999 |
Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Contraindications; | 1999 |
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 1999 |
Thromboprophylaxis for atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as To | 1999 |
Aspirin and dipyridamole for the secondary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Combinations; Humans; Meta-Analysis as Topic; | 1999 |
Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-C | 1999 |
Aspirin and the risk of hemorrhagic stroke.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Female; Humans; Male; Meta-Analysis as Topi | 1999 |
What is the most difficult DUE your P&T Committee has ever conducted? How did you overcome its obstacles?
Topics: Ambulatory Care; Aspirin; Cerebrovascular Disorders; Drug Utilization; Hospital Bed Capacity, 100 to | 1992 |
Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders | 1999 |
Management of stroke in Auckland Hospital in 1996.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Femal | 1999 |
Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorder | 1999 |
[Anticoagulation in aged patients with chronic non-rheumatic atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascul | 1999 |
Forecasting the future of stroke therapy.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy; Forecasting; Humans; United States | 1985 |
Warfarin vs aspirin and AFASAK 2.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; F | 1999 |
Underuse of aspirin for secondary prevention of vascular disease.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Drug Utilization Review; Hospitalizatio | 1999 |
Case report of fibromuscular dysplasia presenting as stroke in a 16-year-old boy.
Topics: Adolescent; Angiography; Aspirin; Carotid Artery, Internal; Cerebrovascular Disorders; Fibromuscular | 1999 |
[Role of antiplatelet in the prevention and treatment of thrombotic diseases].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 1997 |
Low doses of aspirin in stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enda | 1999 |
Treatment for the secondary prevention of stroke in older patients: the influence of dementia status.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dementia; Drug Utilizat | 1999 |
Temporal trends in the use of anticoagulants among older adults with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Drug Therapy; Electro | 1999 |
Antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls.
Topics: Accidental Falls; Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Decision Support Te | 1999 |
Secondary stroke prevention with drugs: single or combined therapy?
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Drug Therapy, Combina | 1999 |
Underuse of anticoagulation in older patients with chronic atrial fibrillation: malpractice or accuracy?
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; C | 1999 |
Additional risk factors in atrial fibrillation patients not receiving warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dr | 1999 |
Is intensive drug therapy appropriate for older patients?
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorder | 1999 |
Prospective study of aspirin use and risk of stroke in women.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Cohort Studies; Female; Humans; Incidence; Middle Aged; P | 1999 |
Anticoagulation in atrial fibrillation in older people.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Contraindications; Hu | 1999 |
[Dipyridamole plus acetylsalicylic acid--who is to be trusted?].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; Hu | 1999 |
Low-dose versus high-dose acetylsalicylic acid in carotid endarterectomy.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Myocardial Infarction; Platelet | 1999 |
Atrial fibrillation: the epidemic of the new millennium.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Fibrinolytic Agents; | 1999 |
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Platelet Aggregatio | 2000 |
Aspirin-associated intracerebral hemorrhage: clinical and radiologic features.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studies; Cerebral Hem | 2000 |
Dipyridamole plus aspirin in cerebrovascular disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Cerebrovascular Disorders; Clinical Trials as Topic | 2000 |
Is treatment with aspirin combined with dipyridamole really more cost-effective than aspirin alone?
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Cost-Benefit Analysis; Dipyridamole; D | 2001 |
Stroke risk in older men and women: aspirin, estrogen, exercise, vitamins, and other factors.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; California; Cerebrovascular Disorders; Cohort Studies; Estr | 2001 |
Towards a definition of aspirin resistance: a typological approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrov | 2002 |
Platelet activation in acute cerebral ischaemia. Serial measurements of platelet function in cerebrovascular disease.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Blood Cell Count; Blood Platelets; Cerebrovascu | 1977 |
Aspirin and stroke prevention.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; Male; Risk; S | 1978 |
Microsurgery in stroke management.
Topics: Aspirin; Cerebral Arteries; Cerebral Revascularization; Cerebrovascular Disorders; Female; Humans; I | 1979 |
Does aspirin have a prophylactic vascular effect?
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Hum | 1979 |
[Therapy with anticoagulants and platelet aggregation inhibitors in extracranial vascular stenoses and occlusions].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Cerebrovascular Disorders | 1979 |
Management of the asymptomatic carotid bruit.
Topics: Aspirin; Auscultation; Carotid Artery Diseases; Cerebral Infarction; Cerebrovascular Disorders; Enda | 1979 |
The Canadian cooperative study of platelet suppressant therapy in threatened stroke.
Topics: Aspirin; Blood Platelets; Canada; Cerebrovascular Disorders; Double-Blind Method; Evaluation Studies | 1979 |
Role of antiplatelet agents in cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Humans; Plat | 1979 |
[Serotonin content in the thrombocytes and the effect of acetylsalicylic acid on its rate of liberation in ischemic stroke].
Topics: Absorption; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dose-R | 1979 |
Aspirin does not prevent all strokes.
Topics: Aspirin; Cerebrovascular Disorders; Humans | 1979 |
Aspirin does not prevent all strokes.
Topics: Aspirin; Cerebrovascular Disorders; Humans | 1979 |
Trials of antiplatelet drugs: some methodological considerations.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem | 1979 |
TIA, stroke, and mitral valve prolapse.
Topics: Adult; Aged; Aspirin; Carotid Artery Thrombosis; Cerebrovascular Disorders; Dipyridamole; Echocardio | 1979 |
Platelet suppressing drugs in arterial disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Humans; Myocardial | 1978 |
'Spontaneous' platelet aggregation: its characteristics and relation to aggregation by other agents.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cell Count; Cerebrovascular Disorders; Female; Humans; Ischem | 1978 |
Transient ischemic attacks and the prevention of strokes.
Topics: Anticoagulants; Aspirin; Carotid Artery Thrombosis; Cerebrovascular Disorders; Endarterectomy; Femal | 1978 |
Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study.
Topics: Adult; Aged; Angina Pectoris; Arthritis, Rheumatoid; Aspirin; Cerebrovascular Disorders; Coronary Di | 1978 |
Risk, prognosis of stroke improved in aspirin trials.
Topics: Adolescent; Adult; Aged; Animals; Aspirin; Cerebrovascular Disorders; Child; Female; Humans; Male; M | 1978 |
Stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Humans; Sex Factors; Sulfinpyrazone | 1978 |
Anticoagulants and platelet-inhibiting drugs in stroke.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation; Sulf | 1977 |
Using antithrombotic therapy in ischemic cerebrovascular disease.
Topics: Aspirin; Brain; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Heparin; Humans; Intra | 1977 |
Arachidonate-induced cerebrovascular occlusion in the rat. The role of platelets and aspirin in stroke.
Topics: Animals; Arachidonic Acids; Aspirin; Cerebral Cortex; Cerebrovascular Disorders; Disease Models, Ani | 1976 |
Hematological and vascular concepts in relation to stroke.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Cerebral Arteries; Cerebrovascular Disorders; Endotheli | 1976 |
Complications of percutaneous transfemoral coronary arteriography.
Topics: Angiography; Aspirin; Cardiac Catheterization; Cerebrovascular Disorders; Coronary Angiography; Femo | 1976 |
[Ovulation inhibitors from a neurological viewpoint].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Est | 1976 |
Prevention of stroke.
Topics: Age Factors; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Auscultation; Cerebral Angiograph | 1975 |
Increased platelet aggregability in young patients with stroke. Diagnosis and therapy.
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Cell Survival; Cerebrovascular Di | 1975 |
Editorial: Platelet aggregation.
Topics: Adenosine Diphosphate; Aspirin; Cerebrovascular Disorders; Coronary Disease; Glucose; Humans; Hyperl | 1975 |
Does lone atrial fibrillation constitute a risk of embolization, and how should we manage it?
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Embolism; Humans; Risk F | 1992 |
Dissociation of inhibitory effects of low-dose ASA on thromboxane production and platelet aggregation in ischemic stroke patients.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Platelet Activation; Pl | 1992 |
The role of aspirin in the prevention of cardiovascular and cerebrovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans | 1992 |
Low-dose aspirin and stroke. "It ain't necessarily so".
Topics: Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Trans | 1992 |
Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, | 1992 |
Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, | 1992 |
Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, | 1992 |
Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Cerebrovascular Disorders; Dose-Response Relationship, | 1992 |
Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model.
Topics: Animals; Aspirin; Blood Gas Analysis; Blood Pressure; Carotid Artery Thrombosis; Cerebral Angiograph | 1992 |
Optimal low dosage of acetylsalicylic acid (ASA) for the prevention and treatment of ischemic cerebrovascular disease in geriatric patients.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Humans; Intracranial Embolism and Throm | 1992 |
Ticlopidine for the prevention of thromboembolic stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Thromboembolism; Ticlopidine | 1992 |
Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Co | 1992 |
Anticoagulants for atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged; | 1992 |
From the National Institutes of Health.
Topics: Acute Disease; Acyclovir; Administration, Oral; Antibodies, Viral; Aspirin; Atrial Fibrillation; Cer | 1991 |
Aspirin, warfarin, and recurrent stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Recurrence; Warfarin | 1991 |
Aspirin, warfarin, and recurrent stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Recurrence; Warfarin | 1991 |
Prevention of stroke with ticlopidine: who benefits most? TASS Baseline and Angiographic Data Subgroup.
Topics: Aspirin; Carotid Artery Diseases; Cerebral Angiography; Cerebrovascular Disorders; Female; Humans; L | 1992 |
Cerebral stroke in a semi-pro football player: a case report.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Football; Humans; Male; Manipulation, Orthopedic; Vertebr | 1991 |
Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients.
Topics: Aged; Aspirin; Blood Platelets; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Female; | 1991 |
Stroke prevention in atrial fibrillation trial.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Research | 1991 |
[Effect of chronic antiplatelet treatment on platelet activating factor-induced platelet activity in stroke].
Topics: Adenosine Triphosphate; Adult; Aspirin; Calcium; Cerebrovascular Disorders; Female; Humans; Ibuprofe | 1991 |
Aspirin.
Topics: Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation Disorders; Cell Membr | 1991 |
Aspirin and hemorrhagic stroke.
Topics: Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Humans; Risk Factors | 1991 |
Atrial fibrillation and embolic stroke.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Dipyridamole; Embolism; Humans; Warfa | 1991 |
Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Attitude of Health Personnel; Cerebrovascu | 1991 |
[Is the medical prevention of stroke good enough?].
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Estrogens; Humans; Norway; Risk Factors | 1991 |
[Rapidly progressing carotid artery stenoses: possibilities of ultrasound prediction and effect of thrombocyte aggregation inhibitors].
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Humans; Intracranial | 1990 |
Platelet scintigraphy and survival in juvenile stroke patients.
Topics: Adult; Arteriosclerosis; Aspirin; Blood Platelets; Carotid Arteries; Carotid Artery Diseases; Cell S | 1990 |
Mechanism of stroke in patients taking aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Infarction; Cerebrovascular Disord | 1990 |
[Aspirin against aging? For whom and how much?].
Topics: Arachidonic Acids; Aspirin; Cerebrovascular Disorders; Coronary Disease; Dose-Response Relationship, | 1990 |
Atrial fibrillation--risk marker for stroke.
Topics: Aged; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged; Warfarin | 1990 |
The Physician's Health Study. A neurologist's concern.
Topics: Aspirin; Cerebrovascular Disorders; Cohort Studies; Follow-Up Studies; Humans; Male; Metoprolol; Myo | 1990 |
Aspirin and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans | 1990 |
Aspirin and the primary prevention of myocardial infarction and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Myocardial Infarction | 1990 |
[Ticlopidine Aspirin Stroke Study].
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ticlopidine | 1990 |
Comparison of ticlopidine and aspirin for the prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Cholesterol; Humans; Myocardial Infarction; Research Design; Tic | 1990 |
Low dose acetylsalicylic acid and thromboxane release at the site of plug formation in vivo in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aspirin; Bleeding Time; Cardiovascular Diseases; Cerebrovascular Disorders; | 1990 |
Controlled clinical trials in cerebrovascular disease. A misused tool.
Topics: Aspirin; Cerebral Revascularization; Cerebrovascular Circulation; Cerebrovascular Disorders; Clinica | 1990 |
Aspirin and coronary heart disease. Clinical applications.
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Endothelium, Vascular; Female; Humans; Male; P | 1990 |
Prevention of stroke in atrial fibrillation.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin | 1990 |
Perioperative stroke risk in 173 consecutive patients with a past history of stroke.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anesthesia, General; Aspirin; Cerebrovascular Disorders | 1990 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Statistics as Topic | 1989 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient | 1989 |
Aspirin, ticlopidine, and stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ticlopidine | 1989 |
[The effects of ligustrazine, aspirin and beta-histine on platelet aggregation in patients with acute ischemic stroke].
Topics: Aged; Aged, 80 and over; Aspirin; Betahistine; Cerebrovascular Disorders; Female; Fibrinolytic Agent | 1989 |
Effect of low dose acetylsalicylic acid upon plasma thromboxane B2 levels and platelet aggregation in ischemic stroke patients.
Topics: Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Mal | 1989 |
Effect of therapy on platelet activating factor-induced aggregation in acute stroke.
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Female; Humans; Male; P | 1989 |
Paroxysmal dyskinesias secondary to cerebral vascular disease--reversal with aspirin.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Movement Disorders | 1989 |
[Atrial fibrillation: an indication to prevent stroke].
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Warfarin | 1989 |
[Chronic treatment of vascular diseases with indobufen].
Topics: Adult; Aged; Aspirin; Cerebrovascular Disorders; Dipyridamole; Humans; Isoindoles; Middle Aged; Phen | 1989 |
Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Atrial Fibrillatio | 1986 |
Aspirin and stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Humans | 1988 |
Aspirin, warfarin, and stroke prevention.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Warfarin | 1988 |
Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents.
Topics: Acute Disease; Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dipyridam | 1989 |
Large trial finds ticlopidine superior to aspirin in preventing stroke.
Topics: Aspirin; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; Male; Neutropenia; Random All | 1989 |
Management of transient ischemic attacks.
Topics: Aged; Aging; Anticoagulants; Aspirin; Cerebrovascular Disorders; Diagnosis, Differential; Humans; Is | 1987 |
Protective effect of triflusal and acetylsalicylic acid against arachidonic acid induced cerebrovascular occlusion in anesthetized rats.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Cerebrovascular Disorders; Electroencephalogr | 1987 |
Aspirin all round?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans | 1988 |
Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Combinatio | 1988 |
[Risk factors and antiaggregant treatment in cerebrovascular diseases].
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Blood Coagulation Factors; Cerebrovascular Disorders; Dipyr | 1988 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient | 1988 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient | 1988 |
Aspirin for strokes and transient ischaemic attacks.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy; Humans; Ischemic Attack, Trans | 1988 |
[Aspirin and coronary heart disease].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Male; | 1988 |
Carotid artery disease. A therapeutic enigma.
Topics: Aspirin; Blindness; Carotid Artery Diseases; Cerebrovascular Disorders; Endarterectomy; Eye Diseases | 1988 |
Inhibitory effect of acetylsalicylic acid on platelet function in patients with completed stroke or reversible ischemic neurologic deficit.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cerebrovascular Disorders; | 1988 |
The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Drug Labeling; Hum | 1988 |
Individual variation in platelet aggregability and serum thromboxane B2 concentrations after low-dose aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Plat | 1988 |
Indications and results for splenectomy for beta thalassemia in two hundred and twenty-one pediatric patients.
Topics: Aspirin; Blood Transfusion; Cerebrovascular Disorders; Child; Dipyridamole; Female; Follow-Up Studie | 1988 |
TIAs and carotid endarterectomy: a word of caution.
Topics: Aspirin; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy; Female; Humans; Ischemic Attac | 1988 |
Management of transient ischemic attacks.
Topics: Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Embolism; | 1986 |
Multicenter study indicates one aspirin can do the job of four in preventing stroke.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged | 1987 |
Prevention of postoperative neurologic deficits after carotid endarterectomy. Is platelet inhibition beneficial?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Dipyrid | 1987 |
One aspirin can't prevent a stroke but can prevent a major vascular event.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Transient; Male; Sex Factors | 1987 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |
Pharmacologic approach to ischemic stroke management.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Dipyridamole; Drug Interactions; Heparin; Human | 1986 |
The basis for aspirin dosage in stroke prevention.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Endothelium, | 1987 |
The EC-IC bypass study: does it answer the question.
Topics: Aspirin; Cerebral Revascularization; Cerebrovascular Disorders; Female; Follow-Up Studies; Humans; M | 1986 |
Oesophageal apoplexy associated with aspirin ingestion in polycythaemia rubra vera.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Esophagus; Female; Hemorrhage; Humans; Polycythemia Vera | 1986 |
[Thrombolytic mechanism and its therapeutic application].
Topics: Aspirin; Cerebrovascular Disorders; Fibrinolysis; Fibrinolytic Agents; Humans; Plasminogen Activator | 1986 |
Antithrombotic therapy for cerebrovascular disease. Prevention and treatment of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Endarterectomy; Heparin; Humans; Middle Aged | 1986 |
Spontaneous dissection of the carotid artery: an unusual cause of stroke in younger patients.
Topics: Adult; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Cerebrovasc | 1987 |
Effect of incremental doses of aspirin on bleeding time, platelet aggregation and thromboxane production in patients with cerebrovascular disease.
Topics: Adult; Aged; Aspirin; Bleeding Time; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relati | 1985 |
Carotid endarterectomy. One solution to the stroke problem.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1985 |
Peripheral vascular disease: treatment and referral of the elderly. Part II.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular | 1985 |
Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; F | 1985 |
[Anti-platelet aggregation action and paradoxical effects of acetylsalicylic acid].
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Coronary Disease; Extr | 1985 |
Does dipyridamole have antithrombotic potential?
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; P | 1985 |
[Anti-platelet therapy in ischemic cerebrovascular disorder--clinical and hematological study].
Topics: Adult; Aged; Aspirin; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dipyridamole; Femal | 1985 |
[Amaurosis fugax--differential diagnosis and treatment].
Topics: Anticoagulants; Aspirin; Blindness; Cerebrovascular Disorders; Diagnosis, Differential; Humans; Migr | 1974 |
[Platelet function disorders and ischemic cerebral accidents. Therapeutic prospects].
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Cerebrovascular Disorders; Dipyri | 1972 |
Stroke: malignant and benign syndromes.
Topics: Anticoagulants; Aspirin; Carotid Artery Diseases; Cerebral Hemorrhage; Cerebrovascular Disorders; De | 1973 |
Transient ischemic attack: an early warning system for stroke?
Topics: Aged; Angiography; Anticoagulants; Aspirin; Blood Pressure; Brain Edema; Cerebrovascular Disorders; | 1973 |
Acute cerebral infarction. Evaluation and treatment.
Topics: Angiography; Anticoagulants; Aspirin; Blood Pressure Determination; Cerebrospinal Fluid; Cerebrovasc | 1973 |
Address of the president-elect: the indication for various methods of treatment of occlusive cerebrovascular disease.
Topics: Anticoagulants; Aspirin; Blood Pressure; Cardiac Output; Carotid Arteries; Cerebral Angiography; Cer | 1973 |
Treatment of stroke: medical or surgical?
Topics: Angiography; Antihypertensive Agents; Aspirin; Blood Pressure; Carotid Arteries; Carotid Artery Thro | 1974 |
[Platelet aggregation inhibiting treatment with aspirin. Biological bases. Application to cerebral vascular accidents].
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Blood P | 1972 |